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ABSTRACT
Human herpesvirus- 6  (HHV-6 ) was first isolated from the peripheral blood of six 
individuals with lymphoproliterative or immunosuppressive disorders. Further 
studies identified HHV- 6  DNA sequences in tumour biopsy samples from 
persons with lymphoma. Thus, initial findings suggested a link between HHV- 6  
and lymphoproliferative disease.
This study was designed to examine further the association of HHV- 6  with 
lymphomas and leukaemias by seroepidemiological investigations. Higher 
antibody titres to HHV- 6  were identified in acute myeloid leukaemia, low-grade 
non-Hodgkin's lymphoma, and Hodgkin's disease (HD).
Epidemiological evidence has lead to the proposition that HD, particularly in 
young adults, may have a viral aetiology and Epstein-Barr virus (EBV) has 
consistently been associated with this malignancy. Further analysis of both 
HHV- 6  and EBV serology was carried out and the results suggested that the 
associations of both viruses with HD were relatively independent of each other. 
Thus, HD may be the result of an abnormal response to virus infection including 
EBV and HHV-6 . To date there is little molecular evidence linking HHV- 6  to 
HD, although recent studies have clearly demonstrated the presence of EBV 
within the tumour cells of the disease.
In 1990, a human herpesvirus, distinct from those previously recognised, was 
isolated and named human herpesvirus-7 (HHV-7). The seroepidemiology of 
this virus in children and adults is presented in this dissertation. Infection with 
HHV-7 is widespread and infection occurs usually early in life. A likely vehicle 
for transmission is saliva.
Herpesviruses have not only been associated with malignancy, but also chronic 
disease such as autoimmune conditions. EBV involvement has been proposed 
in the autoimmune disease, Sjogren's syndrome (SS). More recently HHV- 6  
has been linked to this condition. Viruses present within the epithelium of the 
salivary gland may play a role in the inflammation of such glands which is 
characteristically found in SS. This project studied possible viral involvement in 
SS by utilising the in vitro tissue culture of epithelial cells derived from salivary 
gland biopsies. The model proved useful as a means to study cytokine-
XIII
mediated mechanisms of autoimmunity in particular the role of interferon-y and 
in the identification of putative retroviral antigens in salivary tissue.
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CHAPTER 1 
GENERAL INTRODUCTION
1
1.1 HERPESVIRUSES
1.1.1 The Family Herpesviridae
Herpesviruses are highly disseminated in nature and have been isolated from 
many animal species. The family herpesviridae comprises over 100 viruses 
with similar biochemical and morphological characteristics (Roizman and 
Baines, 1991; Roizman eta /., 1992).
Inclusion of viruses into the family herpesviridae is based on the architecture of 
the virion, which can be separated into 4 distinct morphological elements, by 
electron microscopy. A typical herpesvirion consists of: (i) a core containing the 
linear double-stranded DNA; (ii) an icosadeltahedral capsid of 100-120 
nanometres (nm) in diameter (Wildy et al., 1960) containing 12 pentameric and 
150 hexameric capsomeres; (iii) an amorphous sometimes asymmetric 
tegument which surrounds the capsid; (iv) an envelope derived from host cell 
internal membranes in which viral glycoprotein spikes are embedded and 
project from its surface (Fig. 1.1.1). The size of herpesvirions ranges from 120 
to 300nm (Roizman and Furlong, 1974).
Herpesviruses are further characterised by the presence of a linear double­
stranded DNA genome ranging from approximately 120 to 230 kilobase pairs in 
size (reviewed by Roizman, 1990). A property of herpesviruses is their ability 
to remain in a latent state within the host following primary infection. The sites 
of latency vary between herpesviruses, but include lymphocytes, monocytes 
and neuronal tissue.
Amongst the most fully characterised herpesviruses are 5 of the 7 isolated from 
humans, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella- 
zoster virus (VZV), human cytomegalovirus (CMV), and Epstein-Barr virus 
(EBV). Recent and ongoing studies continue to clarify the properties of HHV-6 . 
The most recently identified human herpesvirus-7 (HHV-7) is the least 
characterised of the human herpesviruses. Other animal herpesviruses that 
have been the subject of much investigation are pseudorabies virus (PRV), 
bovine herpesvirus type 1, and equine herpesviruses-1 and -4 (EHV-1 and -4) 
which can cause economically important diseases in their hosts.
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Figure 1.1.1
Herpesvirus Virion Structure
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Figure 1.1.1 Schematic diagram of a herpesvirus virion
1.1.2 Classification Of Herpesviruses
Herpesviruses can be classified into subgroups based on different criteria 
including genome structure or biological properties. As the genome structures 
of the majority of herpesviruses are not well defined, the present classification 
scheme is based on the biological behaviour of the isolate.
(i) Classification by biological properties
The majority of herpesviruses have been assigned to 3 subfamilies based on 
biological criteria. These are the alpha, beta and gamma herpesviruses 
(Roizman, 1982; Roizman et al., 1992). This classification is based on 
evidence that infection by herpesviruses can vary with respect to: (i) host range 
and cell tropism; (ii) the rate at which the virus multiplies in culture and at which 
infected cells are destroyed; (iii) site of latency.
a. Alphaherpesviruses
Alphaherpesviruses have a variable host range, a relatively short replication 
cycle, rapid infection in culture, efficient destruction of infected cells, and 
establish latency primarily within neurons or lymphoid tissue. This subfamily 
includes HSV-1, HSV-2, VZV, PRV, and EHV-1 and -4.
b. Betaherpesviruses
Betaherpesviruses exhibit a restricted host range. The viral replicative cycle is 
slow and latency is often maintained in lymphoid cells and secretory glands. 
Members of this subfamily include CMV. More tentatively assigned to this 
group are HHV- 6  and HHV-7.
c. Gammaherpesviruses
Gammaherpesviruses have a limited host range. All members replicate in 
lymphoblastoid cells in vitro and may cause lytic infections in epithelioid and 
fibroblastic cells. Viruses tend to be lymphotropic, infecting either T or B cells. 
Gammaherpesviruses can be sub-divided into two groups based on their 
lymphotropism. 7 I viruses preferentially are B cell lymphotropic and 7 2  viruses 
T cell lymphotropic. In lymphocytes, the replicative cycle is often pre-lytic or
3
lytic, but without the production of infectious virus. Latency frequently occurs in 
lymphoid tissue. This subfamily of herpesviruses includes EBV.
(ii) Classification bv genome structure
Herpesviruses can be sub-divided into different groups based on their genome 
sequence arrangement. Herpesviruses contain copies of terminal sequences 
greater than 100 base pairs in size. According to the variation in the presence 
and location of these sequence, herpesviruses can be divided into 6  groups, 
designated A to F (Roizman et al., 1992) (Fig. 1.1.2). Based on this genome 
structure, HHV- 6  appears to fall into group A. EBV is categorised as group C, 
and VZV as group D. Group E viral genomes are exemplified by those of HSV- 
1, HSV-2, and CMV.
(iii) Classification by nucleotide sequence
The comparison of nucleotide sequence data will probably result in the most 
accurate classification of herpesviruses. However to date, as for genome 
structure, nucleotide sequences are available from only a minority of 
herpesviruses. At present the sequences of at least 10 herpesviruses are 
known or almost completed, including the human viruses HSV, VZV, EBV, 
CMV, and HHV- 6  (McGeoch et al., 1988; Davison and Scott, 1986; Chee etal., 
1990; Baer et al., 1984; Lawrence et al., 1990). According to biological 
properties, HHV- 6  was initially tentatively assigned to the gammaherpesviruses 
based on its lymphotropism. Further characteristaion of the virus has 
suggested properties more in line with the betaherpesviruses and sequence 
data (Lawrence et al., 1990) suggests a closer homology to CMV at the 
molecular level. Although the current classification scheme is based on 
biological properties, classification by nucleotide sequence is becoming 
increasingly common. As for HHV-6 , limited sequencing of herpesviruses may 
allow adequate comparison with more complete sequence data from others to 
allow categorisation in the appropriate taxonomic group.
1.1.3 Herpesvirus Life Cycle
Lytic infection by herpesviruses consists of a number of stages beginning with 
viral entry into the cell and finally resulting in the release of progeny virus and 
host cell death (Fig. 1.1.3).
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Figure 1.1.2 The herpesviruses can be divided into six groups designated A to 
F depending on the presence and reiterations of terminal sequences. Group F 
viruses, which are not represented in the figure, have no reiterations. Group A 
viruses have a large sequence from one terminus repeated at the other. In 
group B viruses the terminal sequence is repeated at both termini although the 
number of repeats can vary. Group C viruses have a number of reiterations at 
both termini and there may be unrelated sequences directly repeated within the 
unique sequences of the genome. Group D viruses have a terminal sequence 
that is repeated in an inverted orientation within the genome. Group E viruses 
have sequences from both termini that are repeated and arranged together in 
an inverted orientation within the unique sequence of the genome.
CCV=channel catfish virus, HVS=herpesvirus saimiri, H.=herpes, 
HV=herpesvirus, MDV=Marek's disease virus, HVT=herpesvirus of turkeys.
Figure 1.1.2
Herpesvirus Genome Structures
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Figure 1.1.2 Schematic representation of the five types of herpesvirus genome 
structure as defined in Roizman e ta l . (1992).
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Figure 1.1.3
Herpesvirus Life Cycle
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Figure 1.1.3 Schematic representation of the herpesvirus lytic cycle (Subak-
Sharpe, 1992).
The virion adsorbs and enters the cell by virtue of an interaction between viral 
envelope glycoproteins and receptors at the cell surface. Amongst the cellular 
receptors identified to date is the C3d receptor for complement (CR2 or CD21) 
(Fingeroth et a/., 1984) used by EBV. Entry of viruses within phagocytic 
vesicles (Dales and Silverberg, 1969) is less likely.
Following entry of the virion into the cell the capsid is removed. Transcription of 
the viral genome in the nucleus is followed by translation of viral proteins in the 
cytoplasm in a co-ordinated fashion that can be temporally separated into 3 
groups (Honess and Roizman, 1974). The first group, immediate-early 
proteins, activate transcription of the second group, the early proteins, which 
consist of enzymes such as deoxypyrimidine kinase and DNA polymerase 
required for the replication of viral DNA. Expression of late proteins including 
the structural components of the virion may be activated by early proteins.
Finally, viral DNA and structural proteins are assembled into progeny virions. 
The core and capsid are assembled within the nucleus. Envelopment of the 
capsid occurs by a budding process through several internal membranes 
including the inner nuclear membrane (Roizman and Furlong, 1974). 
Subsequently virions may be transported in vacuoles and secreted from the cell 
(Roizman, 1978).
Host cell death may occur in two ways. Host cell DNA and protein synthesis 
can be shut-off in an infected cell (Wagner and Roizman, 1968). Alternatively, 
the presence of viral peptides in association with major histocompatibility 
complex (MHC) class 1 molecules in the host cell plasma membrane can target 
an immune response against the viral antigens leading to the destruction of the 
cell.
A characteristic of herpesviruses is their ability to persist in their natural host in 
a non-infectious form. They can remain for years avoiding detection by the host 
immune response. In cells harbouring latent virus, the viral genomes take the 
form of closed circular molecules and only a small subset of viral genes, the 
latency-associated transcripts (LAT), are expressed. In cells infected with HSV, 
LAT arises from the DNA strand complementary to an immediate early gene 
ICPO (Stevens et al., 1987) and, as an antisense message, could inhibit 
transcription of this immediate early gene. However, viral mutants that lack 
LAT have also been reported to establish latency, which questions their
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necessity (Whitley, 1990). EBV differs from the other human herpesviruses in 
that there is extensive gene expression during latency (discussed 1.1.4.iv). On 
reactivation from latency, productive infection results in the death of the host 
cell and release of infectious virus. Mechanisms by which reactivation is 
triggered are unclear. For HSV-1, external or internal stimuli such as physical 
trauma, immunosuppressive agents and stress may result in activation (Hill, 
1985). Exposure to ultra-violet light is also associated with reactivation from 
latency possibly mediated through host cellular factors.
1.1.4 Human Herpesviruses
(i) Herpes simplex viruses
The HSVs comprise two viruses, HSV-1 and HSV-2, that are distinguished 
according to antigenic and nucleotide sequence differences. HSVs are 
distributed world-wide and have been reported in developing and developed 
countries, including remote Brazilian tribes (Black, 1975). Records of human 
HSV infections date to ancient Greek times (Nahmias and Dowdle, 1968).
The epidemiology of HSV infections have been reviewed previously (Rawls and 
Campione-Piccardo, 1981; Whitley, 1990). HSVs are transmitted from infected 
to susceptible individuals during close personal contact (reviewed by Whitley,
1990). Virus must come in contact with mucosal surfaces or abraded skin for 
infection to occur. A consequence of viral replication at the site of infection is 
the passage of the virus within neurons to the dorsal root ganglia where latency 
is established. Primary HSV-1 infection rarely becomes systemic although viral 
dissemination is more common in neonatal HSV infection leading to multiorgan 
involvement. Similarly virus dissemination may occur in immunosuppressed 
patients where the host immunity/viral balance is altered.
The mouth and lips are the most common sites of HSV-1 infections, although 
many organs can become infected (reviewed by Nahmias etal., 1981). Primary 
infection can occur at any age, although it is particularly common in children. 
Great variability exists in the clinical symptomatology of HSV infections ranging 
from asymptomatic infection to combinations of fever, sore throat, ulcerative 
and vesicular lesions, gingivostomatitis, oedema, localised lymphadenopathy, 
anorexia and malaise. Delayed primary infection by HSV later in life can result 
in pharyngitis in association with a mononucleosis syndrome. The frequency of
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reactivation of HSV-1 varies among individuals although factors such as fever, 
stress, and exposure to ultra-violet light may be involved (Whitley, 1985; Hill, 
1985). Oropharyngeal disease is a common consequence of primary and, less 
frequently, reactivated HSV-1 infection
Infection with HSV-2 is more commonly the consequence of genital 
transmission through sexual contact (Josey et al., 1966). Most genital 
infections are caused by HSV-2. However, a proportion are attributable to 
HSV-1 although genital HSV-1 infections are usually less severe and less prone 
to reactivation (Corey et al., 1983). HSV-1 and HSV-2 infections can be 
present in the eye, the skin, and the nervous system (Whitley, 1990) and HSV 
infection has also been associated with cervical cancer (discussed 1.2.3).
The method of choice for the diagnosis of HSV infection is specific viral 
identification either by virus isolation or by direct detection of HSV in lesion 
tissue (Herrmann and Stewart, 1981). Serological tests are of more limited 
value. Since HSV infection is common, the detection of HSV antibodies 
provides little information regarding the time of infection. Serodiagnosis is 
dependent on the identification of a significant rise in HSV antibody titre or the 
detection of HSV antibodies of the IgM subclass (Herrmann and Stewart, 1981). 
Certain serological assays for HSV are of limited efficacy in the identification of 
HSV type-specific antibodies. Antigenic differences between HSV-1 and HSV-2 
glycoprotein G have facilitated the identification of antibodies to either virus type 
(Lee etal., 1985).
Serological studies provide information on the prevalence of HSV in the 
population and allow the examination of factors associated with susceptibility to 
exposure. Seroepidemiological surveys have identified socioeconomic status 
and geographical location as affecting the acquisition of antibodies to both 
HSV-1 and HSV-2 (Rawls and Campione-Piccardo, 1981; Whitley, 1985; 
Whitley, 1990). In developing countries, HSV-1 seroconversion occurs earlier 
in life than developed countries. In developed countries and higher 
socioeconomic groups, primary infection may be delayed until adolescence and 
adulthood, perhaps reflecting reduced person-to-person contact in these 
groups during childhood. Antibodies to HSV-2 are not usually detected until 
puberty and seroprevalence rates are associated with past sexual history 
(reviewed by Corey, 1985). As for HSV-1, socioeconomic group and
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geographical location are factors that can influence the prevalence of HSV-2 
infection.
(ii) Varicella-zoster virus
VZV infection can produce two distinct clinical syndromes, varicella 
(chickenpox) and herpes zoster (shingles). Varicella has been recognised for 
centuries as a relatively benign infection of childhood. Herpes zoster is usually 
found in older persons and the immunocompromised and is associated with 
reactivation of VZV from latency. VZV was first isolated in tissue culture by 
Weller and Stoddard (1952) from vesicle fluid of both varicella and zoster 
patients. Viral isolates obtained from varicella or zoster patients were found to 
be identical on the basis of antigenicity and DNA restriction enodonuclease 
digestion patterns (Richards et al., 1979). DNA from an isolate of VZV has 
been completely sequenced and has a genome size of 124 kilobase pairs 
(Davison and Scott, 1986).
The transmission of VZV to a susceptible host requires close contact with an 
individual with varicella or herpes zoster (reviewed by Zaia, 1981; Gelb, 1990). 
The virus appears to enter through the mucosa of the upper respiratory tract 
and oropharynx or alternatively through the conjunctiva. Virus replicates and 
spreads from this site and disseminates via the bloodstream to the skin. The 
cutaneous lesions of VZV originate with the infection of capillary endothelial 
cells, then epithelial cells of the epidermis which leads to the formation of 
vesicles. These vesicles become sites of inflammation with the infiltration of 
polymorphonuclear cells and macrophages. Following primary infection, VZV 
remains latent in sensory ganglia. Upon reactivation, herpes zoster occurs. 
The stimuli for reactivation are unclear but may include immunosuppression 
(Hope-Simpson, 1965). The histopathology of the skin lesions of herpes zoster 
is identical to varicella, but also includes acute inflammation of the 
corresponding sensory nerve and ganglion.
The majority of persons living in industrialised societies within the temperate 
climate zone contract varicella during childhood (Preblud et al., 1984). Primary 
VZV infections show a marked seasonality with peak incidence in early spring 
and late winter. In tropical regions, primary infection in adulthood is more 
common than in temperate climate zone. Herpes zoster usually occurs in
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persons over the age of 45 years and there is no evidence that socioeconomic 
class affects the incidence of VZV infections (Gelb, 1990).
VZV infection usually runs a benign, self-limiting course, although primary 
infection in certain patient groups can lead to complications. Life-threatening 
illness in neonates can result from infection in utero especially if the mother is 
infected immediately prior to birth. In children with underlying illness such as 
leukaemia, more severe illness can result on infection with VZV. Increased 
prevalence and severity of herpes zoster is found in immunosuppressed 
individuals.
The diagnosis of VZV infections, varicella and herpes zoster, most often rests 
on the appearance and distribution of the characteristic skin lesions. The 
clinical presentation of primary infection can vary including inapparent infection 
in a minority of cases. Laboratory diagnosis of VZV infections include 
identification of herpesvirus particles by electron microscopy and isolation of 
virus from, or detection of VZV antigens in, vesicular fluid (Frey et al., 1981). 
Serological diagnosis is based on the detection of a fourfold increase in VZV 
antibody titre or the detection of VZV antibody of the IgM subclass (Wiedbrauk 
and Johnston, 1992).
A variety of serological assays are used to determine the VZV humoral immune 
status of an individual more often than diagnosis of infection itself. Such testing 
identifies VZV antibody negative persons who are at risk from VZV infection. 
Susceptible persons such as cancer patients receiving immunosuppressive 
therapy or pregnant mothers who have had contact with a varicella or zoster 
patient may be targetted for passive immune therapy.
(iii) Cytomegalovirus
Cytomegaloviruses are ubiquitous agents that frequently infect animals, 
including humans. Humans are believed to be the only reservoir for human 
CMV, hereafter referred to as CMV, and transmission of the virus occurs by 
direct or indirect person to person contact.
The isolation of CMV was independently reported by three groups (Smith, 1956; 
Rowe et al., 1956; Weller et al., 1957). There are a large number of genetic
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variants of CMV and some strains may be more virulent compared to others 
(Huang etal., 1976).
CMV is a virus of low pathogenicity in humans, but primary infection and 
reactivation or reinfection have been associated with clinical disease (reviewed 
by Weller, 1981). CMV characteristically produces cell enlargement with 
intranuclear inclusions which are termed cytomegalic cells. Such cells can be 
found in a variety of organs such as the kidney, liver, lungs, and salivary 
glands, particularly parotid glands. CMV exhibits a tropism for ductal epithelial 
cells although polymorphonuclear leukocytes and monocytes may harbour 
CMV at various stages following infection (Saltzman et al., 1988; Schrier etal.,
1985). In non-viraemic healthy CMV carriers the virus is not normally present in 
polymorphonuclear cells whereas adherent peripheral blood mononuclear cells, 
likely to be monocytes, harbour the virus and act as a site of persistence 
(Taylor-Wiedeman etal., 1993).
Congenital or neonatal infections by CMV can result in illness (reviewed by Ho,
1991). Approximately 20% of congenitally infected babies are symptomatic at 
birth. The risk of intrauterine infection following primary infection of the mother 
is high, although intrauterine transmission can also follow CMV reactivation in 
the mother. Cytomegalic inclusion disease in the newborn most often involves 
reticuloendothelial and central nervous systems with or without eye and 
auditory damage (reviewed by Alford and Britt, 1990; Ho, 1991). Perinatal 
infection can be acquired either at delivery from exposure to virus in the 
maternal genital tract, post-delivery through infected breast milk, or by nursery 
spread. Infection is usually sub-clinical although symptomatic infection such as 
pneumonitis may occur as a relatively rare event (Ho, 1991). In young children 
aged under 7 years, CMV infection may cause hepatitis or respiratory infection 
(Alford and Britt, 1990). In adults CMV may also be transmitted by sexual 
contact, although other routes such as oral contact are more important.
CMV infection in older children and adults can result in a mononucleosis 
syndrome, most commonly following primary infection, but less frequently as a 
result of reactivation or reinfection. CMV mononucleosis can also occur 
following blood transfusion either as a primary or reactivated infection. 
Infectious mononucleosis (IM) can be defined as an acute febrile illness 
characterised haematologically by lymphocytosis of 50% or more, of which 10% 
at least are atypical, and serologically by the presence of heterophile antibody
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determined by the Paul-Bunnell test (discussed 4.1). The clinical course of 
CMV mononucleosis is usually mild and a proportion of infectious 
mononucleosis (IM)-like cases are attributable to CMV infection.
Infection with CMV either primary, reactivated or by reinfection can result in 
more severe illness in immunocompromised persons. Populations at greatest 
risk are those receiving immunosuppressive therapy such as organ transplant 
patients or cancer patients, and persons with acquired immune deficiency 
syndrome (AIDS). Clinical illness can include a mononucleosis syndrome, 
pneumonia, and chorioretinitis, especially in AIDS patients (Alford and Britt, 
1990).
The most specific method for establishing a diagnosis of CMV infection is virus 
isolation (Stagno ef a/., 1981; Alford and Britt, 1990). A disadvantage with this 
technique is the time required to successfully isolate virus. However, the use of 
monoclonal antibodies to specific CMV proteins in the Detection of Early 
Antigen Fluorescent Foci (DEAFF) test has provided a more rapid detection 
system for CMV in short-term tissue culture or biopsy samples. The 
polymerase chain reaction assay can be used to detect CMV in different clinical 
samples such as peripheral blood and urine. The presence of CMV IgM 
antibodies is also good evidence of primary infection and a significant rise of 
CMV IgG antibody titres in sequential serum samples may imply recurrent CMV 
infection. Reinfection can be distinguished from reactivation by restriction 
enzyme analysis of viral DNA indicating involvement of different viral strains.
Serological surveys have proved useful as a means of studying the 
epidemiology of CMV (reviewed by Alford et al.t 1981). CMV is acquired 
commonly during childhood. Rates of infection can vary according to locale, 
and even between different age and socioeconomic groups within the same 
geographical location. Rates of infection are influenced by both hygeine and 
closeness of contacts within population groups. Climate and season do not 
appear to affect infection rates.
(iv) Epstein-Barr virus
EBV is an enveloped icosahedral virus that contains a 172 kilobase pair DNA 
genome (Baer et al., 1984). EBV was originally discovered in 1964 by Epstein 
and colleagues who reported the ultrastructural demonstration of a herpes-like
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virus in lymphoblastoid cell lines (LCLs) established from Burkitt's lymphoma 
(BL) explants (Epstein et al., 1964). Burkitt suggested that a particular 
lymphoma , which took his name and was the most common tumour affecting 
children in certain parts of East Africa, might be caused by a virus (Burkitt, 
1962). Since the initial visualisation of EBV in these cultures, the life cycle, 
biological properties, epidemiology, and disease associations of this virus have 
been extensively studied.
EBV, like other herpesviruses, can produce either silent or symptomatic primary 
infection. Primary infection usually occurs during childhood (reviewed by Evans 
and Niederman, 1989) and the virus persists in the host for life. The vast 
majority of childhood infections are either asymptomatic or associated with mild, 
non-specific upper respiratory tract symptoms. Reactivations, which are rarely 
symptomatic, may be reflected by increased virus in saliva and a rise in 
antibody titres to EBV antigens. The classical clinical syndrome associated with 
primary EBV infection is IM (Henle et al., 1968) which is most commonly seen 
in adolescents and young adults. The mononucleosis is a polyclonal 
transformation of B cells (Brown et al., 1984) and the majority of clinical 
manifestations of IM are attributable to immune responses to the proliferating B 
cells. Serial analysis of T and B cell populations in IM patients have shown that 
there is an increase in B cell numbers in the first week of illness which returns 
to normal after several weeks. The number of T cells reaches its peak after the 
second week and remains high for over a month (Mangi et al., 1974). The 
increased B cell numbers are likely to represent EBV-induced proliferation and 
the increased T cells reflect an immunological response against the virus. 
Atypical lymphocytes, primarily T cells are found in the blood during IM 
(Sheldon etal., 1973).
Viral transmission in adults requires intimate salivary contact. Transmission by 
blood transfusion has also been noted (Gerber et al., 1969). The main site of 
entry of EBV following exposure to an infectious fluid such as saliva, is the 
oropharynx. The virus replicates in many epithelial compartments such as the 
salivary glands and buccal and pharyngeal epithelial cells (reviewed by Miller, 
1990). A range of viral antigens consisting of latent, early and late gene 
products have been detected in oropharynx epithelia indicating a probable site 
of infectious virus production. Virus produced in the oropharynx can infect B 
cells that circulate through this anatomical site or alternatively be secreted in 
saliva. Around 15-20% of normal seropositive individuals will secrete EBV at
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any one time (Strauch et al, 1974), although if saliva is concentrated before 
testing for EBV, the majority of saliva samples are EBV positive (Yao et al.,
1985). This would suggest that the oropharynx is a site of chronic productive 
infection rather than a site of EBV latency. The virus has also been detected in 
vaginal secretions and cervical epithelial cells although the role of sexual 
contact or mother to infant transmission during delivery is not known (Sixbey et 
al., 1986).
Recent studies favour the concept that the virus persists in the host through 
carriage in B cells, mainly in a non-productive, latent state. Two lines of 
evidence suggest this. The first is that treatments including irradiation and 
cytotoxic drugs that are used in patients receiving bone marrow transplants 
eradicates EBV from the host, most probably by destroying the cellular 
compartment where the virus is latent (Gratama et al, 1988). Haemopoietic 
cells are most affected by such treatment. Secondly, shedding of EBV in saliva 
is eliminated in persons treated orally with the antiviral drug acyclovir. The 
virus however, remains detectable in the B cell population (Yao etal., 1989).
A property of EBV is its ability to infect and immortalise resting B cells in vitro to 
produce LCLs. This process has been proposed to occur in two stages (Miller,
1990). The first is the triggering of B cell activation following binding of the virus 
to the cell via the C3d complement receptor (CD21). The second phase 
requires the expression of EBV latent genes and results in a permanent 
blastogenesis of the B cell. A number of EBV genes are expressed in LCLs. 
These are the latent genes encoding six EB nuclear antigens (EBNAs), latent 
membrane protein (LMP)-1, 2a and 2b, and two small EBV-encoded RNAs 
(EBER-1 and EBER-2).
The role of expression of each of these latent genes is an area of intensive 
study (reviewed by Knutson and Sugden, 1989; Kieff and Liebowitz, 1990). 
The in vitro infection of B cells by EBV results in the expression of latent gene 
products and continuous cell growth. Changes in the phenotype of the cell also 
occurs with the upregulation of cellular activation markers such as CD23 and 
adhesion molecules. The expression of the cellular oncogene, bcl-2, which 
protects cells from programmed cell death, is also induced. The transfection of 
individual genes into B cells has facilitated the identification of the gene 
products responsible for these growth and phenotypic changes. EBNA-2 and 
EBNA-3c have been shown to upregulate CD23 (Wang et al., 1987; Wang et
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al., 1990) which is thought to be critical in the production of LCLs. LMP-1 has 
been shown to upregulate bcl-2 and adhesion molecules as well as CD23 
(Henderson etal., 1991; Wang etal., 1990). LMP-1 has also been reported to 
transform rat fibroblast cell lines (Wang et al., 1985) and can protect B cells 
from apoptosis by induction of bcl-2 (Gregory et al., 1991). Thus, EBNA-2 and 
LMP-1 appear to be essential for B cell immortalisation. In agreement with this 
is the fact that viral strains, such as P3HR-1, which have a deletion spanning 
the EBNA-2 gene, are non-transforming. LCLs often contain a small fraction of 
cells spontaneously entering the lytic cycle. A switch from latency to replication 
can be activated in vitro by chemicals such as 1 2 -0 -tetradecanoyl phorbol-13- 
acetate (TPA) (Zur Hausen et al., 1978). TPA initiates the protein kinase C- 
mediated activation of transcription of the BZLF1 gene. The product of this 
gene is the ZEBRA protein which targets to the nucleus where it turns on the R 
protein encoding gene, BRLF1. Together ZEBRA and R proteins act 
coordinately to turn on the first EBV early genes (Kieff and Liebowitz, 1990).
Another pattern of gene expression during latency was identified in certain 
Burkitt's lymphoma cell lines which maintained a similar surface phenotype to 
BL tumour cells in vivo. In contrast to LCLs, which display the full range of 
latent gene products and spontaneous entry into the lytic cycle, these BL cell 
lines express only EBNA-1 (Rowe et al., 1987) and low levels of B cell 
activation markers and adhesion molecules (Gregory et al., 1988). Such BL 
cell lines do not enter the lytic cycle spontaneously, but this can be induced with 
TPA. It now appears that there exists a futher pattern of latency that is 
intermediate between that of BL cells and LCLs. A study by Rowe et al. (1992) 
examined the expression of latent genes in BL cell lines following stimulation 
with anti-immunoglobulin. BL cells could move directly to the expression of 
early lytic antigens without the expression of other latent genes. A second 
pathway in a population of cells was the activation of full latent gene expression 
and conversion to a cellular phenotype similar to LCLs. However, a third 
pathway of EBV gene activation was found which consisted of EBNA-1 and 
LMP expression with no induction of the lytic cycle. Rowe et al. (1992) have 
referred to the distinct forms of latent gene expression as latency (Lat) I, Lat II, 
and Lat III. Lat I corresponds to a BL-like cell, with expression limited to EBNA- 
1. Lat II refers to the pattern observed in cells which express EBNA-1 and 
LMPs. Lat III is used to describe cells expressing the full spectum of EBNAs 
and LMP such as LCLs. The circumstances under which Lat II expression 
occurs in vivo is unclear. The added expression of LMP may provide a
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proliferative advantage to EBV-infected B cells, although as detailed below, 
LMP is immunogenic and the target of cytotoxic T cells.
Immunity to EBV includes both a cell-mediated and humoral response. The 
proliferation of EBV-infected B cells is controlled by cellular immune 
mechanisms which include human leukocyte antigen (HLA) non-restricted 
natural killer cells and HLA-restricted cytotoxic T cells (reviewed by Rickinson,
1986). The target antigens of a protective cytotoxic T cell response can vary 
amongst individuals based on the presence of MHC class I alleles (reviewed by 
Kurilla, 1993). Thus, EBNA-2 is recognised efficiently by cytotoxic T cells in 
association with a number of alleles including HLA-A2 and -B7 whereas LMP-1 
peptides are presented by HLA-A24, -B8 , -B40 and -B51. Most individuals 
recognise several, but not the complete set of EBV latent gene proteins. There 
is no evidence that EBNA-1 is recognised by cytotoxic T cells. Thus, long lived 
B cells in vivo with latent gene expression restricted to EBNA-1 would allow the 
persistence of the virus in the host. Such cells would subsequently be 
recognised by cytotoxic T cells were their pattern of latency to move to Lat II or 
Lat III.
Neutralising antibody may play a role in limiting the spread of the virus from a 
site of oropharyngeal replication. Together, the cell-mediated and humoral 
responses suppress EBV-induced B cell proliferation and most oropharyngeal 
spread of the virus. The development of an effective cell-mediated immune 
response restricts IM to a self-limiting illness. However, fatal IM can occur 
rarely and in males may be linked to a genetic X-linked lymphoproliferative 
syndrome (reviewed by Purtilo et al., 1992). The host's immune control over 
EBV may also be affected by immunosuppressive treatment (Crawford et al.,
1986).
EBV-associated lymphoproliferative disease can occur in patients with either 
congenital or acquired immunodeficiency states. Acquired immunodeficiency 
may be caused by immunosuppressive drug therapy eg. Cyclosporin A in organ 
transplant patients or in persons with AIDS. Increased viral production in both 
epithelial and lymphoid compartments as a result of a deficiency in EBV 
immunosurveillance may lead to increased numbers of transformed cells and 
finally lymphoproliferative disease. In transplant patients, EBV-induced 
lymphoproliferation can result in oligoclonal B cell populations which may give 
rise to a clonal population with the features of frank lymphoma (Cleary et al.,
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1986; Miller, 1990). In AIDS patients, EBV-associated lesions can include 
diffuse polyclonal lymphomas, lymphocytic interstitial pneumonitis, and oral 
hairy leukoplakia (Greenspan etal, 1985).
EBV is linked to a number of malignancies in addition to BL, including non- 
Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), and nasopharyngeal 
carcinoma (NPC). The role of EBV in cancer is discussed later in this chapter 
(see 1.2.3.ii).
Serological investigations have provided much information on the epidemiology 
of EBV. The ability to detect antibodies to particular EBV antigens has allowed 
a more detailed interpretation of EBV serology. The specificities of EBV 
humoral immunity appear to alter in health and EBV-associated disease. EBV- 
viral capsid antigen (VCA) IgG antibodies usually persist for life following initial 
infection and their presence can be used as a marker for past exposure to the 
virus. Antibodies to EBV-early antigens (EA) are present transiently following 
primary infection and appear following episodes of viral reactivation. The 
presence of EBV-EA antibodies suggests ongoing viral replication (Ooka et al.,
1991). Patterns of EBV antibody reactivities have proved useful in 
demonstrating the association of EBV with disease and have been used to 
predict persons at high risk from the cancers BL and NPC (reviewed by Evans 
and De-Th6 , 1989; De-Th6  etal., 1989).
The detection of IgG antibody to EBV-VCA by indirect immunofluorescence 
assay (IFA) has been the main technique used to examine EBV 
seroepidemiology (Evans and Niederman, 1989). EBV infection can occur very 
early in life, shortly after the disappearance of maternally-derived antibodies. 
The age at which primary infection occurs can vary with geographical locale 
and socioeconomic group within the same area. Primary infection later in life, 
delayed until the second or third decades often results in the development of 
IM. Primary infection can occur at any age including the elderly, where EBV- 
induced IM has been reported (Kirov etal., 1989).
(v) Human herpesvirus-6
Salahuddin et al. (1986) at the National Cancer Institute, National Institutes of 
Health, USA, reported the isolation of HHV- 6  in studies that were initiated to try 
and discover a virus or viruses involved in AIDS-associated lymphoma and
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haematological malignancies. The authors described the identification of a new 
herpesvirus which they termed human B-lymphotropic virus (HBLV), after its 
apparent B cell tropism in cord blood lymphocyte cultures. Virus was isolated 
from the peripheral blood leukocytes of six individuals. Two of these individuals 
were infected with HIV, one with AIDS-related lymphoma and the other with 
dermatopathic lymphadenopathy. The other four isolates reported were 
derived from, a person with angioimmunoblastic lymphadenopathy, one with 
cutaneous T cell lymphoma, one with immunoblastic lymphoma, and one with 
acute lymphocytic leukaemia. Molecular analysis of the viral genome confirmed 
HBLV as a novel herpesvirus (Josephs etal., 1986).
In 1987, Downing etal. and Tedder etal. independently reported the isolation of 
herpesviruses from AIDS patients, and antigenic and molecular analyses 
suggested these were closely related or identical to HBLV. However, these two 
studies suggested that T cells rather than B cells were the target cell population 
for HBLV infection of cord blood lymphocytes, a fact confirmed for the original 
isolates by Lusso etal. (1987). These findings prompted a renaming of HBLV 
to HHV- 6  in accordance with the internationlal nomenclature of herpesviruses 
(Ablashi et al., 1987). In 1988, further HHV- 6  isolates were made from 
immunocompromised individuals (Agut etal., 1988; Lopez etal., 1988).
The ability to isolate HHV- 6  from patients with lymphoproliferative disorders led 
to the proposition that HHV- 6  could somehow be aetiologically linked to these 
disease groups. Studies to define more clearly the association of HHV- 6  with 
haematological malignancies were therefore initiated, including the studies 
reported in Chapters 2 and 3.
1.2 VIRUSES AND MALIGNANCY
Viruses from 7 different families have been associated with malignancies 
occurring either in the natural host of the virus or in experimental animal 
models. These virus families and associated cancers are described in Table 
1.2.1.
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Table 1.2.1
TUMOUR VIRUS GROUPS AND ASSOCIATED CANCERS
TAXONOMIC GROUP
I. RNA VIRUSES
1. Retroviruses 
Oncoviruses
2. Flaviviruses (Hepatitis C Virus)
II. DNA VIRUSES
2. Hepadnaviruses
3. Polyomaviruses
4. Papillomaviruses
5. Adenoviruses
6 . Herpesviruses
7. Poxviruses
ASSOCIATED CANCERS
Haematopoietic cancers 
involving lymphoid, myeloid, or 
erythroid cells; various 
sarcomas and carcinomas 
Hepatocellular carcinoma
Hepatocellular carcinoma 
Various solid tumours 
Papillomas and carcinomas 
Various solid tumours 
Lymphomas and carcinomas 
Myxomas and fibromas
Table of tumour virus groups and associated cancers (Benjamin and Vogt, 
1990).
1.2.1 Action of viruses in tumour development
(i) RNA viruses
All RNA viruses that are oncogenic belong to the retrovirus subfamily, 
oncoviruses. The mechanisms however by which these viruses can promote 
cell transformation are varied. At present there are 3 proposed mechanisms by 
which retroviruses induce tumours and transform cells.
a. Transducing retroviruses
Transducing retroviruses contain within their genome a gene that codes for a 
viral oncogene. The product of these oncogenes (oncoproteins) can influence 
the control of cell growth and differentiation. The viral oncogenes are derived 
originally from cellular oncogenes that have become incorporated into the viral 
genome, usually with the subsequent loss of viral sequences. The normal 
cellular equivalent, proto-oncogenes, are not normally oncogenic, although 
structural or functional changes can reveal the transforming potential of these 
genes. In some instances, dysregulated expression of the oncogene is 
sufficient to induce transformation. Structural and functional changes in the 
viral oncogene are likely to have resulted from deletions and point mutations in 
its sequence. Many different animal retroviruses have been found to contain 
viral oncogenes and the cellular homologue of the oncoprotein identified 
(reviewed by Benjamin and Vogt, 1990). The cellular homologue of viral 
oncoproteins include a growth factor, growth factor receptors, molecules 
involved in signal transduction, and transcription factors, all proteins that are 
important in the regulation of cell growth. No transducing retroviruses are 
known to be human pathogens.
b. Cis-activating retroviruses
This class of RNA tumour viruses do not contain viral oncogenes, but induce 
tumours if insertion into the host genome as a provirus occurs at particular sites 
and subsequently deregulates the expression of a cellular proto-oncogene. 
Amongst cis-activating retroviruses are murine leukaemia virus and avian 
leukosis virus (ALV). Feline leukaemia virus (FeLV) can either be cis-activating 
or transducing as FeLV/myc recombinant viruses have been reported (Neil and 
Onions, 1985). ALV can cause a B cell tumour in young chickens that over
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expresses the proto-oncogene c-myc. The provirus has been found to insert 
close to the c-myc proto-oncogene (Hayward et al., 1981). Friend murine 
leukaemia virus is also classed as a cis-activating retrovirus. This virus causes 
erythroid malignancies which may occur in two stages. Virus stocks contain 
two agents, a replication-competent and a replication-defective virus called 
spleen focus forming virus (SFFV), with the former acting as a helper virus for 
the latter. SFFV encodes an altered env protein, gp55, which binds to the 
erythropoietin receptor and may induce proliferation (Li et al., 1990). The 
presence of helper virus increases the probability of a second event whereby 
SFFV integrates into preferred sites of the host genome. One site has been 
termed Spi-1 and the virus has also been found to integrate into the cellular 
proto-oncogene p53 gene (David etal., 1988) inactivating it. This cellular proto­
oncogene functions as a tumour suppressor gene (Levine et al., 1991). To 
date no cis-activating retroviruses have been found in humans.
c. Trans-activating retroviruses
In this model a non-structural virus-coded protein acts as a transcriptional 
regulator to alter the expression of one or more genes important in the control 
of cell growth and thus induce cell transformation. A virus that could function in 
this manner is human T-lymphotropic virus type 1 (HTLV-1). HTLV-1 is 
associated with adult T cell leukaemia/lymphoma (ATLL), a malignancy of T cell 
origin. Of the possible viral oncogenes encoded by HTLV-1, the best studied is 
tax. The tax protein is a transcription factor and has been shown to induce a 
high level of expression of both interleukin-2 (IL-2) and the IL-2 receptor alpha, 
granulocyte-monocyte colony-stimulating factor, and the proto-oncogene c-fos 
(reviewed by Hjelle, 1991). It is possible that tax is involved in the initiation of 
transformation by mediating the presumed autocrine stimulation of T cells. The 
majority of persons infected with HTLV-1 do not develop ATLL and the period 
from time of infection to malignancy is a number of years. Therefore, further 
and as yet ill-defined changes such as a chromosomal abnormality may result 
in the emergence of a monoclonal T cell blast.
(ii) DNA viruses
DNA viruses associated with malignancies are distributed among six family 
groups (Table 1.1.1). Polyomaviruses and adenoviruses do not cause tumours 
in their natural hosts, although the mechanisms by which they can induce
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transformation have been extensively studied in tissue culture and experimental 
animals. Viruses from the other 4 groups have been linked to naturally- 
occurring cancers, both benign and malignant, in humans and animals.
a. DNA viral oncoproteins
Studies on adenovirus and polyomavirus have shown that these viruses code 
for oncoproteins that are directly associated with cell transformation. The 
middle T antigen of simian virus 40 (SV40) interacts with the cellular proto­
oncogene Src. This interaction stimulates the protein kinase activity of Src and 
disrupts its normal regulatory role (Benjamin and Vogt, 1990). Polyomaviruses 
(SV40 large T antigen), adenoviruses (E1B and E1A proteins) and 
papillomaviruses (E6  and E7 gene products) code for proteins that stably bind 
and inactivate two cellular nuclear phosphoproteins, p53 and retinoblastoma 
gene product (Rb) which normally function as tumour suppressor genes (Levine 
etal., 1991). Thus, in experimental systems, DNA viruses have been shown to 
carry viral oncogenes.
b. Viral-mediated evasion from immunosurveillance
Viruses could facilitate the development of malignancies by interfering with the 
recognition of the tumour cells by the immune system (reviewed by Maudsley 
and Pound, 1991). Recognition of virally-infected cells by the immune system, 
predominantly cytotoxic T cells, relies on the presentation of viral antigen in the 
form of short peptides in association with MHC class I molecules. Interference 
in this presentation process would lead to the evasion of the infected and 
potential tumour cell from immune-mediated lysis. Adenovirus type 12 E1A 
antigen acts at the level of transcription to decrease constitutive as well as 
cytokine-induced MHC class I expression. Adenovirus type 2 E3 protein 
decreases MHC class I expression by interfering in the transport of the 
molecule to the cell surface. Viruses may also alter the cell surface expression 
of adhesion molecules which are important in the recognition of infected cells 
by the immune system. EBV positive BL cell lines exhibited a down regulation 
af 2 adhesion molecules, leukocyte functional antigen-3 and intercellular 
adhesion molecule-1 (Gregory et al., 1988). As a result tumour cells may 
escape virus-specific immunosurveillance.
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c. Indirect action of viruses
Viruses such as HIV may be involved in tumourogenesis indirectly by creating 
an immunoincompetent state. The impairment of the immune system could 
result in the failure of immunosurveillance to check the growth of malignant 
cells. Alternatively, the destruction of cells of the immune system by a virus 
could lead to the compensatory recruitment of haemopoietic precursor cells. 
This increased proliferation would provide a greater chance of mutational 
changes leading to the emergence of a tumour cell. In this respect certain 
types of cancer such as lymphomas occur with increased frequency in persons 
with AIDS (Beral et al., 1991). In the absence of a viral-mediated 
immunosuppression, immunosurveillance may be affected by other 
environmental factors such as chemical agents (Newcombe, 1992; Mueller et 
al., 1992) or as a result of another disease process such as rheumatoid arthritis 
(Porter et al., 1991) and subsequently increase the risk of lymphoma 
development.
1.2.2 Association Of Viruses With Cancer
One of the most difficult problems in studying the involvement of viruses in 
disease is encountered in the demonstration of a causal relationship between 
virus infection and malignancy. In humans, the time period between initial 
infection and the appearance of a tumour may be a number of years and only a 
small percentage of persons with the virus will develop the malignancy. This 
would seem to be the case for HTLV-1 and ATLL. Only a small percentage of 
HTLV-1 infected persons develop ATL which may take many years after 
infection to occur (Hjelle, 1991). Transducing retroviruses that do produce 
tumours rapidly following infection are not known to be human pathogens. Viral 
involvement is also likely to be one step in a multi-step process that leads to the 
emergence of a tumour cell. Other factors may include chromosomal 
abnormalities or environmental agents. Thus, the demonstration of a cause 
and effect relationship between the virus and malignancy becomes 
complicated. Amongst the different families of viruses, those with a capacity for 
persistence following primary infection such as herpesviruses, hepadnaviruses, 
retroviruses, papovaviruses, and adenoviruses are the most likely candidates 
for the causation of certain cancers and chronic diseases.
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In animals, the oncogenic nature of a virus can be demonstrated experimentally 
by its ability to induce tumours and mechanisms of transformation can be 
studied in detail. However, investigations of a more observational nature are 
required for the study of viral involvement in human cancers. The design of 
studies to determine viral elements in the causation of human malignancies has 
been outlined by Evans (1989) and include different approaches.
One method involves the use of animal models to identify the oncogenic 
potential of human viruses. A drawback to this approach is that the results are 
not necessarily indicative of such capabilities in the natural human host.
A second method is to study the pattern of the immune response to the virus. 
Immune parameters can be compared between cancer patients and controls to 
highlight differences in the host/viral balance in health and disease. Such 
immune system markers include the presence and titre of antibody to viral 
antigens or the strength of the cell-mediated response to the virus.
A third, and perhaps the most important approach is the demonstration of the 
virus, either viral nucleic acid or viral proteins, in tumour cells. This has only 
become feasible over the last decade with the development of suitable viral- 
specific molecular and antibody probes.
All three of the above approaches have been applied in studies aimed at 
dissecting the role of human viruses in a range of malignancies. EBV, hepatitis 
B virus, papillomaviruses, and HTLV-1 have consistently been linked to specific 
malignancies (reviewed by Zur Hausen, 1991). The transforming capabilities of 
human herpesviruses have recently been reviewed (Knipe, 1982; MacNab,
1987). All six human herpesviruses including HHV- 6  (Razzaque, 1990) have 
been shown to transform cell lines in vitro which induce tumours when injected 
into mice. EBV only has been shown to contain a transforming protein (LMP) 
(Wang et al., 1985). However, herpesviruses that lack a viral oncoprotein or 
specific DNA sequence that transforms cells, may play a role in oncogenic 
transformation by activating cellular genes, as has been proposed for HSV and 
CMV (MacNab, 1987).
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1.2.3 Association Of Human Herpesviruses With Malignancy
(i) HSV and human malignancies
HSVs have been associated with human cancers of several sites. The majority 
of investigations have examined the role of HSV-2 in squamous cell carcinoma 
of the cervix (reviewed by Rawls, 1985). An early observation in the 
epidemiology of cervical carcinoma was the demonstration that the tumour 
occurred very rarely in nuns and with a greater frequency in married as 
compared to unmarried women. This observation led to the proposition that a 
sexually transmitted disease was somehow involved in the development of 
cervical cancer (reviewed by Melnick et al., 1989). The association of viruses 
as aetiological agents was supported by the detection of preinvasive cervical 
cancer cytological abnormalities in women with a past history of genital herpes 
infection which is mainly attributable to HSV-2.
A large number of serological studies found statistically significant associations 
between antibody to HSV-2 and cervical carcinoma (Rawls, 1985; Whitley,
1990). Women with cervical cancer as a group have consistently shown either 
higher seroprevalence or antibody titres to HSV-2 compared to control 
populations. The demonstration of a direct association of HSV-2 with cervical 
cancer was difficult. HSV-2 infection could occur in a similar population and at 
a similar frequency as another agent because of certain lifestyle factors which 
is involved in the genesis of cervical carcinoma.
The ability to detect HSV-1 or HSV-2 nucleic acid sequences or HSV-encoded 
proteins inconsistently in cervical cancer using a number of methodological 
approaches questions the role of HSVs in this malignancy (MacNab, 1987; 
Whitley, 1990). More recently the detection of particular genotypes of HPV in 
cervical cancer indicates a more important role for this group of viruses (Zur 
Hausen, 1991). The fact that HPVs can also be sexually transmitted (Ho et al., 
1993) helps explain the epidemiological link between HSVs and cervical cancer. 
The potential role of HSV-2, which has transforming capabilities in vitro 
(Tevethia, 1985), as a cofactor in cervical cancer remains to be clarified.
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(ii) EBV and human malignancies
EBV, the primary aetiological agent of IM, has also been linked to a range of 
neoplastic conditions including BL, NPC, HD, and NHL.
a. Burkitt's lymphoma
The initial isolation of EBV from a BL-derived lymphoblastoid cell line suggested 
an association between the virus and the malignancy (Epstein etal., 1964). BL 
is a malignant lymphoma that belongs to the high-grade malignant lymphoma, 
small noncleaved cell group (Rosenberg, 1982). BL tumour cells are a 
monomorphic outgrowth of undifferentiated B cells, all of which are positive for 
immunoglobulin heavy chain expression and commonly display light-chain 
expression (Evans and De-Thb, 1989).
BL is described as endemic or non-endemic based on its geographical 
distribution. Endemic BL (eBL) or African BL occurs with high incidence in 
equatorial Africa and Papua New Guinea where it is the commonest childhood 
cancer (Burkitt, 1983). The distribution of eBL is identical to the geographical 
distribution of holoendemic Plasmodium falciparum malaria suggesting a role 
for malarial infection in BL development. Sporadic BL (sBL) or non-African BL 
is seen in older children and adults in other areas of the world. Sporadic BL 
presents predominantly with intra-abdominal tumours whereas eBL classically 
involves the jaw and abdomen. Sporadic BL and eBL are histologically and 
cytologically identical. BL is considered to be a model for the multi-step 
development of a cancer and, as such, cofactors have been recognised that are 
associated with the development of the tumour (Klein, 1983). Epidemiological 
studies have highlighted the involvement of three factors that are important in 
the development of the cancer.
Malaria: A factor that predisposes an individual to the development of eBL is 
malarial infection. Malaria is known to have a profound immunosuppressive 
effect and disrupt the efficacy of cell-mediated immunosurveillance (Weidanz, 
1982). In addition, antigens of Plasmodium falciparum may act as mitogens to 
B cells resulting in chronic antigenic stimulation. Such disruption could facilitate 
the emergence of the tumour cell of BL.
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Chromosomal translocations: A common cofactor in both eBL and sBL is the 
presence of a chromosomal translocation in the tumour cell population 
(Shiramizu et al., 1991). The translocation commonly results in the 
rearrangement of the c-myc proto-oncogene, a gene important in the regulation 
of cellular growth, from chromosome 8  to within the immunoglobulin heavy 
chain genes of chromosome 14. Other less common translocations involve the 
rearrangement of c-myc to either of the immunoglobulin light-chain gene sites. 
Each of the 3 translocations results in the activation and deregulation of the c- 
myc oncogene which is believed to be a crucial and necessary event in the 
pathogenesis of BL (Cory, 1986).
Role of EBV in BL: Similar to a chromosomal translocation, the involvement of 
EBV is associated with both eBL and sBL, although not in all cases. EBV 
involvement is almost always found in eBL and less frequently in sBL (Evans 
and De-Th6,1989). The association of EBV with BL has been demonstrated by 
both seroepidemiological and molecular approaches.
BL patients were found to have higher antibody titres to EBV-VCA compared to 
control populations. This is particularly a feature of eBL groups (Henle et al., 
1969). In American (sporadic) BL one study found 20% of cases lacked 
demonstrable EBV antibody and fewer cases displayed higher EBV antibody 
titres as compared to eBL cases (Evans and De-Th6 , 1989). The elevated 
antibody titres in BL appear to be restricted to EBV. The serology of other 
viruses in BL has not been researched in depth although one such study 
described antibody titres to HSV, CMV and measles virus as being similar 
either before or after the development of BL compared to controls (De-Thb et 
al., 1978). Children with EBV-VCA antibody titres at least fourfold above the 
geometric mean titre (GMT) of the normal population group have an increased 
risk of developing BL estimated to be approximately 30 times (De-Th6  et al., 
1978). Thus, there is strong serological evidence for a role for EBV in BL, 
particularly eBL.
Molecular studies provide further evidence for an association between EBV and 
the development of BL. Biopsies of BL from endemic cases commonly contain 
EBV detectable by hybridisation with EBV-specific DNA probes (Zur Hausen et 
al., 1970). For sBL, EBV DNA has been found in approximately 20% of cases 
(Ziegler etal., 1976). Tumour cells contain the complete EBV genome which is
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mainly in episomal form although integrated EBV DNA may also be present 
(Evans and De-The, 1989).
Relationship of cofactors in the pathogenesis of BL: The identification of 3 
cofactors closely associated with BL has led to predictions as to the 
pathogenesis of BL (Evans and De-The, 1989).
For eBL, it is thought necessary for EBV infection to occur early in life. During 
episodes of acute malaria, immunosurveillance including any EBV specific 
cytotoxic T cell response may be suppressed. EBV-induced B cell proliferation 
could result, aided by the mitogenic stimulation of B cells by antigens of 
Plasmodium falciparum. The resulting proliferation of B cells provides a greater 
opportunity for an abnormal cell to emerge following a specific chromosomal 
translocation and oncogene activation. In sBL, in the absence of malarial 
infection and possibly EBV involvement, the process is dependent on other 
factors that lead to B cell proliferation, chromosomal translocation and the 
development of BL.
b. Nasopharyngeal carcinoma
The most common nasopharyngeal cancer is NPC, a tumour of epithelial origin. 
NPC accounts for up to 90% of nasopharyngeal neoplasms in the USA and up 
to 98% in some areas of Asia (reviewed by Gaffey and Weiss, 1990). 
Histologically undifferentiated NPC is characterised cytologically by malignant 
cells with indistinct cytoplasmic borders resulting in a syncytial pattern of 
growth and a reactive inflammatory infiltrate consisting predominantly of 
lymphocytes. As has been determined for BL, there is good evidence of a viral 
aetiology for NPC.
The association of EBV with NPC is strong. EBV DNA is detectable in the 
majority of cases of undifferentiated NPC (Zur Hausen et al., 1970) and has 
been observed in differentiated forms of the carcinoma as well (Raab-Traub et 
al., 1987). On the basis that the episomal form of EBV can vary in size 
depending on the number of terminal repeats, it has been possible to 
demonstrate that clonal EBV is present in each NPC tumour. The presence of 
clonal EBV suggests that the virus was present in the progenitor tumour cell 
and argues for a direct role for the virus in the development of the malignancy 
(Raab-Traub and Flynn, 1986). The role of EBV in NPC is unclear.
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Reactivation of EBV from latency in the nasopharynx may represent the 
ultimate or penultimate step prior to the clinical onset of disease (De-The and 
Zeng, 1986).
There is a characteristic EBV antibody pattern associated with NPC. Patients 
with undifferentiated NPC have high EBV-VCA, EBV-EA and EBNA antibody 
titres. The presence of EBV specific antibodies of the IgA subclass in both 
serum and saliva may also identify persons at high risk from NPC and a rise in 
EBV specific IgA antibody titre is associated with advancing stages of the 
disease (De-The etal, 1989). The presence of elevated antibody titres to EBV- 
EA and of the IgA subclass may represent the immune response to reactivation 
of EBV and its replication in the nasopharynx prior to the development of the 
tumour. Recently, using a molecular serological approach, Littler et al. (1991) 
developed assays that detect antibodies to particular EBV-EA such as EBV 
thymidine kinase. Preliminary analysis found that antibodies to such antigens 
were useful predictors of NPC. As for BL, molecular and serological 
investigations have proved invaluable in elucidating the involvement of EBV in 
NPC.
Other factors that are associated with NPC development are less well defined. 
NPC has a worldwide occurrence although it is more common in regions such 
as the southernmost provinces of China. Influences such as genetic factors 
(De-The et al., 1989) or environmental factors may be important. Exposure to 
nitrosamines in salted fish or chemical compounds contained in certain plants 
which can affect EBV latency and replication (Ito, 1986) have been linked to 
increased NPC cases in particular geographical locations.
c. Non-Hodgkin's lymphoma
NHLs, predominantly of B cell origin, are common in immunodeficient patients 
and have been associated with EBV. A number of causes of immunodeficiency 
are possible including acquired immunosuppression of which the best example 
is AIDS. NHLs are found with increased frequency in persons infected with 
HIV. EBV has been detected in up to 50% of HIV-associated NHLs (Hamilton- 
Dutoit et al., 1991) and is found in the brain tissue of virtually all cases of AIDS- 
related primary lymphoma of the central nervous system (MacMahon et al.,
1991). The majority of HIV-associated NHLs also show evidence of c-myc
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gene rearrangements similar to the translocations present in BL (Groopman et 
al., 1986; Subar et al., 1988). '
Induced immunosuppression is most commonly encountered in allograft 
transplant recipients. In this group of patients the incidence of NHL can range 
from 1% to 15% (Cleary etal, 1986) and disease may regress with a reduction 
in immunosuppressive treatment. EBV has been detected in the majority of 
NHLs arising in post transplant patients. At present the exact nature of the role 
of EBV in such malignancies is unclear although EBV-induced B cell clonal 
expansion with concomitant genetic alterations has been proposed (Gaffey and 
Weiss, 1990).
A third immunosuppressed group are patients with congenital
immunodeficiencies. Such persons have an extremely high incidence of NHL 
compared to control populations. Congenital disorders include X-linked 
lymphoproliferative disease, Chediak-Higashi syndrome and severe combined 
immunodeficiency (Purtilo et al., 1992). Again, NHLs in these groups of
patients are usually of the B cell lineage and contain EBV genomic material.
The majority of EBV-associated NHLs are B cell lymphomas. However, EBV 
has been detected rarely in T cell malignant lymphomas such as
angioimmunoblastic lymphadenopathy (AILD) and peripheral pleiomorphic T 
cell lymphomas (Korbjuhn et al., 1993). However, EBV is not clonal in AILD 
and not all of the tumour cells contain the virus (R. Jarrett, personal 
communication). EBV has also been detected in Ki-1 (CD30)-positive 
anaplastic large cell lymphomas (Herbst etal, 1991a).
d. Hodgkin's disease
For over two decades seroepidemiological and more recently molecular 
evidence has suggested an association between EBV and HD (discussed 
Chapter 3).
Serological studies have been used to investigate the potential role of a number 
of viruses in HD, from which a consistent association of EBV with the disease 
has emerged. As a group, patients with HD have elevated antibody levels to 
EBV antigens including both EBV-VCA and EBV-EA (Levine et al., 1971a; 
Henderson et al., 1973; Henle and Henle, 1973; Evans et al., 1978). Raised
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antibody titres to EBV have been tound to precede the diagnosis of HD (Mueller 
et a/., 1989). These seroepidemiological studies were instrumental in 
highlighting the possible involvement of EBV in HD. However, only 30-40% of 
HD cases have been reported to exhibit elevated antibody titres to EBV (Evans 
and Gutensohn, 1984) which could signify a separate non-EBV associated 
subset. In such a subset of HD, the role of other viruses has to be considered.
Early molecular studies failed to detect EBV genomes in HD tumour biopsies 
(Pagano et a/., 1973; Lindahl et al., 1974). In 1987, Weiss et al. reported the 
detection of EBV genomes in 4 of 21 cases of HD by Southern blot 
hybridisation. More recently other studies have confirmed the detection of EBV 
nucleic acid sequences in HD biopsy material (Anagnostopoulos et al., 1989; 
Weiss et al., 1989; Gledhill et al., 1991). In combination with the serological 
studies the case for EBV involvement in at least a subset HD grows more 
convincing.
(iii) HHV-6 and human malignancies
Following the initial isolation of HHV- 6  from patients with immunosuppressive 
and lymphoproliferative disorders (see 1.1.4.5) two molecular studies were 
initiated to look for the presence of HHV- 6  DNA in biopsy tissues from patients 
with a variety of lymphomas and leukaemias. Josephs et al. (1988) detected 
viral sequences in 3 lymphomas of B cell derivation. These lymphomas were 
an EBV positive eBL, a follicular large cell lymphoma, and two EBV negative 
tumours from a patient with Sjogren's syndrome (SS). Jarrett et al. (1988) 
detected HHV- 6  specific DNA sequences in two cases of NHL from 117 tissue 
samples examined. One was a T cell lymphoma from a person with a 
preceeding history of angioimmunoblastic lymphadenopathy and the other was 
a B cell lymphoma that occurred in a patient with SS.
The molecular detection of HHV- 6  in a series of lymphoma patients provided 
further evidence for the involvement of HHV- 6  in lymphoid malignancies. It is 
interesting that both studies independently reported the detection of HHV- 6  in 
NHLs that occurred in the context of SS.
SS is an autoimmune disease first recognised by Henrik Sjogren that can occur 
either on its own or in association with another connective tissue disease. SS is 
characterised by the symptoms of dry eyes and mouth which result from the
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autoimmune-mediated destruction of lacrimal and salivary glands. A 
recognised consequence of SS is the increased risk of developing lymphoma, 
particularly B cell NHL (Kassan et al., 1978). The aetiology of this disease is 
unknown although factors such as viral infection have been proposed (Flescher 
and Talal, 1991). EBV has been linked to the pathogenesis of SS (Fox et al., 
1986b) and the association of EBV with NHL is well documented. The 
detection of HHV- 6  positive NHLs in SS patients could reflect the involvement 
of HHV- 6  not only in tumour development, but in the actual autoimmune 
disease itself.
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1.3 OBJECTIVE OF THE PROJECT
The objective of this project was to further characterise the relationship of HHV- 
6  with disease. Seroepidemiological investigations were adopted in order to 
investigate:
(i) The association of HHV- 6  with a range of human leukaemias and 
lymphomas. Such an experimental approach has successfully been used 
previously to highlight the association of EBV with BL, NPC and HD.
(ii) The role of HHV- 6  in IM-like illness. The majority of IM illness is attributable 
to primary EBV infection although less frequently other herpesvirus infections 
can result in this clinical outcome. Therefore, the association of HHV- 6  
infection with IM-like disease was investigated.
During the course of this project the isolation of a novel herpesvirus, HHV-7, 
was reported (Frenkel etal., 1990). The studies were extended to examine the 
seroepidemiology of HHV-7 in children and adults.
A final aim of the project was to examine the role of viruses in Sjogren's 
syndrome. Viruses have been associated with the pathogenesis of SS as well 
as the subsequent development of NHL. A novel in vitro model was designed 
with which to study viral involvement in SS.
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CHAPTER 2
THE SEROEPIDEMIOLOGY OF HHV- 6  FROM A CASE-CONTROL STUDY 
OF LEUKAEMIA AND LYMPHOMA
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2.1 INTRODUCTION
HHV- 6  was first isolated from 6  patients with lymphoproliferative disease and 
immunosuppressive disorders (Salahuddin et al., 1986). The virus was initially 
termed human B lymphotropic virus as it was thought to show a tropism for 
freshly isolated B cells. Initial serological studies suggested that the virus was 
of low prevalence in the population. Sera from the six persons from whom the 
viral isolates had been made reacted immunologically with each of the six 
isolates (Salahuddin et al., 1986). However, only 4 of 220 randomly selected 
healthy donors were seropositive.
Shortly afterwards Downing et al. (1987) and Tedder et al. (1987) reported 
further isolates of HHV- 6  which were derived from patients with AIDS. Tedder 
etal. (1987) found 18% of British blood donors were HHV- 6  seropositive by an 
indirect immunofluorescence assay when restricting positive scoring of sera to 
those with unambiguous staining. These original findings suggested a possible 
association between HHV- 6  and lymphoproliferative disease or 
immunosuppression. HHV- 6  appeared to have a low seroprevalence in the 
general population.
Since that time a number of laboratories have used a variety of techniques to 
investigate the epidemiology of HHV- 6  and determine its role in human disease. 
Seroepidemiological studies have been the most common approach.
Briggs etal. (1988) reported the prevalence of antibody to HHV- 6  by age. That 
study found the acquisition of HHV- 6  antibodies occurred early in life and that 
60% of children aged 2 years were seropositive. Antibodies, most probably 
maternally-derived, were usually detected at birth and declined in the first few 
months of life. Rates of seropositivity were at their lowest around 6  months of 
age and rose from this time, presumably as infants experienced primary 
infection. Fifty-two percent of healthy blood donors were seropositive. The 
authors also suggested that the serological response to HHV- 6  in females may 
differ from that in males.
Further serological studies confirmed a more widespread nature of HHV- 6  
infection than was initially proposed (Brown et al., 1988; Pietroboni et al., 
1988b; Krueger etal., 1988; Linde etal., 1988; Saxinger etal., 1988) with levels 
of HHV- 6  seropositivity in adult populations ranging from 63% to 97%.
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HHV- 6  has been detected by the polymerase chain reaction (PCR) in the saliva 
and peripheral blood in the majority of healthy persons (Gopal et al., 1990; 
Jarrett etal., 1990). Furthermore, HHV-6 -specific DNA and protein have been 
localised in major (Fox etal., 1990a) and minor salivary glands (Krueger etal., 
1990) using in situ hybridisation and immunohistological techniques. There is, 
therefore, good evidence that HHV- 6  persists following primary infection and 
that the salivary glands are a site of replication. Saliva is likely to be an 
important vehicle for transmission of HHV-6 . Two groups have reported the 
isolation of HHV- 6  from the saliva of healthy persons (Harnett etal., 1990; Levy 
etal., 1990a).
Virus isolation from the peripheral blood of healthy persons has proved difficult. 
It is likely that the virus can only be isolated from this source during primary 
infection or episodes of virus reactivation. A number of isolates have been 
obtained from the blood of HIV-1 infected individuals (Lopez et al., 1988; 
Pietroboni et al., 1988b). Yamanishi et al. (1988) demonstrated the frequent 
isolation of HHV- 6  from the peripheral blood of infants with exanthem subitum 
(roseola infantum) or sixth disease. The authors identified HHV- 6  
seroconversion in the sera of this group of children providing strong evidence 
for an aetiological role for HHV- 6  in this disease. This aetiological link has 
subsequently been supported by further studies (Takahashi etal., 1988; Asano 
etal., 1989; Enders et al., 1990; Kondo et al., 1990). Exanthem subitum is 
most commonly seen in infants under the age of 2, the age group where HHV- 6  
primary infection is most likely to occur. More recently, HHV- 6  has been 
proposed as a major cause of acute febrile illness in young children 
(Pruksananonda etal., 1992).
Virus isolation, seroconversion, the presence of HHV-6 -specific IgM class 
antibodies and a rise in IgG antibody titres have been used to study the 
association between HHV- 6  and a range of clinical presentations in adults and 
children. In adults, reports suggest that HHV- 6  related disease may range from 
unapparent infection or mild afebrile illness with non-specific symptoms 
(Niederman et al., 1988) to IM-like symptoms and fatigue (Kirchesch et al.,
1988). HHV- 6  infection has also been associated with hepatitis (Dubedat and 
Kappagoda, 1989; Ward etal., 1989; Irving and Cunningham, 1990; Steeper et 
al., 1990; Asano et al., 1990; Tajiri et al., 1990) and chronic fatigue syndrome 
(Ablashi etal., 1988).
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The original association of HHV- 6  with lymphoproliferative disease was 
supported by later studies identifying HHV-6 -specific DNA sequences by 
Southern blot hybridisation in tissue samples from patients with lymphoid 
malignancies (Josephs et al., 1988; Jarrett et al., 1988). These studies 
however, could provide no information as to the cellular source of the virus in 
the tissue biopsy. In addition, Ablashi et al. (1988) reported higher HHV- 6  
antibody titres in African BL and HD, but not in NPC and chronic lymphocytic 
leukaemia (CLL). Biberfeld et al. (1988) also found higher HHV- 6  
seroprevalence in HD.
HHV- 6  is not the first virus to be associated with HD. Since 1970, serological 
studies have linked EBV with HD (Johansson et al., 1970; Levine etal., 1971a) 
and molecular studies have recently provided stronger evidence for a role of 
EBV in at least some cases of HD (Weiss et al., 1987). Epidemiological 
evidence supports the hypothesis that HD has a viral aetiology particularly in 
young adults (Gutensohn and Cole, 1980). It is possible that more than one 
virus could be involved in HD and based on the epidemiology of the 
malignancy, MacMahon (1966) proposed that multiple aetiologies may be 
present.
One of the drawbacks in the use of serology when investigating the association 
of HHV- 6  with disease is the fact that over 50% of the healthy population of the 
UK is seropositive (Briggs et al., 1988). Therefore, the use of case-control 
seroepidemiological studies is necessary.
In order to investigate any association of HHV- 6  seropositivity and antibody titre 
with haematological malignancies, I have screened serum samples from 
appropriate groups (Clark et al., 1990). An epidemiological case-control study 
of leukaemias and lymphomas was conducted in Yorkshire between 1980 and 
1986 to examine factors involved in the aetiology of these malignancies 
(Bernard et al., 1987). Sera were stored from the majority of cases and 
controls to allow epidemiological data to be combined with serological 
investigations.
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2.2 MATERIALS AND METHODS
2.2.1 Source Of Sera
Sera from 477 cases of leukaemia/lymphoma and 463 controls were available 
for analysis. The sera were coded prior to dispatch to the LRF Virus Centre in 
Glasgow from the LRF Clinical Epidemiology Centre in Leeds. Staff in Glasgow 
were blind to the case-control status of each sample. The cases were a cross- 
section of adults aged over 14 years diagnosed while resident in the Yorkshire 
Health Region between 1980 and 1986. They were interviewed and blood 
taken as soon as possible after diagnosis. Controls were selected during the 
same time period from hospital in-patients with a wide variety of non-malignant 
conditions. The original epidemiological study from which these case and 
controls were derived has been analysed by disease subtype: HD (Bernard et 
at., 1987), NHL (Cartwright etal., 1988b), chronic lymphocytic leukaemia (CLL) 
and malignant lymphocytic leukaemia (MLL) (Cartwright et at'., 1987), acute 
myeloid leukaemia (AML) (Cartwright etal., 1988a), chronic myeloid leukaemia 
(CML) (McKinney etal., 1990) and acute lymphoblastic leukaemia (ALL).
After the initial survey, a further group of HD sera and controls from the original 
epidemiological study were analysed. The second group of sera were derived 
to augment the original data and involved sampling which favoured persons 
without siblings in both the HD cases and controls.
2.2.2 Tissue Culture
A sub-clone of the Jurkat cell line, J JHAN, was propagated in RPMI 1640 
supplemented with 400U/ml penicillin, 400pg/ml streptomycin, 2mM L- 
glutamine (complete medium) and 10% heat-inactivated fetal calf serum (FCS) 
(heat-inactivated at 56°C for 30 minutes) (all Life Technologies). Cells were 
split twice a week at a ratio of 1:5 or resuspended at 5x10 ^ cells/ml by total 
medium replacement, gassed with 5% CO2  and incubated in sealed tissue 
culture flasks (Costar) at 37°C.
The AJ strain of HHV- 6  (Tedder et al., 1987) was grown in J JHAN cells. Virus- 
infected cells were passaged onto uninfected J JHAN cells at a ratio of 1:10. 
Viral infection was passaged when between 50-60% of the cells appeared 
infected. Infection was judged by the number of balloon-like and large cells in
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the culture compared to uninfected J JHAN cells. All tissue culture work was 
carried out in a Class II Microbiological Safety Cabinet (Envair or Medical Air 
Technology).
2.2.3 Cell Stocks
Uninfected and HHV- 6  infected J JHAN cells were pelleted by centrifugation at 
250g for 5min in a Beckman GPR benchtop centrifuge. Cells were 
resuspended at 3-5x10® cells/ml in freeze-down medium (complete medium 
containing 20% FCS plus 10% dimethyl sulphoxide-DMSOXSigma). One 
millilitre aliquots in Nunc liquid nitrogen vials were placed in the vapour phase of 
a liquid nitrogen storage tank. After 24 hours the vials were immersed in liquid 
nitrogen and stored until required. Cell lines were recovered by retrieval of vials 
from the liquid nitrogen store and rapid thawing in warm water. Thawed cells 
were added slowly to 5ml complete medium plus 10%FCS, centrifuged, washed 
once, and resuspended in fresh medium.
2.2.4 HHV-6 Indirect Immunofluorescence Assay
The assay was a modification of the indirect immunofluorescence assay 
developed by Henle and Henle (1966) and similar to methods used in HHV- 6  
serological studies by Salahuddin etal. (1986) and Briggs etal. (1988).
(i) Preparation of antigen slides
Infected cells were harvested when approximately 50-60% of cells appeared 
infected. Cell debris was removed by density centrifugation. Twenty-five 
millilitres of cells in culture medium were layered onto 15ml Ficoll-Hypaque 
(Pharmacia) in a 50ml conical tube. The gradient was centrifuged at 900g for 
15min. The interface of the tissue culture medium and Ficoll-Hypaque was 
collected in as small a volume as possible, approximately 5ml, and washed 
twice in 30ml Hank's balanced salts solution (HBSS) (Life Technologies). Cells 
were resuspended at 2.5x10® cells/ml in either HBSS or phosphate buffered 
saline (PBS) (PBS without Calcium or Magnesium, Flow Laboratories or Life 
Technologies). Fifteen microlitres of cell suspension were spotted onto each 
well of a Teflon-coated 8 -well Multiwell slide (Flow Laboratories) and allowed to 
air-dry. Slides were fixed for 10min with ice-cold acetone (May and Baker) and
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stored at -20°C in air-tight slide storage containers until use. Slides were not 
stored for longer than 4 weeks.
(ii) Preparation of sera
Sera were pre-adsorbed with control J JHAN cells to remove non-specific 
antibody binding to J JHAN cellular antigens.
a. Preparation of J JHAN for pre-adsorption
Uninfected J JHAN cells were pelleted and resuspended in PBS or HBSS and 
washed once. The cell pellet, approximately 10^ cells, was resuspended in 1ml 
of PBS or HBSS in a 50ml polypropylene tube. Twenty millilitres of ice-cold 
acetone were added and incubated at 4°C for 5-10min. PBS or HBSS was 
added to a volume of 50ml and centrifuged. The cells were washed twice more 
in PBS or HBSS, resuspended at a final concentration of 1 0 ? cells/ml and 
stored at 4°C until use.
b. Adsorption of sera
A diluent consisting of HBSS plus 5% 0.45pm filtered (Gelman Sciences) horse 
serum (Flow Laboratories) and 0.1% sodium azide (Sigma) was used for the 
adsorption and dilution of sera. One hundred microlitres of acetone-fixed J 
JHAN cells were added to a 0.75ml microcentrifuge tube and pelleted at 
maximum speed in a MSE Microcentrifuge for 30sec. The supernatant was 
discarded. Thirteen microlitres of diluent and 2pl of test serum were added. 
Allowing for the volume of the pellet, the total volume was estimated to be 20pl. 
The pellet was resuspended by vortexing and incubated at 37°C for 40min with 
re-vortexing every 10min. The cells were pelleted as above and the 
supernatant (serum at a dilution of 1:10) stored at 4°C.
Positive and negative control serum samples were used in every assay and 
were adsorbed in a similar manner to test sera. The positive control was a 
serum sample from a member of the Department. The negative control was 
kindly provided by Dr. J. Fox, University College and Middlesex School of 
Medicine, London.
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(iii) Indirect immunofluorescence assay
Sera were initially screened at a dilution of 1:40. Ten microlitres were spotted 
onto wells of HHV- 6  antigen slides. Slides were incubated at 37°C for 40min in 
a moisture chamber then washed 4 times by immersion in PBS over 30min at 
room temperature. As much of the PBS was removed as possible without 
allowing the wells to dry out completely. The conjugate used was a mixed 
solution of purified fluorescein isothiocyanate (FITC)-labelled rabbit anti-human 
IgG heavy chain-specific and FITC-labelled rabbit anti-human IgM heavy chain- 
specific sera (Dako), at a final dilution of 1:25 in diluent. Ten microlitres of 
conjugate were added to each well and slides incubated at 37°C for 40min. 
The slides were washed as above. Slides were read with a Leitz Laborlux 
Ultra-Violet (UV) microscope using a x25 water immersion lens. Sera that 
exhibited any combination of granular, nuclear or cytoplasmic fluorescence 
were scored as positive. Sera scored positive at a dilution of 1:40 were diluted 
two-fold until the antibody end titre was reached. This was defined as the 
reciprocal of the serum dilution at which positive fluorescence was last seen.
2.2.5 Statistical Methods
The serology results were sent to the LRF Centre in Leeds where they were 
linked to the case-control epidemiological data set using the statistical package 
SPSSX (1983) and analysed by Dr. Freda Alexander. The percentage 
seropositive at each of the dilutions 1:40, 1:80, and 1:160 was compared in 
cases and controls, with cases split into leukaemias and lymphomas, and finally 
sub-divided into the 7 disease groups (NHL, HD, MLL, CLL, CML, ALL, and 
AML). Low-grade NHL (LG-NHL) and high-grade NHL (HG-NHL) were also 
distinguished. The analyses were restricted to these three dilutions as beyond 
this the numbers involved were too small for statistical testing. These analyses 
used logistic regression (McCullagh and Nelder, 1983; Payne et al., 1987); in 
each case indicator variables for age in 7 strata and sex were first forced into 
the model. The design of this study was case-control but not matched case- 
control. The original epidemiological survey utilised matching by general 
characteristics (age plus or minus 5 years and sex) to achieve an age-sex 
distribution comparable for cases and controls. The selection of sera for this 
study was based on availability of sera and no attempt was made to match sera 
on retrieval. The analytical method of choice was therefore stratification by age 
and sex. Statistical significance of the differences in proportions has been
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calculated using analysis of deviance with the asymptotic Chi-square 
distribution for the change in deviance. The regression co-efficients yield 
estimates of the odds ratio (OR) from which test-based confidence intervals are 
derived.
In addition, results at different dilutions have been combined by comparing 
GMTs for the groups. Analysis of variance was applied to log(GMT), and sex 
and age adjustments made as before. In each case the ratio of GMT in the 
case group to that in the controls was estimated and its statistical significance 
computed using the F-test (Snedecor and Cochran, 1980). In calculating GMT, 
sera negative at the lowest dilution can be omitted from the calculation (Evans 
and Gutensohn, 1984; Sohier et al., 1974) or allocated an arbitrary non-zero 
origin (Henderson et a!., 1973; Bray et al., 1983). Since this study contained 
substantial numbers of sera negative at the 1:40 dilution, the second solution 
was preferable. Results reported here use 1:12 as an origin which normalised 
the distribution of log(GMT) in the controls. Other alternatives between 1:1 and 
1:16 and omitting all negative sera were also analysed and it was confirmed 
that the results for ratios of GMT were not sensitive to the choice.
The data on the two HD sera and control groups were combined for analysis to 
investigate the effect of childhood social contact using sibship size on young 
and old age groups, with HHV- 6  antibody levels as an indication of exposure to 
common viruses.
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2.3 RESULTS
2.3.1 Reproducibility Of The HHV-6 IFA
Assay controls consisted of positive and negative serum samples included in 
each assay run. The IFA was scored by comparing the staining pattern of the 
positive control sera with test sera. Figure 2.3.1 displays the fluorescent 
staining patterns of HHV- 6  infected cells with the positive and negative control 
sera.
The antibody end titres of a number of sera did not vary when tested at different 
times with various batches of slides highlighting the reproducibility of the IFA. 
The IFA was reproducible between laboratories. Twenty sera were screened 
by Glasgow and Dr. J. Fox, University College and Middlesex School of 
Medicine, London, using HHV- 6  (AJ-strain) infected J JHAN cells. The results 
reported by the two laboratories were similar (data not shown).
2.3.2 Results Of The Statistical Analyses
Initially sera from 940 individuals were sent to the LRF Virus Centre in Glasgow 
and screened for HHV- 6  specific antibodies by an IFA. The sera tested were a 
subset of those obtained in the complete epidemiological study. Details of the 
cases and controls in the original study and the subset from which samples 
were analysed are shown in Table 2.3.1. Overall, cases from which serum 
samples were sent to Glasgow represented the age, sex and geographical 
distribution of disease groups in the original study and consequently the 
incidence of the disease in Yorkshire.
In the control group alone (total of 463 sera), seropositivity at a 1:40 serum 
dilution was placed at 55% (Table 2.3.2). Female controls displayed higher 
seropositivity than males (Fig. 2.3.2). Sixty-three percent of females were 
seropositive at 1:40 serum dilution compared with only 49% of males.
The age distribution of the cases and controls was structured into 7 categories. 
The age categories and the percentage of the study population within these age 
groups are shown in Figure 2.3.3. There was a bias towards older age groups. 
Of the cases and controls 26.5% were over the age of 70 years.
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Figure 2.3.1
HHV-6 IFA: STAINING PATTERN USING POSITIVE AND NEGATIVE
CONTROL SERA
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Figure 2.3.1 Immunofluorescent microscopy of HHV-6 infected J JHAN stained 
with: A. positive control serum; B. negative control serum (x250). Sera used at 
a 1:10 dilution.
Table 2.3.1
DISTRIBUTION OF ANALYSED CASE CONTROL SERA BY DIAGNOSTIC
SUBGROUP
Category Serum analysed Total No. interviewed*
(row%)
CASES:
NHL 103(24) 437
HD 98 (40) 248
MLL 38 (45) 85
CLL 101 (41) 245
CML 40(33) 122
ALL 32 (50) 64
AML 65 (40) 161
CONTROLS: 463 (20) 2442
TOTAL 940 (25) 3804
* Serum samples were not available for all interviewed subjects in the 
Yorkshire case control study
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Figure 2.3.2
HHV- 6  SEROPOSITIVITY BY SEX STATUS 
(controls only)
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Figure 2.3.2 Percentages of sera with antibody end titres from <40 to 1280, 
separated by sex. Slightly higher HHV- 6  seropositivity was observed in females.
Figure 2.3.3
AGE DISTRIBUTION OF CASES AND CONTROLS IN THE STUDY
POPULATION
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Figure 2.3.3 Percentages of cases and controls in age categories. There was a 
bias towards older age groups. Over half of the study population was aged 55 
years or over.
In the formal statistical analyses employing ORs, the lymphomas showed more 
evidence of seropositivity than the leukaemias, although the difference was not 
significant. Seropositivity in cases was significantly in excess of that in the 
controls at all three serum dilutions (1:40, 1:80, and 1:160). Amongst the 7 
disease groups, HD, NHL, and AML showed significantly increased HHV- 6  
seropositivity compared to controls at each serum dilution. When the analyses 
were restricted to NHL and a comparison made between low- and high- grade 
disease, only LG-NHL showed evidence of increased seropositivity compared 
with the controls. The results of the analyses are shown in Table 2.3.3.
When GMT ratios were analysed, similar results to the OR analyses were 
obtained (Table 2.3.3). Thus, lymphoma cases showed a higher GMT ratio 
than leukaemia cases, the difference between the two groups now attaining 
significance. Analysing by disease subtype AML, MLL, HD, and NHL had GMT 
ratios significantly greater than 1. For the latter group the effect was 
concentrated in LG-NHL. These values suggest HHV- 6  antibody titres are 
significantly elevated in these disease groups.
2.3.3 Analysis Of HHV-6 Serology In HD Based On Sibshio Size
The second batch of sera sent to Glasgow included a further 91 samples from 
HD cases. The seropositivity rate in this second group was 83.5% at a 1:40 
serum dilution compared to 77% for the first batch of HD sera, confirming 
increased HHV- 6  seropositivity in HD.
The two batches of HD sera and controls were combined for the analysis of the 
modifying effect of childhood social contact measured by sibship size. The risk 
factor of sibship size used either "no siblings" or "some siblings" as separate 
categories. In addition, the HD cases and controls were split into a younger 
(15-34yr) and older (34-84yr) age groups. Results from 189 HD cases and 195 
controls were available for analysis. Table 2.3.4 gives details of the results. 
There is some evidence from the GMT ratios for increased HHV- 6  antibody 
titres in younger HD cases, particulary those whose early life is likely to have 
lacked social contact.
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2.4 DISCUSSION
Utilising selected sera from an epidemiological case-control study of 
leukaemias and lymphomas conducted in Yorkshire between 1980 and 1986 
(Bernard etal., 1987), we tested for an association of HHV- 6  seropositivity and 
antibody titre with haematological malignancies.
In this study, 55% of the control population (total of 463) were seropositive at a 
1:40 serum dilution. We found higher antibody titres in females compared to 
males, a phenomenon that has previously been reported for other viruses 
including EBV (Biggar etal., 1981).
The large number of sera in the control group make this study one of the most 
extensive HHV- 6  seroepidemiology studies of the general population. The 
results of a number of other HHV- 6  serological surveys are summarised in 
Table 2.4.1. Most of the studies, including this one, utilised an HHV- 6  IFA, 
although HHV- 6  enzyme linked immunosorbent assays (ELISA) and anti­
complement immunofluorescence (ACIF) assays have been used.
HHV- 6  infection is common. More than half of every population tested has 
been seropositive. The different rates of HHV- 6  seropositivity existing among 
the study populations may be attributable to variations in methodology. The 
starting serum dilution used is the most important factor affecting rates of 
seropositivity. As would be expected, workers using 1:10 as the starting serum 
dilution reported higher seroprevalence rates than those using 1:40 (Table 
2.4.1). The HHV- 6  IFA may be more sensitive than an ACIF assay (Couillard et 
al., 1992) although it is not as sensitive as ELISA (Halprin etal., 1986; Saxinger 
et al., 1988). However, defining true negative sera has posed problems in the 
ELISA. IFA using lytically infected cell lines as a source of antigen generally 
appear to be more sensitive than assays utilising HHV- 6  infected umbilical cord 
blood mononuclear cells (CBMCs) (Table 2.4.1). This may be because IL-2, 
which has been shown to have an inhibitory effect on the replication of HHV- 6  
in thymocytes (Roffman and Frenkel, 1990), is used in maintaining CBMCs in 
culture. Different viral strains may replicate more efficiently in different cell 
culture systems (Levy et al., 1990b) and the amount of viral antigen may vary 
with different virus/cell line combinations (Enders et al., 1990; Table 2.4.1). 
Greater sensitivity of the IFA has been reported using infected cells fixed in 
methanol as an alternative to acetone (Couillard etal., 1992).
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HHV- 6  seroprevalence may decline in older groups (Enders et al., 1990; Levy 
et al., 1990a), a finding reflected as declining antibody titres in one study 
(Yanagi et al., 1990). In this study there was a bias towards older age groups. 
For that reason all of the statistical analyses have included adjustments for age 
and also sex to counteract the possible confounding effects of these factors.
In our study, lymphoma and leukaemia groups had both higher seropositivity at 
a serum dilution of 1:40 and higher HHV- 6  antibody titres than the controls. 
Analysing the data both by ORs and by GMT ratios on individual disease 
subtypes, we identified strong differences between HHV- 6  seropositivity in 
AML, HD, and LG-NHL and the controls. Higher antibody prevalence to HHV- 6  
has also been found in malignant lymphoma patients in two other studies, 
particularly HD and HG-NHL, although their design involved smaller sample 
numbers and they were not case-controlled (Ablashi et al., 1988; Biberfeld et 
al., 1988). More recently Torelli etal. (1991) reported increased antibody titres 
to HHV- 6  in HD.
Similar case-controlled serological studies on other herpesviruses in 
leukaemia/lymphoma have identified higher antibody titres against EBV 
antigens in HD (Evans and Gutensohn, 1984), NHL (Dumont et al., 1976) and 
CLL (Levine et al., 1971b). Higher CMV antibody titres have been reported in 
HD (Langenhuysen et al., 1974), although this finding is not consistent (Evans 
et al., 1978; Henderson et al., 1973). Contradictory evidence exists for 
increased seroprevalence of HSV-2 in HD (Catalano and Goldman, 1972; 
Hesse etal., 1977; Evans etal., 1978).
In lymphoproliferative disease, polyclonal B cell proliferation could lead to 
increased antibody levels to a whole range of antigens. The restriction of 
elevated titres to only some herpesviruses indicates a specific antibody 
response. Either de novo infection or increased viral replication caused by 
virus reactivation or altered chronic infection could be reflected by the specific 
humoral response. The identification of HHV- 6  DNA and protein in salivary 
glands (Fox et al., 1990a; Krueger et al., 1990) and the detection of HHV- 6  in 
saliva (Gopal etal., 1990; Jarrett etal., 1990) points towards the oropharynx as 
one site of viral replication and persistence. Although HHV- 6  is detectable in 
the blood of the majority of healthy persons by PCR (Gopal etal., 1990; Jarrett 
et al., 1990), the virus has been difficult to isolate from this source. The 
majority of isolates have been made from the blood of exanthem subitum
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patients or immunosuppressed individuals suggesting HHV- 6  is normally in a 
latent state in blood. Recently Kondo etal. (1991) reported that monocytes are 
a possible site ot latency.
In haematological malignancies, reactivation of HHV- 6  might occur with 
increased frequency. Disease- or therapy- induced immunosuppression could 
promote reactivation. The majority of cases included in our study would have 
started treatment by the time a serum sample was taken. Sera were collected 
after a period of recovery and prior to the next round of therapy. The absence 
of elevated HHV- 6  antibody titres in all patients receiving treatment and no 
association with any particular regimen suggests that treatment-induced 
immunosuppression has a limited effect on antibody titre.
Despite the observations of elevated HHV- 6  antibody titres in AML, HD, and 
LG-NHL, HHV-6 -specific DNA sequences have been detected only rarely by 
Southern blot hybridisation in these conditions. Combining the studies of 
Josephs et al. (1988) and Jarrett et al. (1988) 5 NHL samples were positive 
from 157 NHL, 37 HD and 10 AML patients. These data indicate that HHV- 6  is 
unlikely to be the aetiological agent of AML and the majority of NHL cases.
In HD, de novo infection may account for the data presented here. Our 
analysis reveals strong evidence for increased HHV- 6  seropositivity and GMT 
ratio in HD occurring in young adults without siblings. A number of studies have 
noted an association between HD in children and young adults and both 
personal and community socio-economic status (MacMahon, 1966; Gutensohn, 
1982; Kirchoff et al., 1980; Glaser, 1987). One lifestyle characteristic that is 
positively associated with HD is sibship size (Gutensohn and Cole, 1981). A 
person with no siblings is more likely to develop HD than someone with siblings. 
This feature may indicate a lack of social contact in the family group resulting in 
late exposure to infectious agents.
For HD there is accumulating epidemiological evidence that HD occurring 
among young adults is an unusual consequence of a common viral infection 
(Gutensohn and Cole, 1980), possibly linked to late age at first exposure to the 
virus (Mueller, 1987). A prior history of IM-like disease is a recognised risk 
factor for HD (Munoz et al., 1978), and elevated antibody titres to EBV have 
been documented before the development of HD (Evans and Comstock, 1981;
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Mueller et al., 1989). Such findings could signify that HD is an abnormal 
response to herpesvirus infection, including EBV and HHV-6 .
There is increasing molecular evidence to suggest a role for EBV in at least a 
subset of HD patients (Weiss et al., 1987; Weiss et al., 1989; discussed in 
Chapter 3). This is not the case for HHV-6 . Josephs etal. (1988) and Jarrett et 
al. (1988) did not detect HHV-6 -specific DNA in tumour biopsy tissue from a 
large series of HD patients by Southern blot hybridisation. Detection of virus in 
the putative tumour population of HD is problematic, since the Reed-Sternberg 
(RS) cells often only constitute a small percentage of the total population.
Torelli etal. (1991), using PCR, identified HHV- 6  DNA sequences in 3 of 25 HD 
cases, but not in any of 41 cases of NHL. These findings may reflect the 
different sensitivities of the two detection assays, although 2 of the 3 PCR 
positive HD cases were confirmed by Southern blot hybridisation. The added 
sensitivity of PCR may allow the detection of HHV- 6  in RS cells. Alternatively 
PCR may be amplifying HHV- 6  DNA present within a small number of infected 
monocytes or lymphocytes. The identification of HHV- 6  by in situ hybridisation 
within RS-cells may confirm a role in HD. Krueger et al. (1989) described HHV- 
6  positive cells by in situ hybridisation studies in a number of 
lymphoproliferative conditions including HD. However the authors did not 
report the presence of HHV- 6  within the RS cell population.
Interaction between viruses may affect HHV- 6  antibody titres. HHV- 6  has 
frequently been isolated from persons infected with retroviruses (Salahuddin et 
al., 1986; Downing etal., 1987; Tedder etal., 1987; Lopez et al., 1988; Levy et 
al., 1990b). Co-infection of CD4+ve lymphocytes by HIV-1 and HHV- 6  in vitro 
produces accelerated HIV-1 expression and cellular death (Lusso et al., 1989). 
This may occur owing to the ability of HHV- 6  to transactivate the HIV promoter 
(Lusso et al., 1989; Horvat et al., 1989). It is possible a retrovirus may be 
stimulating herpesvirus replication. However, there is no serological evidence 
that a known retrovirus is involved in HD (Chorba et al., 1988) and in males 
infected with HIV-1, HHV- 6  antibody titres were similar to HIV-1 negative male 
blood donors (Fox et al., 1988). Spira et al. (1990) found that HHV- 6  antibody 
levels were not elevated in patients with AIDS. Linde et al. (1988,1990) have 
shown HHV- 6  IgG antibody levels can be elevated following primary EBV and 
CMV infection. The involvement of another herpesvirus in particular
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malignancies may promote HHV- 6  reactivation that is reflected by increased 
HHV- 6  antibody levels.
Cross-reactive antibodies between HHV- 6  and an antigenically related 
herpesvirus involved in certain malignancies could lead to an apparent 
elevation of HHV- 6  antibody titres. However, cross-reactive antibodies to the 5 
previously identified human herpesviruses do not appear to interfere with the 
HHV- 6  I FA including CMV (Morris etal., 1988; Buchbinder etal., 1989) which is 
most closely related to HHV- 6  at the molecular level (Josephs et al., 1986; 
Efstathiou etal., 1988; Lawrence etal., 1990).
This seroepidemiological study has identified elevated HHV- 6  antibody titres in 
3 conditions, LG-NHL, AML, and HD. To date HHV-6 -specific DNA has been 
detected in tumour tissue of only a limited number of NHL cases. Conclusive 
molecular evidence is lacking for a role of HHV- 6  in HD, although this study has 
provided serological evidence that HHV- 6  antibody titres are elevated in 
younger cases of HD particularly those whose early life may have lacked social 
contact. It remains a possibility that HHV- 6  may be acting as a marker for 
delayed infection to common viruses in young adult cases of HD.
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CHAPTER 3
T H E  S E R O E P ID E M IO L O G Y  O F  H H V -6  A N D  E B V  IN  H O D G K IN 'S  D IS E A S E
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3.1 INTRODUCTION
The aetiology of Hodgkin's disease (HD) is poorly understood. The malignancy 
is unusual in that the bulk of the tumour is composed of reactive cells within 
which the malignant Reed-Sternberg (RS) cells are found. The cellular origin 
of these neoplastic cells remains controversial, but current opinion favours a 
lymphoid origin (reviewed by Drexler, 1992).
Sternberg (1898) and Reed (1902) originally described the typical 
multinucleated giant cells bearing their names and recognised the unique 
relationship of these cells to HD. Both authors believed the process to be 
infectious in nature. Sternberg proposed Mycobacterium tuberculosis, and 
Reed some other unidentified agent. Early in disease there is a functional 
impairment in cell-mediated immunity (Levy et al., 1974) and circulating 
immune complexes are also present, indicating an active immune response 
(Long and Kaplan, 1977).
The diagnosis of HD rests on the identification of the RS cell in an appropriate 
histological setting. HD is divided histologically into four types based on the 
presence of RS cells and variants and the surrounding reactive cell population: 
lymphocyte predominant (LP); nodular sclerosing (NS); mixed cellularity (MC); 
and lymphocyte depleted. Recent data suggest that HDLP is a distinct entity 
which should be classified separately from the other forms of HD (Nicholas et 
al., 1990).
The overall incidence of HD in the UK is 2.4 per 1 0  ^person years (McKinney et 
al., 1989). HD can occur at any age although it is rare in children 4 years of 
age or younger (Kung, 1991). It is one of the most common forms of 
malignancy in young people and has an unusual age distribution which is quite 
distinct from that of the NHLs.
HD shows a bimodal age incidence curve (MacMahon, 1966), although the 
shape of the curve varies in different communities. Correa and O'Conor (1971) 
suggested that there are at least three epidemiological patterns of HD. In type 
I, the first peak of the bimodal age incidence occurs in childhood, there is a low 
incidence in the third decade and a second peak in older age groups. This 
pattern is found in developing countries. The type III pattern, which is seen in 
developed countries, is characterised by low rates in childhood and a
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pronounced first peak in young adults. A second peak is observed in older 
adults. In both developed and developing countries the incidence of HD 
increases or reaches a plateau from 45 years of age (McKinney et al., 1989; 
Correa and O'Conor, 1971). An intermediate pattern, type II, is found in rural 
areas of developed countries and is thought to represent a transition state 
between type I and type III patterns.
The age incidence curves for HDNS and the other subtypes are quite distinct 
(McKinney et al., 1989; Glaser and Swartz, 1990). HDNS has a unimodal age 
incidence curve and accounts for the young adult peak observed in developed 
countries. The other subtypes show a gradual increasing incidence with 
increasing age. HDMC is relatively more common in children and older adults.
Vianna et al. (1971) first reported the aggregation of HD cases suggesting the 
possibility that the disease might occur in clusters. A recent survey in the UK 
(Alexander et al., 1989; Cartwright et al., 1990) found significant evidence of 
spatial clustering with 13% (0-34 years) of cases identified as clusters. The 
pattern of clustering would be consistent with an aetiology involving either 
delayed exposure to a common, but not ubiquitous, infectious agent or infection 
with a virus with a long latent period.
Gutensohn and Cole (1980) hypothesised that HD, particularly in young adults, 
is a consequence of delayed exposure to a common infectious agent. An 
increased risk of developing HD in young adults is associated with a high 
socioeconomic status such as a high standard of living in childhood (Gutensohn 
and Cole, 1980) as well as family and sibship size (Gutensohn and Cole, 1981). 
A child with no siblings is more likely to develop HD than a child with siblings. 
Such factors may influence the age at which common pathogens are first 
encountered. MacMahon (1966) hypothesised that HD is a grouping of at least 
three entities which may have distinct aetiologies. He proposed that these 
groups could be distinguished on the basis of age at onset of disease: 0-14 
years; 15-34 years and 50 years and over. He suggested that HD in young 
adults may be caused by an infectious agent.
Serological studies have investigated the role of many viruses in HD, mainly 
focusing on the herpesviruses. The most consistent findings have been 
reported for EBV. As a group, patients with HD have repeatedly been shown to 
have elevated antibody titres to EBV antigens, including VCA and EA and these
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increased antibody levels have been shown to precede diagnosis (Henle and 
Henle, 1973; Evans et al., 1978; Evans and Gutensohn, 1984; Evans and 
Comstock, 1981; Mueller et al., 1989). Studies that have examined EBV 
serology by HD histological subtype have produced inconsistent results (Levine 
et al., 1971a; Hesse et al., 1977; Evans et al., 1978; Evans and Gutensohn, 
1984). A past history of IM determined by a positive Paul Bunnell test, which is 
linked in the majority of cases to primary EBV infection in adolescence or early 
adulthood, is a recognised risk factor for HD (Munoz etal., 1978).
Weiss etal. (1987) reported the detection of EBV genomes in tumour samples 
from 4 out of 21 cases of HD using Southern blot analysis. Other studies have 
produced similar findings (Anagnostopoulos et al., 1989; Staal et al., 1989; 
Gledhill etal., 1991). However, EBV is not always detectable in tumour tissue 
and in serological studies a subset of HD patients are EBV seronegative 
suggesting no prior infection with this virus (Henle and Henle et al., 1973; 
Evans and Gutensohn, 1984). Therefore, EBV cannot be implicated in all 
cases of HD.
A second herpesvirus linked to haematological malignancies is HHV-6 . We 
found elevated antibody titres to HHV- 6  present in three malignancies including 
HD (Clark etal., 1990; Chapter 2). At present molecular evidence linking HHV- 
6  to HD is weak (Josephs etal., 1988; Jarrett etal., 1988; Torelli etal., 1991).
The identification of elevated antibody titres to both EBV and HHV- 6  could 
signify the involvement of each virus with distinct subsets of HD. Alternatively, 
an undefined interaction between these two viruses in HD could affect antibody 
titres to both of them. In support of the latter idea, Linde et al. (1988,1990) 
demonstrated that HHV- 6  antibody levels are raised following primary EBV or 
CMV infection, perhaps as a result of viral reactivation. In HD, where there is 
increasing molecular evidence for a direct role of EBV, elevated antibody titres 
to HHV- 6  may be a consequence of an interaction with EBV. If such an 
interaction in HD occurs, it would be predicted that elevated HHV- 6  antibody 
levels would tend to concur with elevated EBV antibody levels. However, an 
independent association of HHV- 6  antibody titres with HD might indicate a 
possible role for HHV- 6  in a separate subset of HD cases.
This study was designed to investigate the association of antibody titres to 
HHV- 6  and EBV in HD. The HD case and control sera from the HHV- 6
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seroepidemiology survey were re-screened for antibody titres to two EBV 
antigens, the EBV-VCA and EBV-EA. Antibodies to EBV-VCA are found in all 
individuals who have been infected with the virus, whereas antibodies to EBV- 
EA are detected during primary infection and during viral reactivation. EBV-EA 
antibodies are detectable only occasionally in healthy persons normally in 
association with high EBV-VCA titres.
The results were statistically analysed to determine the degree of correlation 
between antibody titres to the two viruses in HD cases and controls. Further, 
the serological differences between cases and controls for HHV- 6  and EBV 
were examined in age groups corresponding to the peaks of HD age incidence 
curve found in developed countries. The statistical analyses included 
investigating the effect of sibship size, a recognised risk factor for developing 
HD, using the HHV- 6  and EBV serological data.
HD cases can now be categorised as either EBV-associated or non-associated 
based on the presence of EBV within RS cells. This development stemmed 
from the availability of EBV-specific reagents that allow the in situ detection of 
EBV gene products within the RS cells of HD tissue sections (Pallesen et al., 
1991a; Weiss et al., 1991; Armstrong et al, 1992a,1992b). One such assay 
involves the detection of the EBER transcripts in EBV-infected cells (Weiss et 
al., 1991). By virtue of their abundance, estimated to be between 1 0 $ and 10® 
copies per viral genome (Lerner et al., 1981), the EBERs provide an excellent 
target for in situ detection in routinely formalin-fixed and paraffin-embedded 
tissues. In order to examine the association of EBV and HHV- 6  antibody titres 
with EBV-associated and non-associated HD cases, a group of HD patients 
were selected from whom sera and tissue sections were available. The sera 
were tested for antibodies to HHV-6 , EBV-VCA and EBV-EA and the presence 
of EBV in RS cells determined by an EBER RNA in situ hybridisation technique 
as described by Weiss etal. (1991) and Armstrong etal. (1992b) using paraffin- 
embedded biopsy material.
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3.2 MATERIALS AND METHODS
3.2.1 Source Of Sera
Sera from 189 HD cases and 215 controls were available for analysis. The 
sera had been collected as part of the epidemiological case-control study of 
leukaemias and lymphomas conducted in Yorkshire between 1980 and 1986. 
Staff at Glasgow were blind to the case/control status of each serum sample. 
Further details of the sample populations and source of controls are described 
in 2 .2 .1 .
Sera and paraffin-embedded formalin-fixed biopsy tissue from 21 HD patients 
were kindly supplied by Drs. S. Proctor and B. Angus, Royal Victoria Infirmary, 
Newcastle.
3.2.2 Tissue Culture
The EBV-producer B95.8 marmoset cell line and EBV infected non-producer 
Raji cell line were maintained in complete medium (see 2.2.2) containing 
10%FCS. Cells were split twice a week at a ratio of 1:5, gassed with CO2  and 
incubated in sealed Costar tissue culture flasks at 37°C. Cell stocks were 
prepared and kept in liquid nitrogen as described in 2.2.3. B95.8 cells were 
stored in liquid nitrogen in a mixture of 10%DMSO and 90% FCS.
3.2.3 Indirect Immunofluorescence Assays
(i) HHV-6 IFA
All sera, except for those obtained from Newcastle, had been screened for 
HHV-6 -specific antibodies. The latter were tested using the protocol described 
in 2.2.4 except that the conjugate consisted of the FITC-labelled rabbit anti­
human IgG heavy chain specific sera only.
(ii) EBV-VCA IFA
Antibodies against EBV-VCA were detected using the IFA of Henle and Henle 
(1966). The EBV-producing cell line B95.8 was stimulated with 20ng/ml TPA 
(Sigma) for 3 days. At any time between 1-5% of B95.8 cells undergo
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spontaneous virus reactivation to produce infectious virus and subsequently 
express the VCA. By stimulating the cells with TPA the number of cells 
entering a productive cycle of infection is increased (Zur Hausen et al., 1978). 
Following TPA stimulation, the cells were harvested and used as the source of 
antigen on slides in an IFA identical to that detailed in 2.2.4 except the 
conjugate described in 3.2.3.(i) was used. No adsorption step of sera was 
carried out. All sera were initially screened at a dilution of 1:10 and those 
scored positive were diluted two-fold until the end titre was reached. This was 
defined as the reciprocal of the serum dilution at which VCA specific 
fluorescence was last seen.
(iii) EBV-EA IFA
Antibodies against EBV-EA were detected using the IFA described by Long et 
al. (1974). Raji cells were treated with 50pg/ml of 5-lododeoxyuridine (IdU) 
(Sigma) for 3 days and used as the source of antigen in an IFA similar to the 
HHV- 6  IFA described in 2.2.4 except that the conjugate described in 3.2.3.(i) 
was used. Virus activation in either producer or non-producer LCLs can be 
induced by thymidine analogues (Hampar et al., 1972). In non-producing cell 
lines such as Raji, treatment with IdU results in the synthesis of EA but not VCA 
following short-term exposure. No serum adsorption step was carried out. Raji 
cells were air-dried and fixed on slides with ice-cold acetone. Such a method of 
fixation allows antibodies specific to both the diffuse- and restricted- 
components of the early antigen complex to be detected. As for EBV-VCA, 
sera were initially screened at a 1 : 1 0  dilution and an endpoint titration 
determined for EBV-EA positive sera.
(iv) Control sera
An EBV-VCA positive serum sample obtained from a person within the 
department was included in all EBV-VCA IFAs. An EBV-EA positive serum 
sample, kindly donated by Dr. S. Cameron, Glasgow Royal Infirmary, was 
included as an inter-assay control in the EBV-EA IFA.
3.2.4 Statistical Methods
Th statistical analysis was carried out by Dr. Freda Alexander. Antibody end 
titres were used to calculate GMTs. Pearson's correlation analysis was applied
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to the natural logarithm of the antibody end titre (log(end titre)). Multiple 
regression and analysis of variance were applied to log(end titre) with negative 
sera arbitrarily allocated values of 2 for EBV-EA and 4 for EBV-VCA and HHV-
6 . The reasons for giving negative sera an arbitrary antibody titre are set out in 
2.2.5. Case-control differences of log(GMT) were derived with and without 
including the correlation analysis results to adjust for antibody levels to the 
other viral antigens. These have been converted into ratios of GMTs. 
Adjustment for age in 7 strata and sex were included in all analyses.
The second group of HD case and control sera sent to Glasgow (see 2.2.1) 
were derived to augment the original HD cases and controls and involved 
sampling which favoured persons without siblings. Therefore, in addition, 
duplicate analyses have included adjustment for the presence/absence of 
siblings to confirm the results were not substantially altered by the sampling 
criteria.
The serology and EBER in situ results from the Newcastle group of patients 
were analysed by a Mann-Whitney test, using the statistical package Minitab.
3.2.5 EBER In Situ Hybridisation Assay
Thin sections from paraffin-embedded biopsy material were examined for the 
presence of EBV EBER RNA, which is abundantly transcribed in cells latently 
infected by EBV. Section material was hybridised with a biotinylated 
oligonucleotide probe complementary to EBER-1 RNA: 5' AGA CAC CGT CCT 
CAC CAC CCG GGA CTT GTA 3' using methodology described previously 
(Weiss etal., 1991; Armstrong etal., 1992b). Hybridisation was detected using 
an ABC method (Dako) utilising nitro blue tetrozolium as the chromogenic 
substrate. A distinct blue-black colour within the nucleus was considered a 
positive reaction. A known positive case was included in each assay and 
sections were hybridised with a nonsense probe with a base composition 
identical to that of the EBER-1 probe as a negative control. This assay was 
kindly performed by Alison Armstrong.
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3.3 RESULTS
Antibody endpoint titrations to two EBV antigens, EBV-VCA and EBV-EA were 
determined in sera from 189 HD cases and 215 suitable controls. The sera had 
previously been screened for antibodies to the AJ strain of HHV- 6  (Clark et al., 
1990; Chapter 2). GMTs for EBV-VCA and EBV-EA were calculated by 
case/control and either age (Table 3.3.1) or sex status (Table 3.3.2). There 
was evidence for slightly higher GMTs in females compared to males in both 
the case and control groups. Such a trend has previously been reported 
(Biggar etal., 1981).
3.3.1 Correlation Analysis
The serological data were statistically analysed to determine the degree of 
correlation amongst antibody titres to HHV-6 , EBV-VCA, and EBV-EA. The 
case and control groups were analysed separately and the correlation analysis 
results are shown in Table 3.3.3. There was a highly significant correlation 
between EBV-VCA and EBV-EA antibody titres in both the case and control 
groups. This was more evident in the cases. There was also a statistically 
significant correlation between HHV- 6  antibody titres and EBV-EA in both the 
cases and the controls. The correlation coefficient of HHV- 6  with EBV-VCA 
was statistically significant in only the control group (p<0 .1 ).
A problem with correlation coefficients is that they can often be misleading 
when the data are extensive but the results of no practical importance. This 
can be true when two measurements such as antibody titres to two antigens 
are taken as proxies for each other. As an alternative analyses, multiple 
regression modelling confirmed significant associations between HHV- 6  and 
EBV-EA antibody titres in both the cases and controls after adjusting for age 
and sex. In the controls, only a weak correlation between HHV- 6  and EBV-VCA 
was found (F. Alexander, personal communication).
3.3.2 GMT Ratio Analysis
When GMT ratios were calculated, there was a statistically significant difference 
between the cases and controls for EBV-VCA, EBV-EA and HHV- 6  (Table 
3.3.4, unadjusted column). Thus, cases had significantly higher antibody titres 
to all 3 antigens compared to the controls.
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Table 3.3.1
GMT OF EBV SEROLOGY BY AGE AND CASE CONTROL STATUS
Cases Controls
Age
(years)
EBV-VCA EBV-EA EBV-VCA EBV-EA
15-25 697.0 19.7 195.8 7.9
26-35 449.2 12.1 410.4 6.4
36-54 1135.1 22.1 465.3 7.5
55-59 1248.7 21.7 604.1 6.8
60-64 1043.9 20.1 784.7 9.3
65-69 1689.0 31.9 681.6 17.3
-s
i 0 1 608.2 11.1 515.0 8.3
Table 3.3.2
GMT OF EBV SEROLOGY BY SEX AND CASE CONTROL STATUS
Cases Controls
EBV-VCA EBV-EA EBV-VCA EBV-EA
Male 718.0 14.9 349.8 6.9
Female 851.9 22.3 436.7 9 . 2
Table 3.3.3
PEARSON CORRELATION COEFFICIENTS AMONGST HHV-6 . EBV-EA. 
AND EBV-VCA ANTIBODY TITRES
EBV-EA EBV-VCA HHV- 6
Cases onlv:
EBV-EA 1.00 0.58 0.17
EBV-VCA 1.00 0.05
HHV- 6  1.00
Controls onlv:
EBV-EA 1.00 0.37 0.17
EBV-VCA 1.00 0.10
HHV- 6  1.00
EBV-EA and EBV-VCA correlations highly significant (p<0.001). 
EBV-EA and HHV- 6  correlations also significant (p<0.05).
Table 3.3.4
EBV AND HHV- 6  GMT HD CASE : CONTROL RATIOS (95% Cl)
Unadjusted Adjusted1
EBV-EA 2.35 1.70
(1.62-3.42) (1.22-2.38)
p<0 .0 1  p<0 .0 1
EBV-VCA 2.04 1.33
(1.38-3.03) (0.93-1.90)
p<0.01 NS
HHV- 6  2.47 2.25
(1.97-3.11) (1.78-2.83)
p<0 .0 1  p<0 .0 1
1 For EBV, analyses adjusted for influences of age, sex and antibody titres 
to the other EBV antigen.
For HHV-6 , analyses adjusted for influences of age, sex and antibody titres 
to both EBV antigens.
NS = not significant.
In further analysis of GMT case:control ratios, controlling for degrees of 
association amongst antibody titres to the 3 antigens was included, as well as 
adjustments for age and sex variation. The correlation analysis provided a 
measure of the strength of association amongst the antibody titres to each 
antigen. By incorporating the correlation analysis results into the GMT ratio 
calculations, the relative independence of the caseicontrol difference for each 
antigen was obtained. For example, with control for EBV-VCA antibody levels, 
does a case control difference still remain for EBV-EA antibody or is their 
elevation simply correlated with elevated EBV-VCA antibody? The results are 
shown in Table 3.3.4, adjusted column. There was still a significant, although 
reduced, difference between cases and controls for antibody to EBV-EA, but 
not EBV-VCA. The GMT ratio for EBV-EA is now 1.70 (95%CI 1.22-2.38, 
p<0.01), but for EBV-VCA 1.33 (95%CI 0.93-1.90, not significant). These 
findings suggested that antibody titres to EBV-EA were more closely associated 
with HD status than EBV-VCA and therefore future analyses were restricted to 
EBV-EA only. The statistically significant difference between cases and 
controls remained for HHV- 6  antibody when associations between HHV- 6  and 
EBV-EA/EBV-VCA were removed from the analysis. This would suggest that 
HHV- 6  and EBV antibody titres found in HD are in part, at least, independent.
3.3.3 Analysis Of Serolooical Results Based On Aae
MacMahon (1966) proposed that multiple aetiologies existed in HD depending 
on age. In order to test this hypothesis, the cases and controls were divided 
into three age groups, a younger (aged 15-34), a middle age group (aged 35- 
54), and an older group (aged 55 and over). The younger group corresponds 
to the first incidence curve peak seen in developed countries (MacMahon, 
1966; McKinney et al., 1989). Analysis of the GMT ratios were restricted to 
EBV-EA and HHV- 6  and the results are shown in Table 3.3.5. The differences 
between the cases and controls for EBV-EA in the 3 age groups were similar, 
although a slightly increased ratio value was found in the middle age group. 
For HHV-6 , the younger age group had a higher GMT ratio compared to the 
middle and older groups. This result may represent a stronger association 
between HHV- 6  and HD in that particular age group. However, the GMT ratios 
in the 3 age groups were not statistically different for either EBV-EA or HHV-6 .
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Table 3.3.5
EBV-EA AND HHV- 6  GMT HD CASE ; CONTROL RATIOS BY 3 AGE
GROUPS (95% Cl)
Aae Group EBV-EA 1 JdMViS2
Younger 1.79 2.89
(aged 15-34 years) (1.01-3.17) (2.02-4.12)
p<0.05 p<0.01
Middle 2.51 1.70
(aged 35-54) (1.13-5.55) (1.08-2.68)
p<0.05 p<0.05
Older 1.35 2.01
(aged 55-84) (0.59-3.11) (1.30-3.12)
NS p<0.01
"I Analyses adjusted for age, sex and antibody titres to HHV-6 .
2 Analyses adjusted for age, sex and antibody titres to EBV-EA and EBV- 
VCA.
NS=not significant.
3.3.4 Analysis Of Serological Results Based On Sibshio Size
Certain lifestyle risk factors such as being an only child or child of low birth 
order have been associated with HD (Gutensohn and Cole, 1980; Bernard et 
al., 1987). The effect of sibship size on HD using HHV- 6  serology data was 
described in Chapter 2. These analyses were extended to include the EBV-EA 
serology results. The findings are shown in Table 3.3.6. The ratio values 
indicate a stronger association of HHV- 6  with HD in younger HD cases lacking 
siblings. This finding was not repeated for EBV-EA. However, the GMT ratio 
values for HHV- 6  in the 'no siblings' and 'some siblings' groups in both age 
categories were not statistically different.
3.3.5 Comparison Of HHV-6 And EBV Serology With EBV-Associated And 
Non-Associated HD Cases
An additional group of 21 sera from HD cases were tested for the presence of 
EBV-VCA, EBV-EA and HHV- 6  antibodies to allow a comparison of viral 
serology with molecularly-determined EBV-associated or non-associated HD 
cases. This classification was based on the detection of EBER transcripts in 
RS cells from paraffin-embedded biopsy material (Fig. 3.3.1). Seven of the 21 
cases were EBV-EBER RS cell positive (RS+). There was no significant 
difference between the EBV-RS(+) and EBV-RS(-) groups for antibody levels to 
the two EBV antigens or HHV-6 . There was however an indication that HHV- 6  
antibody titres tended to be higher in the non-EBV associated cases. Care has 
to be taken in the interpretation of these results as the study population is 
modest. The statistical analyses did not include adjustment for age and sex, 
two possible confounders in the analyses of serological data. Thus, the ability 
to classify HD cases into two groups depending on EBV-RS cell status was not 
mirrored by analyses of EBV or HHV- 6  serology.
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Table 3.3.6
EBV-EA AND HHV- 6  GMT HD CASE : CONTROL RATIOS BY AGE
GROUP AND SIBLING STATUS (95% Cl)
Aae Group EBV-EA1 HHV-62
Younger:
(aged 15-34 years)
No siblings 2.92 8.33
(0.34-24.65) (2.90-23.96)
NS p<0.01
Some siblings 1.73 2.53
(0.98-3.07) (1.74-3.69)
NS p<0.01
Older
(aged 35-84 years)
No siblings 2.51 1.48
(0.34-18.60) (0.31-7.05)
NS NS
Some siblings 1.82 1.82
(0.99-3.36) (1.30-2.55)
NS p<0.01
1 Analyses adjusted for age, sex and antibody titres to HHV-6 .
2 Analyses adjusted for age, sex and antibody titres to EBV-EA and EBV- 
VCA.
NS=not significant
Figure 3.3.1
DETECTION OF EBER TRANSCRIPTS IN REED-STERNBERG CELLS BY IN
S ITU  HYBRIDISATION
Figure 3.3.1 Detection of EBER transcripts in RS cells by an in s itu  hybridisation 
assay using formalin-fixed paraffin-embedded HD lymph node tissue. The EBER 
positive cells are stained black. Kindly provided by Alison Armstrong.
3.4 DISCUSSION
The serology of HHV- 6  and EBV was examined in HD using sera derived from 
an epidemiological case-control study of leukaemias and lymphomas.
In this study, statistically significant differences between the cases and controls 
for antibody titres to EBV-VCA, EBV-EA and HHV- 6  were found. Elevated 
antibody titres to both viruses have been reported previously (Henle and Henle, 
1973; Evans and Gutensohn, 1984; Ablashi et al., 1988; Clark et a/., 1990; 
Chapter 2). In HD, the elevated antibody titres are unlikely to have resulted 
from polyclonal B cell proliferation as increased humoral responses are 
restricted to these two viruses. The elevated antibody levels to HHV- 6  and EBV 
could reflect the direct involvement of either virus in the malignancy.
The replication of one herpesvirus may affect the reactivation and replication of 
another. The results of our correlation analysis suggest that such an interaction 
between EBV and HHV- 6  in HD is not strong and that the serological 
associations of HHV- 6  or EBV with HD are, in part, independent.
However, interactions between HHV- 6  and other herpesviruses have been 
proposed. Elevated HHV- 6  and CMV antibody titres have been reported in 
persons with EBV-induced IM (Linde et al., 1990). Reactivation of 
herpesviruses can not fully explain the latter phenomenon as antibody levels to 
measles virus were also raised. Polyclonal B cell proliferation found in IM could 
explain the rise in antibody titres to a number of unrelated antigens. The same 
study reported that in IM patients who subsequently seroconverted to CMV, 
only HHV- 6  antibody levels were raised. In the case of CMV infection, antigenic 
cross-reactivity or selective reactivation of HHV- 6  could account for the 
increased antibody levels to HHV-6 .
Chou and Scott (1990) also reported increased IgG antibody titres to HHV- 6  in 
transplant patients with secondary and particularly primary CMV infection. 
Likewise, Ward et al. (1993) have demonstrated HHV- 6  reactivation in organ 
transplant recipients with proven primary EBV or CMV infections. The 
possibility exists that an interaction between CMV and HHV- 6  in HD results in 
elevated HHV- 6  antibody titres. This would seem unlikely however, as higher 
CMV antibody levels in HD have not been reported consistently (Evans et al.,
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1978; Langenhuysen et al., 1974; Henderson et al., 1973; Evans and 
Gutensohn, 1984).
EBV was initially linked to HD based on the findings of serological studies. Our 
results confirm the presence of elevated antibody titres to EBV antigens in HD. 
Our analysis also suggests that antibody titres to EBV-EA are more closely 
associated with disease status than EBV-VCA. A closer association of EBV-EA 
antibodies with disease status can in part explain the statistically significant 
correlation with HHV- 6  antibody titres which are themselves independently 
associated with HD. In a previous study, Evans and Gutensohn (1984) 
proposed that antibody to EBV-VCA was more closely associated with HD 
compared to EBV-EA. A possible reason for this inconsistency is that the 
design of statistical testing was different between the two studies. That study 
used relative risk values to examine the difference between cases and controls, 
whereas GMT case:control ratios were used here.
There is now strong evidence to indicate a direct role for EBV in the 
pathogenesis of a subset of HD cases based on molecular studies. Clonal EBV 
has been detected in HD biopsy tissue (Weiss et al., 1987). More recently 
EBV-specific reagents have made possible the identification of the virus in RS 
cells of biopsy material (Pallesen etal., 1991a; Weiss etal., 1991; Armstrong et 
al., 1992a,b). To-date EBV type A has predominantly been detected in HD 
tissue (Gledhill etal., 1991; Boyle etal., 1993; Lin etal., 1993).
This ability has facilitated studies examining the epidemiological association of 
EBV with HD. A stronger association has been suggested for paediatric and 
older adult cases of HD and also with the MC subtype (Gledhill et al., 1991; 
Jarrett et al., 1991; Armstrong et al., 1992b, Armstrong et al., 1993). Young 
adult cases of HD, which make up the first age incidence peak in developed 
countries and are predominantly of the NS subtype, tend not to be EBV- 
associated. In this study, EBV-EA GMT case control ratios were not 
significantly different among the younger, middle and older age groups. Thus, 
serological and molecular patterns of EBV association with HD did not overlap.
In support of this, there was no significant difference in antibody titres to EBV- 
VCA and EBV-EA in EBV-associated and non-associated cases, based on the 
detection of EBER transcripts in RS cells. The statistical analyses is open to 
criticism as no adjustments for age and sex were included. However, the
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findings question the significance and relevance of elevated antibody titres to 
these particular EBV antigens in HD.
EBV-VCA and EBV-EA are expressed during the lytic cycle of viral replication 
and presumably are targetted by the immune system, resulting in elevated 
antibody titres. The pattern of EBV gene expression in RS cells is suggestive of 
a latent rather than lytic cycle and is similar to that observed in NPC (Young et 
al., 1988). EBV gene expression in NPC is restricted to EBNA-1 and LMP-1 
with an absence of EBNA-2. Expression of LMP-1 has been recognised in RS 
cells (Herbst et al., 1991b; Pallesen et al., 1991a; Armstrong et al., 1992a) 
whereas the expression of EBNA-2 appears to be absent (Herbst etal., 1991b; 
Pallesen et al., 1991a). EBNA-1 is thought to be expressed in RS cells since 
analysis suggests that the EBV genomes in HD are maintained in an episomal 
state (Jarrett et al., 1991). At the transcriptional level, LMP-2A and -2B have 
also been demonstrated in RS cells (Deacon et al., 1993). The role of LMP in 
RS cells is not known. Molecular analysis of the LMP region has found 
polymorphism in both the coding and untranslated regions in a series of HD 
cases (Knecht et al., 1993). However, the regions that encode the protein 
domains associated with transforming capabilities and immune recognition 
were conserved. Thus, HD and NPC tumour cells exhibit EBV latent gene 
expression characteristic of a Lat II pattern (Rowe et al., 1992). Pallesen et al. 
(1991b) reported the expression of the EBV-protein encoded by the BZLF1 
gene in a minority of RS cells in 3 of 47 HD cases examined. BZLF1 protein is 
an immediate early gene product that plays an important role in initiating the 
EBV lytic cycle (Grogan etal., 1987). These 3 cases were also LMP positive by 
immunostaining although no EA or VCA were detected in RS cells. Similarly, 
Joske et al. (1992) detected transcripts from the LMP-coding gene in 9 of 20 
cases of HD, with only one case also positive for RNA transcripts of the active 
replication gene BLLF1. Therefore, the stimulating antigens for the immune 
system, EBV-VCA and EBV-EA, are unlikely to be expressed highly in the 
tumour cells of HD.
In NPC patients, antibodies to EBV-EA and EBV-VCA of the IgA subclass are 
detectable and their presence is assumed to represent reactivation of EBV from 
latency and a pre-NPC condition (De-The etal., 1989). In NPC, viral replication 
including production of antigens associated with the lytic cycle may be an early 
event in the path towards malignancy and replicative forms of the virus have 
been demonstrated in tumour cells (Raab-Traub and Flynn, 1986). Whether
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increased EBV lytic cycle replication, perhaps in RS cells, is an early event in 
HD remains to be clarified. In BL, where elevated antibody titres to EBV lytic 
antigens have also been recognised, the pattern of latent gene expression in 
tumour cells is limited to the expression of EBNA-1 only (Rowe et al., 1986). 
However, Gutierrez et al. (1993) were able to detect replicative forms of EBV in 
BL tumour tissue and proposed that this reactivation may account for the 
serological changes present in BL.
In the absence of lytic antigen expression within the tumour cells of HD, the 
host/viral balance could be affected by tumour development or subsequent 
therapy. Increased EBV replication in a non-neoplastic cell population could 
account for increased antibody titres to EBV-EA and EBV-VCA.
The significance of an independent serological association of HHV- 6  with HD is 
unclear. It is perhaps relevant that there is a stronger association of HHV- 6  
with young adult cases of HD. In both the multiple aetiology (MacMahon, 1966) 
and delayed exposure (Gutensohn and Cole, 1980) hypotheses for the 
aetiology of HD, viral infection is suspected in this particular age category. To 
date, molecular evidence linking HHV- 6  to HD is incomplete. Torelli et al. 
(1991) identified HHV- 6  DNA in tumour tissue from 3 of 25 persons with HD 
examined by Southern blot or PCR. Interestingly the 3 patients were young 
adult women with HDNS subtype. Josephs et al. (1988) and Gledhill et al. 
(1991), who extended the series previously examined by Jarrett et al. (1988), 
failed to detect HHV- 6  in HD cases by Southern blot hybridisation.
Raised HHV- 6  antibody titres in HD may reflect late exposure to the virus. 
Although HHV- 6  infection occurs early in life (Briggs et al., 1988), delayed 
primary infection until adulthood has been associated with clinical illness similar 
to EBV-IM (Niederman et al., 1988; Steeper et al., 1990; Chapter 4). Delayed 
exposure to HHV- 6  may mirror delayed infection with other agents, including 
the virus hypothesised to be involved in young adult HD cases and unlikely to 
be EBV. Alternatively, HHV- 6  reactivation may be more common in young 
adult cases of HD. Reactivation could be induced by either another virus or the 
disease process itself.
Factors such as therapy after diagnosis may affect HHV- 6  antibody titres. As 
detailed in Chapter 2, the majority of sera were taken from persons receiving 
anti-tumour therapy. Levine et al. (1992b) recently investigated HHV- 6  and
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EBV serology in patients before and after the initiation of chemotherapy. They 
found that HHV- 6  antibody titres in pre-treatment sera were not significantly 
different from controls. Significant changes in titres were related to clinical 
course in HD patients, as HHV- 6  IFA titres increased significantly in follow-up of 
patients who relapsed and decreased significantly over time in patients who did 
not.
The development of assays that allow the detection of particular HHV- 6  
antigens may be useful in dissecting the antibody response to the virus in HD. 
At present the prototype assay (Salahuddin etal., 1986; Briggs etal., 1988) and 
assay used in this study determine antibody reactivity to the whole range of lytic 
HHV- 6  antigens. More recently, a HHV-6 -EA antibody assay (Iyengar et al., 
1991) has been described. Interestingly, a higher prevalence of HHV-6 -EA 
specific antibodies, suggestive of viral replication, was found in HD (Iyengar et 
al., 1991). If HHV- 6  were to be present in tumour cells it is possible that no lytic 
cycle antigens would be expressed. Antigen expression may be absent or 
restricted to putative latent gene products, in which case measurement of the 
immune response to lytic cycle associated antigens may be irrelevant. Luppi et 
al. (1993) have reported the detection of integrated HHV- 6  in vivo in 3 persons, 
one with HD. Two of the 3 cases were HHV- 6  seronegative using an HHV- 6  
IFA with lytically infected cells as antigen. Likewise, Jarrett et al. (1990) were 
able to detect HHV- 6  in PBMCs from seronegative individuals. Thus, future 
studies should examine the serological response to particular HHV- 6  antigens. 
Similarly, a number of the HD case and control sera in this study are being 
examined for the serological response to particular EBV latent gene products 
which might prove useful in distinguishing EBV-associated from non-associated 
cases (in collaboration with Dr. L.S. Young).
In summary, our analyses identified independent associations of EBV and HHV- 
6  antibody titres with HD. In the absence of direct evidence linking HHV- 6  to 
HD, antibody levels to HHV- 6  may be acting as a marker for exposure to 
common viruses, particularly in young adult cases. The involvement though of 
EBV in certain subsets of HD is now well established. Increased antibody titres 
to EBV lytic cycle antigens however, did not correlate with the presence of EBV 
in RS cells which questions the relevance of this particular EBV serology in HD.
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CHAPTER 4
THE ASSOCIATION OF HHV- 6  WITH IM-L1KE ILLNESS.
THE PREVALENCE OF ANTIBODY TO HHV-7 BY AGE AND ITS ISOLATION
FROM SALIVA
4.1 INTRODUCTION
There are a number of parallels that can be drawn between EBV and HHV-6 . 
Infection with both viruses occurs sub-clinically in the majority of persons during 
childhood. Primary EBV infection early in life may present with symptoms that 
resemble an upper respiratory infection and are non-specific. Primary infection 
with HHV- 6  can result in exanthem subitum (Yamanishi et a/., 1988). If 
infection with EBV is delayed until the second decade of life or beyond, IM may 
result. HHV- 6  infection beyond childhood may occasionally result in a similar 
outcome: Niederman et a!. (1988) detected HHV- 6  specific IgM and high titre 
IgG antibodies in 3 adult patients with self-limiting, mild illness similar to IM.
Large-scale epidemiological studies demonstrated that IM occurred in patients 
without pre-existing EBV antibodies and was accompanied by an acquisition of 
EBV antibodies in the majority of cases (Niederman et a!., 1968; Sawyer et at., 
1971). Classically, IM refers to illness in young adults associated with 
characteristic reactive blood smears, fever, sore throat, cervical 
lymphadenopathy, and frequently serologically detectable heterophile 
antibodies (Lee eta /., 1968; Evans and Niederman, 1989).
The majority of persons who develop EBV-induced IM produce heterophile 
antibodies. These are antibodies specific for antigens from another species 
and can be detected by specific laboratory tests. In IM, heterophile antibodies 
were originally described by Paul and Bunnell (1932) as sheep erythrocyte 
agglutinins and are present in about 90% of IM cases at some point during the 
illness. Beef erythrocyte haemolysins and agglutinating antibodies to horse, 
goat and camel erythrocytes are also demonstrable in IM. The classic 
heterophile antibody titre is reported as the highest serum dilution at which 
sheep or horse erythrocytes are agglutinated after adsorption of serum by 
guinea pig kidney. Heterophile antibodies appear at the onset of illness or 
shortly after and their presence may be detected for over a year depending on 
the assay employed (Evans etal., 1975).
Cases of IM-like illness that are heterophile antibody negative can occur. In 
paediatric populations, EBV-induced IM tends to take a milder course and is 
often heterophile antibody negative compared to young adults. The most 
frequently known cause of heterophile negative IM is CMV (Horwitz et at.,
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1977). Less common causes are drugs, adenoviruses, rubella, toxoplasmosis 
and HIV (Evans, 1978; Steeper etal., 1987).
In the absence of detectable heterophile antibody, the detection of EBV specific 
IgM or EBV-EA-diffuse(D)-component specific IgG antibodies are crucial for the 
diagnosis of EBV-induced IM. IgM antibodies specific for EBV-VCA are usually 
present in sera at the time of clinical presentation. These IgM antibodies may 
persist for 3 to 6  months. Antibodies to EBV-EA-D appear later than EBV IgM 
antibody and are only present in 75% of typical EBV-induced IM cases (Henle 
efa/., 1971).
The extent to which primary HHV- 6  infection is responsible for non-EBV 
associated and perhaps heterophile antibody negative IM is unclear. Often 
patients with glandular fever or IM-like illness do not have a diagnosis of EBV- 
induced IM substantiated following virus serological investigations. The ability 
to attribute another viral cause to IM after tests for EBV are negative would be 
advantageous. Heterophile antibody negative IM-like syndromes must be 
separated from potentially more serious illnesses such as acute leukaemia and 
malignant lymphoma.
The majority of HHV- 6  serological studies in health and disease have utilised 
assays that detected HHV- 6  specific IgG antibodies. I have developed an IFA 
to detect HHV- 6  specific IgM antibodies since their presence is likely to reflect 
active viral replication perhaps as a result of primary infection. Sera from 
patients who presented with symptoms suggesting an IM-like illness were 
chosen to be screened for HHV- 6  specific IgM and IgG antibodies. The sera 
had previously been tested for EBV specific IgM and heterophile antibodies. 
Over two thirds of the sera were from persons who were EBV IgM antibody 
negative.
The serological response to a virus is likely to consist of antibody specificities 
directed against a number of viral antigens. For example, antibodies to EBV- 
VCA arise following primary infection and persist for life, thereby acting as a 
marker for past infection. Antibodies to EBV-EA appear transiently following 
initial infection. In IM, EBV-EA-D specific antibodies may be present for up to 6  
months (Lamy et al., 1982). During EBV reactivation, often found in 
immunocompromised patients (Lange et al., 1980), pregnant women (Fleisher 
and Bolognese, 1983) and elderly people (Sumaya, 1977), the persistence or
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recurrence of elevated EBV-EA antibodies is found. In the case of EBV, the 
detection of EA specific antibodies has been used successfully to identify active 
infections and establish disease associations (Ooka etal., 1991).
The availability of a screening test to detect HHV-6 -EA antibodies may prove 
useful in distinguishing active viral replication and be used to examine the 
relationship of the virus with disease. Serological assays for HHV- 6  use 
multiple antigens as substrates. Some HHV- 6  proteins synthesised during the 
HHV- 6  replication cycle have been identified (Balachandran et al., 1989; Littler 
etal., 1990; Balachandran etal., 1991; Okuno etal., 1992; Neipel etal., 1992) 
including early antigens expressed in the presence of DNA synthesis inhibitors. 
The HHV- 6  prototype I FA, described in 2.2.4, was adapted to restrict viral 
antigen expression to early antigens only. The sera from patients with IM-like 
illness were tested for HHV-6 -EA specific IgG antibodies by this adapted IFA.
The mode of transmission of HHV- 6  is at present unknown. Although the 
majority of HHV- 6  laboratory isolates have been derived from peripheral blood 
samples, the ubiquitous nature of the virus and its prevalence in young children 
suggests that the virus is relatively easy to acquire. In parallel with EBV, a 
likely vehicle for transmission is saliva. EBV can be cultured from throat 
washings from 10-20% of normal healthy adults, from 50% of renal transplant 
recipients, and from the majority of seriously ill leukaemia and lymphoma 
patients (Strauch etal., 1974; Chang etal., 1973). IM has also been spread by 
blood transfusion and open heart surgery as the "postpump perfusion" 
syndrome (Gerber etal., 1969). There have been few reports describing the 
successful isolation of HHV- 6  from saliva (Pietroboni et al., 1988a; Levy et al., 
1990a; Harnett et al., 1990), suggesting the virus is difficult to isolate from this 
source. In this study, attempts to isolate virus from saliva were made using 
three different protocols.
In 1990, Frenkel etal. isolated a novel herpesvirus from the mitogen-stimulated 
purified CD4+ve T cells of a healthy person. This new virus had the 
morphology of a herpesvirus and limited DNA homology with HHV-6 . The virus 
was named human herpesvirus-7 (HHV-7). Since that time further isolates of 
HHV-7 have been made from saliva (Wyatt and Frenkel, 1992) and the 
peripheral blood of a person with chronic fatigue syndrome (Berneman et al., 
1992b).
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The seroprevalence of HHV-7 in the general population has been studied to a 
limited extent only (Wyatt et al., 1991). In order to investigate the age at which 
infection with HHV-7 occurs, sera were collected from hospitalised children. 
The sera were screened for antibodies to not only HHV-7, but HHV- 6  and EBV, 
to compare the ages at which infection by these three viruses occurred. The 
ability of HHV-7 to infect different cell lines in vitro was also investigated. To 
date, HHV-7 has been propagated in mitogen-stimulated CBMCs. The 
preparation and supply of cord blood limits the amount of virus that can be 
obtained and a permissive continuous cell line would aid further studies on this 
new virus.
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4.2 MATERIALS AND METHODS
4.2.1 Source Of Sera
Two hundred and thirty two serum samples were kindly provided by Dr. G.B. 
Clements and Mr. J Stewart at the Regional Virus Laboratories, Ruchill 
Hospital, Glasgow. The sera were taken from persons with a wide range of 
symptoms associated with IM and had been tested for the presence of EBV- 
IgM antibodies and heterophile antibodies using an Monospot test (Ortho 
Diagnostics). Fifty two of the sera were found to be EBV-IgM seropositive and 
79 were heterophile antibody positive.
Eleven serum samples from children aged 1 to 3 years were kindly provided by 
Dr. J. Fox, University College and Middlesex School of Medicine, London. 
Sequential serum samples from 6  patients taken at 0, 2 and 6  months which, at 
the initial or second sample, were HHV- 6  IgM positive were kindly provided by 
Dr. H. Kangro, St. Bartholomews Hospital, London.
Two hundred and thirteen serum samples taken from hospitalised children for 
diagnostic investigations were kindly provided by Dr. P. Mackie, Royal Hospital 
for Sick Children, Glasgow.
4.2.2 Indirect Immunofluorescence Assays 
(I) HHV-6. EBV-VCA. and CMV IFAs
The IFAs used to detect antibodies to HHV- 6  and EBV-VCA have been 
described in 2.2.4 and 3.2.3. A change from the protocol outlined in 2.2.4 was 
that the FITC-labelled rabbit anti-human IgG conjugate only was used. The 
assay to detect CMV specific IgM antibodies (Gullsorb) was used according to 
the manufacturers instructions.
(ii) HHV-6 IgM IFA
The original HHV- 6  IFA was modified to detect HHV- 6  specific IgM antibodies. 
Prior to screening, sera were pretreated with Gullsorb IgG Inactivation Reagent 
to remove competitive HHV- 6  IgG class antibodies and the target for 
rheumatoid factor antibodies. The product of this treatment is a 1:10 dilution of
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sera devoid of IgG antibodies. Ten microlitres of sera at a 1:10 dilution were 
spotted onto each well of an HHV- 6  antigen slide and incubated for 3 hours in a 
moisture chamber at 37°C. The slide was washed four times with PBS over 30 
minutes. Ten microlitres of a 1:25 dilution of FITC-labelled rabbit anti-human 
IgM heavy chain specific antisera (Dako) were spotted onto each well and 
incubated as above for a further 40 minutes. The slides were then washed as 
above and viewed under UV light. Sera from 232 patients with symptoms 
associated with IM were screened by this HHV- 6  IgM antibody assay. The 
same sera were also screened for HHV- 6  IgG specific antibodies as detailed 
above (see 4.2.2.i).
(iii) HHV-6-EA IFA
The assay was based on a method designed to restrict CMV antigen 
expression to EA only in infected fibroblasts (The et al., 1974). In the CMV 
protocol the DNA inhibitor cytosine arabinoside (Ara-C) was used at a 
concentration of 20pg/ml to block DNA synthesis completely as judged by 
thymidine incorporation followed by autoradiography.
In order to determine the optimal concentration of Ara-C which inhibited DNA 
synthesis of J JHAN cells, the ability of serial dilutions of Ara-C to inhibit the 
uptake of thymidine was measured. Briefly, 1 0  ^ J JHAN cells in a volume of 
90pl complete medium plus 10%FCS were placed in wells of a flat-bottomed 
96-well tissue culture plate (Flow Laboratories). A stock solution of Ara-C 
(Sigma) in PBS at a concentration of 1 mg/ml was sterilised by autoclaving. A 
series of ten-fold dilutions were set up to give a final concentration ranging from 
0.1ng/ml to 100pg/ml Ara-C when 10pl of the dilution were added to each well. 
As controls, J JHAN cells without Ara-C or complete medium plus 10%FCS 
without cells were included. Each Ara-C dilution and controls were tested in 
triplicate. The plate was incubated at 37°C in 5% CO2  overnight. Wells were 
pulsed with 1pCi tritiated methyl thymidine (Amersham) for 8  hours at 37°C. 
The contents of wells were harvested onto glass fibre filters (Flow Laboratories) 
using a Dynatech Titretek Cell Harvester. Incorporation of thymidine was 
measured on a Beckman scintillation counter. The lowest concentration of Ara- 
C at which complete inhibition of thymidine incorporation was last seen was 
1pg/ml. In the design of the HHV-6 -EA IFA, this concentration of Ara-C was 
used throughout.
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Infection of cells with murine sarcoma virus is enhanced by pretreatment with 
the polycation diethylaminoethyl-Dextran (DEAE-D) (Duc-Nguyen, 1968). A 
similar pretreatment step with DEAE-D has been reported to enhance HHV- 6  
infection in vitro (Levy et a!., 1990b). DEAE-D (Sigma) at a final concentration 
of 25pg/ml was added to each of two flasks containing 1 0 ® J JHAN cells/ml 
(total volume 25ml). Flasks were incubated at 37°C for 30 minutes. Cells were 
washed twice in complete medium. Cell pellets were resuspended in 8 ml cell- 
free HHV- 6  infected tissue culture medium previously harvested from HHV- 6  
infected J JHAN cultures when maximum cytopathic effect was apparent and 
passed through a 0.45pm pore filter (Gelman Sciences). The cells were 
incubated at 37°C for 4 hours and 17ml of complete medium was added. To 
one flask 1pg/ml Ara-C was added. The flasks were incubated at 37°C for 3 
days.
To determine the enhancing effect of DEAE-D treatment on HHV- 6  infection, 
two flasks were set up as above but without addition of Ara-C. The cells in one 
flask were mock-treated with medium without DEAE-D. After 3 days the level of 
infectivity of cells was determined by preparation of HHV- 6  antigen slides and 
IFA using HHV- 6  positive and negative sera. The level of HHV- 6  antigen 
positive cells in the DEAE-D treated culture was higher (43.5% compared to 
34.9%) than in the untreated J JHAN cells. However, the increase in the 
number of HHV- 6  infected cells following DEAE-D treatment was not sufficient 
to merit its continued use.
The preparation of HHV-6 -EA IFA slides and the IFA itself were identical to that 
described in 2.2.4 except that the FITC-labelled anti-human IgG conjugate only 
was used. Three groups of sera were screened by both the HHV-6 -EA IFA and 
the prototype HHV- 6  IFA. One group was sera from persons with IM-like 
illness, the second group was 11 sera from children aged 1 to 3 years and the 
third set was sequential serum samples from 6  persons containing at least one 
HHV- 6  IgM positive sample. All sera were screened at a 1:10 dilution.
4.2.3 Isolation Of Virus From Saliva
(i) Preparation of blood mononuclear cells
Umbilical cord bloods were kindly provided by Royal Maternity and Southern 
General Hospitals, Glasgow and Royal Alexandra Hospital, Paisley. Adult
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peripheral blood was obtained from healthy persons within the Department of 
Veterinary Pathology. Mononuclear cells were separated from whole blood by 
gradient centrifugation. Collected blood, already diluted 1:2, was further diluted 
two-fold in HBSS and 25ml layered onto 15ml Ficoll Hypaque (Pharmacia). The 
gradient was centrifuged at 800pfor 30 minutes and the interface collected and 
washed twice in HBSS. Mononuclear cells were resuspended at 1 0 $ cells/ml in 
complete medium containing 20% FCS and stimulated with 5pg/ml 
phytohaemagglutinin-M (PHA) (BCL) for 3 days. After PHA-stimulation, 
cultures were refed with medium supplemented with 5U/ml human recombinant 
IL-2 (Cetus or Amersham).
(ii) Saliva co-cultures
Saliva samples were collected from volunteers within the Department of 
Veterinary Pathology. The volunteers were asked to provide a saliva specimen 
into a sterile universal container (Sterilin) and saliva was stored at 4°C until 
use. Saliva was never stored for longer than 4 hours before being processed. 
Initially 4 saliva samples were collected. The samples were spun in a 
microcentrifuge for 5 minutes. The supernatant was removed and diluted 1:1 in 
RPMI 1640 and passed through a 0.45pm filter (Gelman Sciences). The cell 
pellet was washed five times with RPMI 1640 containing 800U/ml penicillin, 
800pg/ml streptomycin, 300pg/ml gentamicin and 5pg/ml fungizone, following 
pelleting by 2 minutes centrifugation. The cell pellet was then freeze thawed 3 
times and resuspended in 100pl complete medium. Either 100pl of cell-free 
saliva or saliva cells were added to 2.5x10® PBMCs previously stimulated with 
PHA for 48 hours in a 1 ml volume and incubated for 1.5 hours at 37°C. The 
volume was then made up to 5ml with complete medium plus 20%FCS. 
Cultures were fed every 3 days and tested at time-points by IFA for the 
expression of viral antigens using HHV- 6  positive and negative sera. Cultures 
were kept until the majority of cells were dead as determined by their failure to 
take up the dye crystal violet.
The protocol was subsequently altered to that described by Levy et al. (1990a). 
Briefly, whole saliva samples were diluted 1:3 in RPMI 1640, passed through a 
0.45pm filter and 0.4ml inoculated onto 3x10® PBMCs stimulated previously 
with PHA. As above, cells were examined for viral antigens by IFA.
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Following the study by Wyatt and Frenkel (1992), the protocol was further 
modified to the procedure used to isolate HHV-7. Saliva samples were diluted 
1:3 in complete medium containing 20%FCS and centrifuged at 2000gfor 10 
minutes. The supernatant was passed through a 0.45|im filter and the samples 
mixed 1:1 with 10® PHA-stimulated CBMCs/ml. As above, cells were sampled 
at time-points for the expression of viral antigens with HHV- 6  positive and 
negative sera using IFA. HHV-7 positive and negative serum controls were 
also included.
4.2.4 Electron Microscopy
Cells from 2 saliva/CBMCs co-cultures were examined for the presence of viral 
particles by electron microscopy (EM). Cells in culture medium were mixed 
(1:1 v/v) with a fixative of 1.3% paraformaldehyde/1.6% gluteraldehyde and 
centrifuged at 400g for 7 minutes. One millilitre of fresh fixative was then 
added. Post-fixation of the cells was carried out using Osmium fix in Millong's 
buffer. The samples were dehydrated through a series of acetone washes. 
The samples were then impregnated with araldite resin and embedded and 
cured in EM capsules. Sections were cut and examined by EM using a Zeiss 
transmission microscope. The processing of the cell pellets following the initial 
fixation step and their subsequent examination was carried out by staff in the 
EM unit of the department under the supervision of Dr. Helen Laird.
4.2.5 Propagation Of HHV-7 In Vitro
The original isolate of HHV-7 (RK-strain) was kindly provided by Dr. N. Frenkel, 
National Institute of Allergy and Infectious Diseases, USA. Virus was 
propagated in PHA-stimulated CBMCs. Virus was passaged onto uninfected 
cells when greater than 50% of cells appeared infected by altered morphology 
in culture or by expression of viral antigens by IFA. HHV-7 infected CBMCs 
were cocultivated with a number of continuous cell lines. Infected CBMCs were 
mixed with the target cell line at a ratio of 1:5. Viral cytopathic effect 
characterised by large cells and viral antigen expression using IFA with HHV-7 
positive and negative sera were used to examine the co-cultures for evidence 
of HHV-7 infection.
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4.2.6 HHV-7 IFA
The HHV-7 IFA was identical to the HHV- 6  IFA described in 2.2.4. HHV-7 (RK- 
strain)-infected CBMCs were used as a source of antigen. Uninfected CBMCs 
were used as controls. Sera from 213 children from the Royal Hospital for Sick 
Children and 29 adults from within the Department of Veterinary Pathology 
were tested by IFA for antibodies to HHV-7 at a serum dilution of 1:10 in 
HBSS. The children's sera were also tested for the presence of antibodies to 
HHV- 6  and EBV-VCA by IFA. The sera of children aged 1 to 4 years (12-59 
months) seropositive at a 1:10 dilution for either HHV-7 of HHV- 6  were re­
screened at a dilution of 1:80. The serology results in the 1 +2 years and 3+4 
years age groups were statistically analysed in three groups based on antibody 
titres (10,10-40, £80), for correlation between HHV- 6  and HHV-7 antibody titres 
using a Spearman's p rank correlation analysis, on the statistical package 
Minitab.
4.2.7 Identification Of Two Herpesvirus Isolates
Two viral isolates were derived from saliva samples following co-cultivation with 
CBMCs. Viral antigen expression was determined using characterised human 
sera which consisted of HHV- 6  positive and negative and HHV-7 positive and 
negative controls. The two isolates were tested by IFA for reactivity with mouse 
monoclonal antibodies (MoAbs) to known human herpesviruses. The IFA was 
similar to that described in 2.2.4 except that an FITC-labelled goat anti-mouse 
IgG conjugate (Sigma) was used. The antibody reagents were: a pool of HHV- 
6  specific MoAbs used at a 1:10 dilution, provided by Dr. J. Fox, University 
College and Middlesex School of Medicine, London; a MoAb that reacts with 
EBV-VCA (DuPont) used at a 1:10 dilution; a MoAb that reacts with the late 
nuclear protein of CMV (DuPont) used at a 1:10 dilution.
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4.3 RESULTS
The serology of HHV- 6  has mainly relied on IFAs and ELISAs that have been 
designed to detect IgG class antibodies specific to a range of viral antigens. In 
this study the HHV- 6  IFA was adapted to detect either antibodies of the IgM 
subclass, which are present following primary infection, or antibodies to HHV-6 - 
EA which are likely to be detectable following active viral replication.
4.3.1 HHV-6 Serology In IM-Like Illness
A total of 232 serum samples from persons with a variety of symptoms 
associated with IM-like illness were screened by both HHV- 6  IgG and IgM IFAs. 
One hundred and seventy seven of the sera were HHV- 6  IgG antibody positive. 
Ten serum samples were HHV- 6  IgM seropositive (all 10 were also HHV- 6  IgG 
seropositive) with titres ranging from 10 to 160 (Table 4.3.1). The same group 
of sera had previously been tested for the presence of both heterophile and 
EBV IgM antibodies. Eight of the 10 HHV- 6  IgM positive sera were both 
heterophile and EBV IgM seropositive, suggestive of primary EBV infection. A 
further patient, although EBV IgM seronegative, was heterophile antibody 
positive and had a raised EBV IgG titre, consistent with a diagnosis of EBV- 
induced IM. Two of the HHV- 6  IgM positive sera were also CMV IgM 
seropositive (Table 4.3.1).
Only one person in this study population was HHV- 6  IgM seropositive, 
heterophile antibody and EBV IgM seronegative. This person was also 
seropositive for EBV-VCA and EBNAs (data not shown) indicative of prior 
exposure to EBV. The serological findings suggested either primary or 
reactivated HHV- 6  infection in this individual and an absence of CMV or EBV 
infection or reactivation.
4.3.2 Development Of HHV-6-EA IFA
The 232 sera from persons with IM-like illness were also tested for antibodies to 
HHV-6 -EA by the modified IFA. Only 3 of the sera were found to be positive by 
this assay (Fig. 4.3.1). A further two groups of sera were screened in which the 
detection of EA antibodies would be predicted. Sequential serum samples 
from 6  individuals who had detectable HHV- 6  IgM antibodies in either the initial 
or second serum samples were tested. None of these sera were HHV-6 -EA
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Figure 4.3.1
DETECTION OF ANTIBODY TO HHV-6-EARLY ANTIGEN BY IFA
Figure 4.3.1 Immunofluorescent microscopy of an IFA designed to detect HHV- 
6-EA antibody. Infected J JHAN were treated with an inhibitor of DNA synthesis 
to prevent expression of HHV-6 late proteins and used as a source of antigen. 
Three of 232 sera from persons with IM-like illness were positive by this assay at 
a 1:10 serum dilution. Staining patterns obtained with two sera from patients 
with IM-like illness are shown. Both sera were HHV-6 antibody positive using the 
IFA described in 2.2.4. A. Positive staining which suggests the serum sample 
contained HHV-6-EA antibody B. Negative staining which suggests the serum 
was HHV-6-EA antibody negative (x250).
antibody positive. In a group of 11 sera from young children, where recent 
HHV- 6  infection was presumed, two serum samples were scored positive by 
HHV-6 -EA IFA (Table 4.3.2). These 2 serum samples were derived from the 
same child and were taken 5 weeks apart. A stronger reactivity was observed 
with the first serum sample.
The modified IFA appeared unsuitable for the detection of HHV-6 -EA specific 
antibodies. The level of EA present in Ara-C treated infected J JHAN may be 
limited and thus, affect the sensitivity of the assay. Possibly the method of 
fixation did not preserve the reactive epitopes of HHV-6 -EA. Alternatively, the 
positive staining pattern visualised with a limited number of serum samples was 
non-specific. However, the same sera tested on uninfected Ara-C treated J 
JHAN were negative.
4.3.3 Isolation Of Virus From Saliva
The first protocol adopted to isolate virus from both cell-free and cellular saliva 
was unsuccessful. This procedure involved washes of saliva cells in high 
concentrations of antibiotics and freeze-thawing in order to avoid bacterial and 
fungal contamination in tissue culture. Such pretreatment of saliva may affect 
the viability of infectious virus. However, no virus was isolated from cell-free 
saliva cultures where such pretreatment was not necessary.
The isolation protocol of Levy et al. (1990a) was adopted for a further 8  saliva 
samples. At day 9 of co-culture with PBMCs, no viral antigen expression was 
detected by IFA with HHV- 6  positive and negative control human sera. After 13 
days, 2 co-cultures were positively stained with both the HHV- 6  positive and 
negative sera. No viable material from these cultures was available to passage 
the infection to fresh PBMCs. Attempts to passage the infection with stored 
tissue culture supernatants were unsuccessful. However, the reactivity with 
characterised human sera suggested that the infectious agents were not HHV- 
6.
Two co-cultures of cell-free saliva and CBMCs were set-up according to the 
procedure of Wyatt and Frenkel (1992) used to isolate HHV-7. In both cases 
viral antigen expression was detected at 7 and 10 days of co-culture 
respectively. Up to 50% of cells were stained with both the HHV- 6  positive and 
negative control sera (both HHV-7 seropositive). Reactivity was detected with
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Table 4.3.2
ANTIBODY STATUS OF CHILDREN'S SERA TO HHV- 6  ANTIGENS
Sample Number
1
2
3
4
5
6
7
8
9
10 
11
HHV- 6  positive control 
HHV- 6  negative control
HHV-6 -prototype IFA
+
+
+
+
+
+
+
+
+
+
+
+
HHV-6 -EA IFA
+
+
an HHV-7 seropositive control, but not with an HHV-7 negative control (weakly 
HHV- 6  seropositive). The infection was passaged in both cases to fresh PHA- 
stimulated CMBCs maintained on IL-2. Examination of infected CBMCs by 
electron microscopy detected the presence of herpesvirus particles in both co­
cultures (Fig. 4.3.2).
4.3.4 Prevalence Of Antibody To HHV-7. HHV-6. And EBV Bv Aae
The ages of acquisition of antibodies to HHV-7, HHV- 6  and EBV were 
examined using sera from 213 children ranging in age from < 2  months to > 1 0  
years. There was a decline in the prevalence of antibodies to all 3 viruses over 
the first 6  months of age (Table 4.3.3) consistent with the decline of maternally- 
derived antibodies. A rise in the seroprevalence of the 3 viruses in 10+11 
month old children suggested primary infection in a number of children. As 
previously reported the majority of children (31/41, 82.9%) had seroconverted 
to HHV- 6  by the age of 2 years. Similarly, the majority of 1+2 year olds were 
HHV-7 seropositive (27/41, 65.9%). Although fewer children were HHV-7 
seropositive in this age group compared to HHV- 6  the difference was not 
statistically significant. The rate of HHV-7 seropositivity rose to 28/30 (93.3%) 
in 3+4 year olds compared to 21/30 (70.0%) seropositive for HHV-6 , a 
statistically significant difference. In the 1+2 year olds, the lowest rate of 
seropositivity to the 3 viruses was found for EBV (21/41, 51.2%). Table 4.3.4 
reports the number of sera in each age group that were either dual or triple 
seropositive for HHV-7, HHV-6 , and EBV.
Our results differed from the initial study of HHV-7 seroprevalence in children 
which reported that infection was uncommon in 1 +2 year olds (Wyatt et a/., 
1991). In 1+2 year olds where HHV- 6  infection is common, it was possible that 
antibodies cross-reactive with HHV-7 could have been detected at our 
screening dilution of 1:10. The problem of cross-reactive antibodies was 
addressed by Wyatt et al. (1991) who investigated HHV-7 antibody titres in 
patients with exanthem subitum. There was some evidence that low titres to 
HHV-7 (<80) were present in sera during the convalescent phase although 
concurrent HHV-7 infection could not be ruled out.
We therefore screened the sera in the 1+2 and 3+4 year old age groups for 
HHV- 6  and HHV-7 antibodies at a dilution of 1:80. At this higher dilution 17/41 
(41.5%) of the 1+2 and 13/25 (52.0%) of the 3+4 year olds were HHV-7
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Figure 4.3.2
DETECTION OF HERPESVIRUS PARTICLES IN SALIVA CO-CULTURE 
CELLS BY ELECTRON MICROSCOPY
Figure 4.3.2 Detection of herpesvirus particles in a co-culture of CBMCs and cell- 
free saliva (from volunteer RJ) by electron microscopy. The virus particles 
shown are extracellular (x100,000).
Table 4.3.3
SEROPOSITIVITY TO HHV-7. HHV-6. AND EBV BY AGE
AGE No. of Sera No. HHV-7 No. HHV-6 No. EBV
SeroDositive SeroDositive SeroDositive
Months
<2 18 17 (94.4%) 15(83.3%) 17 (94.4%)
2+3 11 8 (72.7%) 4 (36.4%) 11 (100%)
4+5 13 2(15.4%) 4 (30.8%) 8(61.5%)
6+7 10 2 (20.0%) 3 (30.0%) 5 (50.0%)
8+9 10 6 (60.0%) 6 (60.0%) 5 (50.0%)
10+11 12 7 (58.3%) 7 (58.3%) 7 (58.3%)
Years
1+2 41 27 (65.9%) 34 (82.9%) 21 (51.2%)
41 17(41.5%)* 20 (48.8%)*
3+4 30 28 (93.3%) 21 (70.0%) 21 (70.0%)
25 13(52.0%)* 13(52.0%)*
5+6 18 15 (83.3%) 14(77.8%) 13 (72.2%)
7+8 16 12 (75.0%) 14 (87.5%) 11 (68.8%)
9+10 16 15 (93.8%) 11 (68.8%) 12 (75.0%)
>10 18 14(77.8%) 18(100%) 13 (72.2%)
Adults 29 28 (96.6%) ND ND
* Sera screened at dilution of 1:80 
ND = Not Done
Table 4.3.4
DUAL AND TRIPLE SEROPOSITIVITY TO HHV-7. HHV-6 . AND EBV BY AGE
AGE No. of Sera No. HHV-7/ No. HHV-7/ No. HHV-6/ No. HHV-7/
HHV- 6 EBV EBV EBV/HHV-6
Seropositive Seropositive Seropositive SeroDositive
Months
<2 18 0 (0%) 6 (33.3%) 0 (0%) 11 (61.1%)
2+3 11 0 (0%) 4 (36.4%) 1 (9.1%) 3 (27.3%)
4+5 13 0 (0%) 1 (7.7%) 1 (7.7%) 1 (7.7%)
6+7 10 0 (0%) 1 (10.0%) 1 (10.0%) 1 (10.0%)
8+9 .10 2 (20.0%) 3 (30.0%) 1 (10.0%) 1 (10.0%)
10+11 12 1 (8.3%) 1 (8.3%) 0 (0%) 4 (33.3%)
Years
1+2 41 12(29.3%) 3 (7.3%) 6(14.6%) 11 (26.8%)
3+4 30 5(16.7%) 5(16.7%) 0 (0%) 15 (50.0%)
5+6 18 3(16.7%) 2(11.1%) 1 (5.6%) 9 (50.0%)
7+8 16 3(18.8%) 1 (6.3%) 3(18.8%) 7 (43.8%)
9+10 16 2(12.5%) 4 (25.0%) 0 (0%) 8 (50.0%)
>10 18 3(16.7%) 0 (0%) 2(11.1%) 11 (61.1%)
seropositive, compared to 20/41 (48.8%) and 13/25 (52.0%) for HHV- 6  in these 
age groups respectively. Analysing the serology results in the 1+2 and 3+4 
year old age groups following division into 3 groups on the basis of antibody 
titre (<10, 10-40, £80), little correlation was found between HHV- 6  and HHV-7 
antibody titres. For the 1+2 year olds the Spearman's p rank correlation 
analysis = 0.021 and for the 3+4 year olds, the value was 0.193. Although not 
totally ruling out the presence of cross-reactive antibodies it would appear that 
in our study population HHV-7 infection occurred at a younger age than 
previously reported.
4.3.5 Propagation Of HHV-7 In Continuous Cell Lines
A disadvantage of the present system used to propagate HHV-7 is the 
requirement for CBMCs. A number of continuous cell lines were tested for their 
ability to support HHV-7 infection. Table 4.3.5 describes the results. None of 
the cell lines initially tested were permissive for HHV-7 infection. Following the 
success of Berneman et al., (1992a) to infect the immature T cell line SUP-T1 
with the Jl strain of HHV-7, we successfully infected SUP-T1 cells with HHV-7 
(RK-strain) and the two putative isolates of HHV-7 (DC and RJ) derived from 
saliva (see 4.3.3). In all cases infection was suspected by the appearance of 
large cells as well as balloon-like cells (Fig. 4.3.3) and confirmed by 
identification of viral antigens using an IFA with HHV-7 positive and negative 
sera (Fig. 4.3.4). Adherent cells were present in infected but not uninfected 
cultures. All 3 viruses were passaged onto uninfected cells at a ratio of 1:5 
infected to uninfected cells. In the case of HHV-7 (RK-strain), infection of 
SUPT-1 cells was maintained following inoculation with 0.45pm-filtered tissue 
culture supernatant derived from infected SUP-T1 cells.
SUP-T1 cells infected with the RK-strain of HHV-7 or putative HHV-7 isolates, 
DC or RJ, were used as a source of antigen in an IFA using monoclonal 
antibodies against known human herpesviruses (Table 4.3.6). No reactivity 
was found with a pool of monoclonal antibodies raised against HHV- 6  and a 
monoclonal antibody specific for EBV-VCA. Very weak reactivity was found 
with all 3 isolates using a monoclonal antibody specific for the late nuclear 
protein of CMV. Our preliminary analyses would suggest that the saliva 
herpesvirus isolates are further isolates of HHV-7.
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Table 4.3.5
ABILITY TO INFECT CELL LINES WITH HHV-7 (RK-STRAIN)
CellJine Cell TvDe Origin HHV-7 Infection
GHI T ALL -
HPB T ALL -
Peer 78 T ALL -
JM T ALL -
CEM T ALL -
C8166 HTLV-1 Trans. Cord Blood -
U937 Promonocytic HL -
L540 - HD -
HO - HD -
HSB-2 T ALL -
SUP-T1 T NHL +
CBMCs T and B - +
ALL=acute lymphoblastic leukaemia, HL=histiocytic lymphoma, 
HD=Hodgkin's disease, NHL=Non-Hodgkin's lymphoma, CBMCs=PHA- 
stimulated cord blood mononuclear cells, Trans=transformed.
Figure 4.3.3
MORPHOLOGY OF HHV-7 (RK-STRAIN) INFECTED SUP-T1 CELLS IN CELL
CULTURE
A.
Figure 4.3.3 Appearance of HHV-7 infected and uninfected SUP-T1 cell cultures 
as viewed by light microscopy. A. Uninfected culture. B. HHV-7(RK-strain) 
infected culture which characteristically contains large, balloon-like cells (x200).
Figure 4.3.4
DETECTION OF VIRAL ANTIGENS -7 (RK-STRAIN) INFECTED SUP-
T1 CELLS BY IFA
A.
B.
Figure 4.3.4 Immunofluorescent microscopy of HHV-7 (RK-strain) infected SUP- 
T1 using human sera. A. HHV-7 antibody negative, HHV-6 antibody positive 
serum. B. HHV-7 antibody positive, HHV-6 antibody negative serum. Both sera 
were used at a 1:10 dilution (x250).
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4.4 DISCUSSION
The strongest association between HHV- 6  and disease at present is that 
primary infection can result in the childhood illness exanthem subitum 
(Yamanishi et al., 1988). Beyond childhood the clinical outcome of HHV- 6  
infection is less clear.
A number of early case reports suggested HHV- 6  infection was associated with 
IM-like illness in adults (Kirchesch et al., 1988; Niederman et al., 1988; Irving 
and Cunningham, 1990) allowing parallels in the epidemiology of EBV and 
HHV- 6  to be drawn. The majority of children are infected sub-clinically with 
EBV and HHV- 6  early in life. However, if primary infection is delayed until the 
second decade of life or beyond then IM can result. In our group of patients 
with a wide variety of symptoms associated with IM, only one case of probable 
HHV-6 -induced IM-like illness was identified. This patient was diagnosed by 
her General Practitioner as having a post-viral syndrome involving fatigue and 
depression over a period of 5 months. It is not possible to determine if HHV- 6  
infection or reactivation occurred either as a primary event or subsequently 
during the course of illness. Interestingly, the clinical presentation of this case 
is similar to a group of patients with chronic fatigue who have a pattern of 
illness suggestive of glandular fever and are associated serologically with HHV- 
6  (Read et al., 1990). HHV- 6  active replication as a result of viral reactivation 
may occur with increased frequency in adults with chronic fatigue syndrome 
(CFS) (Josephs et al., 1991; Buchwald et al., 1992). However, the clinical 
relevance of HHV- 6  reactivation in CFS is unclear.
The majority of IM cases are attributable to primary EBV infection. The 
remainder of cases, which usually lack heterophile antibodies, can be 
attributable to a number of other infections particularly CMV and perhaps less 
frequently, HHV-6 . Horwitz et al. (1992) have suggested that in a study group 
of 253 patients with heterophile negative IM-like illness, HHV- 6  infection was 
responsible for 5% of the cases. Other EBV-negative IM cases have been 
associated with IgM antibody to HHV- 6  (Irving and Cunningham, 1990; Steeper 
e ta l, 1990).
We detected HHV- 6  IgM antibodies in the sera of 9 persons with apparent EBV- 
induced IM. These findings may represent a dual infection with EBV and HHV- 
6 . Dual infection with EBV and HHV- 6  has been described previously (Bertram
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etal., 1991) although reactivation of HHV- 6  following primary EBV infection was 
suggested to occur more frequently. The detection of HHV- 6  IgM antibodies 
can occur not only following primary infection, but also virus reactivation (Fox et 
al., 1990b). An as yet undefined interaction between EBV during primary 
infection and latent HHV- 6  may result in reactivation and increased HHV- 6  IgG 
antibody titres. Likewise, a similar interaction between CMV and HHV- 6  
resulting in the frequent reactivation of the latter has been reported in 
immunosuppressed organ transplant recipients (Ward et al., 1991; Ward et al., 
1993) and immunocompetent patients (Irving et al., 1990) with proven primary 
CMV infection. HHV- 6  reactivation has also been reported in children with 
acute measles infection (Suga etal., 1992).
The effect on clinical outcome of either dual infection or reactivation of HHV- 6  in 
EBV-induced IM is unknown. Hepatic dysfunction has been noted to be more 
significant in patients with dual EBV/HHV- 6  infections than in patients with 
either infection alone (Bertram et al., 1991). Similarly the role of HHV- 6  in 
interstitial pneumonitis in bone marrow transplant patients may be complicated 
by dual infection with CMV (Carrigan, 1992). It is clear that HHV- 6  serological 
results in diseases such as IM must be interpreted in the context of findings of 
serological assays for other infectious agents such as EBV and CMV.
Antibodies to specific viral antigens can be more appropriate in detecting recent 
or active viral infection. Antibodies to EBV-EA and CMV-EA are detectable in 
the sera of persons following primary infection and episodes of active 
replication. Our HHV-6 -EA IFA failed to detect HHV-6 -EA specific antibodies in 
sera where their presence might be expected. It is probable that the assay was 
not of an adequate sensitivity although a similar experimental approach had 
been used successfully to detect antibodies to CMV-EA.
Using a different approach Iyengar et al. (1991) developed an HHV-6 -EA 
antibody assay by purifying HHV-6 -EA from infected cell lysates with an HHV-6 - 
EA MoAb. Antibodies to HHV-6 -EA were found in 30% of healthy individuals 
and 29% of persons with heterophile negative IM suggesting recent viral 
replication. Interestingly 62.5% of HD sera were HHV-6 -EA antibody positive 
indicating that HHV- 6  replication occurs at a greater frequency in that 
malignancy.
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There are a number of possible modes of transmission of HHV-6 . Congenital 
transmission of HHV- 6  has been reported (Dunne and Demmler, 1992; Aubin et 
al., 1992). The detection of HHV- 6  in oropharynx and salivary glands of healthy 
adults (Fox et al., 1990a; Gopal et al., 1990) and the isolation of virus from 
saliva (Harnett et al., 1990; Levy et al., 1990a) suggests the virus may be 
transmitted through contact with infected oral secretions.
We were unable to isolate infectious HHV- 6  from saliva by 3 different isolation 
protocols. Despite this, a number of the same saliva specimens were used in 
the study of Jarrett et al. (1990) and found to be positive for HHV- 6  by PCR. 
The HHV- 6  PCR strategy used in that study does not amplify sequences from 
other human herpesviruses including HHV-7, providing strong evidence that 
HHV- 6  was present in the saliva. Our results suggest that the virus was not 
present in an infectious form. Others have also been unsuccessful in the 
isolation of HHV- 6  from this source (Yanagi et al., 1990) although Pietroboni et 
al. (1988a), Levy et al. (1990a) and Harnett et al. (1990) have reported the 
isolation of HHV- 6  from saliva. Successful isolation may be dependent on the 
methodology used such as centrifugal enhancement (Harnett et al., 1990). 
Based on the procedure of Levy et al. (1990a), infectious agents from two 
saliva samples were isolated that, after limited analyses, were unlikely to be 
HHV-6 . Levy et al. (1990a) propagated herpesvirus isolates in PBMCs in the 
course of virus isolation. It is possible that HHV- 6  isolates originated from 
reactivated virus from the PBMCs used in co-culture. Wyatt and Frenkel (1992) 
suggested that HHV-7 isolation from saliva may have been outreplicated by 
HHV- 6  rescued from PBMCs.
The HHV- 6  saliva isolates of Harnett et al. (1990) were propagated in CBMCs 
which should be free from HHV- 6  infection. However, in their study, the authors 
identified isolates by reactivity with characterised human sera. From our own 
and others' results (Clark et al., 1993; Wyatt et al., 1991; Berneman et al., 
1992a), the majority of adult human sera are HHV-7 seropositive. The 
clarification of these isolates as HHV- 6  would provide conclusive proof of the 
ability to isolate the virus from saliva.
Preliminary analyses suggests that in our study 2 further isolates of HHV-7 
have been made from the saliva of healthy adults. Molecular studies to identify 
these viruses have confirmed that they are HHV-7 (Z. Berneman, personal 
communication). HHV-7 has been isolated from both peripheral blood and
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saliva. Two further groups have recently reported the frequent isolation of 
HHV-7 from saliva (Black et al., 1993; Hidaka et al., 1993) and one group has 
isolated HHV-7 from the peripheral blood of a child with an illness similar to 
chronic EBV infection (Kawa-Ha etal., 1993). As yet the cell tropism of HHV-7, 
both in vivo and in vitro, has not been fully recognised. In vitro the virus can be 
propagated in activated CBMCs and PBMCs (Frenkel etal., 1990; Berneman et 
al., 1992a,b). Double immunofluorescence studies showed that HHV-7 Jl strain 
predominantly infected T lymphocytes (Berneman et al., 1992a). The authors 
failed to infect all continuous cell lines tested but one, SUP-T1 cells. Likewise, 
we were unable to infect a number of lymphoid cell lines with HHV-7 RK-strain. 
Recently we have been able to infect SUP-T1 with not only HHV-7 RK, but also 
the two putative HHV-7 isolates. To date infection with these 3 viral isolates 
has been maintained by passaging infected cells onto uninfected SUP-T1 cells. 
An HHV-7 permissive continuous cell line will facilitate future studies such as 
serological investigations where the supply and preparation of CBMCs proved 
to be a limiting factor.
At present it is not known whether HHV-7 infection is associated with human 
disease. Epidemiological information is scarce. We found that infection with 
HHV-7 and HHV- 6  was common in children by the age of 2 years. By 4 years 
of age 93.3% of children were HHV-7 seropositive. In contrast, Wyatt et al. 
(1991) found that HHV-7 infection occurred at an older age in children than 
HHV-6 . Sera in our sample population were derived from hospitalised children 
from a different geographical locale which may have influenced the findings. 
Our sample numbers were considerably larger than the 25 sera from children 
aged from newborn to 58 months screened by Wyatt et al. (1991). This would 
be the most likely explanation for the different results.
Wyatt et al. (1991) suggested that antigenic cross-reactivity between HHV- 6  
and HHV-7 may interfere with IFAs. A similar situation had previously been 
proposed to occur between HHV- 6  and CMV (Larcher etal., 1988) although this 
proved to be unfounded for various HHV- 6  serological assays (Morris et al., 
1988; Buchbinder et al., 1989; Coyle et al., 1992). Our analyses did not 
support the idea of cross-reactive antibodies between HHV- 6  and HHV-7 
affecting the IFAs.
The HHV-7 serological results confirm the widespread nature of HHV-7 
infection in the population and indicate that primary infection may occur even
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earlier in life than previously proposed. The relevance of HHV-7 infection to 
human disease remains to be answered by future research.
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CHAPTER 5
AN IN VITRO MODEL TO STUDY VIRAL INVOLVEMENT AND 
MECHANISMS OF AUTOIMMUNITY IN SJOGREN'S SYNDROME
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5.1 INTRODUCTION
Sjogren's syndrome (SS) is a chronic autoimmune disease characterised by 
lymphocytic infiltration and inflammation of exocrine glands, principally salivary 
and lacrimal, leading to diminished or absent glandular secretion. The majority 
of infiltrating cells in SS salivary glands are T cells with a predominantly T 
helper/inducer phenotype (Lindahl et al., 1985). The infiltrate contains a 
smaller population of B cells. In lacrimal glands the infiltrate similarly contains a 
mixture of T and B cells although B cells predominate (Pepose et al., 1990). 
The term SS is generally used but sicca syndrome and less frequently Mikulicz 
disease (Morgan and Castleman, 1953) have been used for various 
expressions of the same condition. Multi-organ involvement, notably of the 
lungs (Constantopoulos et al., 1984), kidneys (Bardana and Montanaro, 1990), 
and skin (Bloch et al., 1965), emphasises the systemic nature of SS. SS may 
be present as a primary disease process (primary SS) or in association with 
another connective tissue disease (secondary SS) such as rheumatoid arthritis, 
systemic lupus erythematosus and occasionally scleroderma (reviewed by Aziz 
etal., 1992).
The aetiology of SS is unknown but is thought to be an interaction of genetic, 
hormonal and environmental factors. There is an increase in the frequency of 
HLA-B8 , DR3 and Dw52 antigens in patients with primary SS (Bardana and 
Montanaro, 1990; Arnett etal., 1988; Fei et al., 1991) and secondary SS has 
been linked to HLA-DR4 (Moutsopoulos et al., 1979). Association with HLA 
may vary with ethnic group. In Japan, a strong association between primary 
and secondary SS with rheumatoid arthritis and HLA-DRw53 has been reported 
(Moriuchi et al., 1986). SS is more common in middle aged to elderly females 
than in males, suggesting hormonal influences in the development of disease.
Viruses are amongst environmental agents that have been considered as 
aetiological factors in SS (Flescher and Talal, 1991). Research has mainly 
focused on two families of viruses, the retroviruses and herpesviruses. More 
recently, contradictory evidence for an association of Hepatitis C virus with SS 
has been reported (Haddad et al., 1992; Aceti et al., 1992; Mariette et al., 
1993).
The role of retroviruses in autoimmunity in general has recently been reviewed 
(Krieg and Steinberg, 1990; Venables and Brookes, 1992a). Clinical features of
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SS including parotid gland enlargement were reported in intravenous drug 
users (Smith et al., 1988) who were at a high risk from HTLV-1, -11, and HIV 
infection (Robert-Guroff et al., 1986). Similarly, a sicca syndrome or SS-like 
illness has been described in persons infected with HIV-1 (Itescu et al., 1989). 
Talal et al., (1990) found antibodies that cross-reacted with the p24 (gag) 
protein of HIV-1 in 30% of SS patients. The authors suggested retroviral 
expression in at least a subset of SS patients. Type A intracisternal retroviral 
particles have been reported in co-cultures of SS salivary gland homogenates 
and the H-9 cell line (Garry et al., 1990). In Japan, where HTLV-1 infection is 
endemic, the virus has been suggested to play a part in the pathogenesis of a 
subset of cases of primary SS (Eguchi et al., 1992). Green et al. (1989) 
developed a transgenic mouse line that expresses the tax gene of HTLV-1. 
These mice developed similar pathology in the salivary gland to that found in 
SS. Thus, separate lines of evidence suggest that retroviral infection may play 
a role in SS.
The herpesviruses CMV and EBV have been proposed as possible causal 
agents of SS (Burns, 1983; Fox et al., 1986b). More recently HHV- 6  has also 
been linked with SS. Higher antibody titres to HHV- 6  were reported in SS 
(Ablashi etal., 1988) although not consistently (Baboonian etal., 1990). HHV- 6  
DNA and protein have been described in major (Fox et al., 1990a) and minor 
(Krueger et al., 1990) salivary glands. HHV- 6  has been detected rarely in 
biopsy tissue from persons with NHL however, there has been a significant 
overrepresentation of HHV- 6  positive NHLs occurring in the context of SS 
(Josephs etal., 1988; Jarrett etal., 1988). The development of malignancy is a 
recognised feature of autoimmune disease (Kinlen, 1992) including SS (Kassan 
etal., 1978).
The risk of lymphoma in SS has been estimated to be 44 times greater than 
expected (Kassan et al., 1978). The risk of lymphoma may be higher in 
patients with parotid gland swelling (Relative Risk=66.7) compared to those 
without (Relative Risk=12.5). The autoimmune disorder may precede the 
development of lymphoma by intervals as long as 20 years. The natural history 
of this progression has been separated into 3 categories. The first stage 
comprises the characteristic features of SS. The term "pseudolymphoma" or 
"pre-lymphoma" has been used to describe the second stage (Talal etal., 1967; 
Anderson and Talal, 1972) where the clinical picture is suggestive of 
malignancy but which cannot be classified as such after tissue biopsy. The
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third stage is the development of a malignant lymphoma. The lymphomas may 
involve salivary glands or major parenchymal organs such as lungs, kidney, 
and gastrointestinal tract (Talal and Bunim, 1964).
The identification of viruses in salivary gland tissue has made use of fixed 
tissues, relying on either frozen or paraffin-embedded sections for 
immunostaining, DNA hybridisation and PCR assays. Labial salivary glands 
have been cultured in vitro for immunological and virological studies (Cremer et 
al., 1974) and Lamey etal. (1984) developed a protocol for the tissue culture of 
epithelial cells from such glands. I have adapted this procedure to obtain 
salivary gland cell populations derived from minor salivary glands taken from 
persons undergoing investigation for xerostomia and therefore, potential SS 
cases. The primary salivary gland cultures provided an opportunity to 
investigate mechanisms of autoimmunity associated with SS, and to examine 
these cultures for the presence of viruses associated with the disease.
Although there are no universally accepted diagnostic criteria for SS, a number 
of classification schemes have been proposed. These can be based on 
objective tests such as measurement of salivary or tear flow rates, however, all 
schemes require the presence of lymphocytic infiltrates around salivary glands 
in biopsy specimens (Fox et al., 1986c; Skopouli et al., 1986; Homma et al., 
1986; Manthorpe et al., 1986). Parotid gland biopsy has been advocated in 
preference to labial glands in these investigations on the grounds that the gland 
is most affected in the disease process (Ferguson et al., 1990). However to 
reduce the risk of damage to important anatomical structures, biopsy of the 
minor salivary glands of the lower lip has been used for many years as the 
histological changes there appear to correlate with those in the parotid and 
submandibular glands (Wise et al., 1988; Bertram and Hjorting-Hansen, 1970; 
Chisholm et al., 1970). Thus, minor salivary glands can be obtained from 
persons, usually presenting with xerostomia, who are undergoing investigation 
for the presence of lymphocytic infiltration.
A common feature of SS is the presence of autoantibodies directed against 
nuclear autoantigens particularly La (SS-B) (Akizuki et al., 1977; Harley et al., 
1986; Harley, 1987). SS patients with anti-La antibodies have more active and 
severe disease (Harley et al., 1986). La is a transcription termination factor for 
RNA polymerase III and selected RNA polymerase II transcripts (Rinke and 
Steitz, 1982; Stefano, 1984; Madore et al., 1984; Gottlieb and Steitz, 1989a,b) 
including the EBV EBER transcripts (Lerner etal., 1981; Howe and Shu, 1988).
87
The mechanism by which anti-La antibodies are generated is unknown. 
Molecular mimicry with a possible viral protein, feline sarcoma virus gag leader 
protein, has been suggested (Kohsaka et al., 1990). McNeilage et al. (1990) 
detected a primary reaction against an immunodominant epitope of the La 
protein in the sera of SS patients which in later stage disease was followed by 
the appearance of anti-La antibodies directed against other regions of the La 
molecule. The initial immunodominant region of La contains the epitope with 
homology to the viral gag protein. Alternatively, the antigen itself may be the 
initial target that is presented to the immune system. Baboonian et al. (1989) 
reported a translocation of La from the cell nucleus to the cytoplasm and cell 
surface following viral infection of a continuous cell line. Cell surface 
expression could promote the presentation of La epitopes to the immune 
system. The effect of viral infection of salivary gland epithelial cells on the 
cellular location of La was investigated.
An immunohistological feature of salivary glands in SS is the aberrant 
expression by epithelial cells of MHC class II molecules (Lindahl et al., 1985; 
Fox et al., 1986a) possibly induced by the cytokine interferon-? (IFN-?) (Fox et 
al., 1986a). The effect of IFN-? on MHC class II expression and the cellular 
location of La in salivary gland cultures was also examined.
The ability to culture salivary gland epithelilal cells In vitro allowed a novel 
approach to investigate the association of EBV and HHV- 6  with SS. The 
presence of these two viruses was examined by PCR in epithelial cell cultures 
derived from patients diagnosed with SS and from persons lacking histological 
evidence of lymphocytic infiltrates in salivary glands. Such persons were given 
a diagnosis of non-specific sialadenitis.
A number of salivary gland epithelial cell populations were also examined by 
immunostaining for the expression of putative retroviral gene products in 
collaboration with workers at the Kennedy Institute of Rheumatology, London. 
Amongst the antibody reagents used was an antisera raised against a peptide 
predicted from an open reading frame of an endogenous retrovirus, HTLV-1 
related endogenous sequence-1 (HRES-1) (Perl et al., 1989) and a MoAb 
directed against HTLV-1 p19 antigen.
Finally, the numbers of salivary gland cells that result from the tissue culture of 
minor salivary glands are limited. Previously, Fox et al. (1986a) reported a
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salivary gland cell line derived from a parotid gland tumour. We attempted to 
immortalise primary salivary gland epithelial cells using an adenovirus/SV40 
hybrid transforming virus that contains the large T antigen of SV40. The virus 
can infect epithelial cells which are permissive for adenovirus and the SV40 
large T is thought to interact with Rb and p53 to promote immortalisation and 
transformation (Levine et al., 1991). SV40 has previously been used to 
immortalize human cell types including keratinocytes and bronchial epithelial 
cells (Steinberg and Defendi, 1983; Reddel etal., 1991).
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5.2 MATERIALS AND METHODS
5.2.1 Buffers And Solutions
Denaturing (Alkali) Buffer Sodium Hydroxide 0.5M
Sodium Chloride 1.5M
adjusted to >pH1 2 . 0
Denhardt's Solution 100x Ficoll 2%
Bovine Serum
Album in (Fraction V) 2%
Polyvinylpyrollidone 2%
Hybridisation Buffer Formamide 35%
Denhardt' solution 5x
Sodium laurylsulphate 0.1%
Tris pH7.4 50mM
EDTA pH8.0 10mM
SSC 3 x
Dextran sulphate 10%
Geneblock (ILS) 250ug/ml
10x T4 Kinase Buffer Tris Cl (pH7.6) 0.5M
Magnesium Chloride 0.1 M
Dithiothreitol 50mM
Spermidine HCI 1mM
EDTA (pH8.0) 1mM
10x Gel Loading Buffer for
Non-Denaturing PAGE Bromophenol Blue 0.42%
Glycerol 50%
made up in TE
Neutralising Buffer Tris base 0.5M
Sodium Chloride 3M
Cone. Hydrochloric 
Acid 3.3%
adjusted to pH8.0
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NIB Bulfer Potassium Chloride 50mM
Tris pH8.3 10mM
Magnesium Chloride 1.5mM
Gelatin 100ug/ml
NP 40/Tween 20 0.45%
SSC Sodium Chloride 0.15M
Sodium Citrate 0.015M
TAE Buffer Tris 40mM
Sodium Acetate 20mM
Sodium Chloride 20mM
EDTA 2mM
adjusted to pH8.0
TBE Buffer Tris 90mM
Boric Acid 90mM
EDTA 2.25mM
adjusted to pH8.0
TE Buffer Tris (pH8.0) 10mM
EDTA (pH8.0) 1mM
All chemicals were supplied by Sigma.
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5.2.2 Source Of Salivary Glands
Salivary glands were kindly provided by the Department of Oral Medicine and 
Pathology, Glasgow Dental School and Hospital, under the supervision of Dr. P- 
J. Lamey. The minor labial salivary glands were obtained by excision biopsy 
from patients undergoing investigation for the symptom of xerostomia. 
Occasionally biopsies were obtained from individuals without evidence of 
xerostomia, but where unrelated surgery required the removal of minor salivary 
gland tissue. The lobules of minor salivary gland were placed immediately in 
transport medium consisting of RPMI 1640, 20%FCS, 800U/ml penicillin, 
800|jg/ml streptomycin, 2mM L-glutamine, 25mM hepes, 150pg/ml gentamicin, 
2.5pg/ml fungizone (all Life Technologies). The biopsies were transported to 
the LRF Virus Centre and processed immediately. Serum samples were also 
obtained at the same time and stored in aliquots at -80°C.
5.2.3 Tissue Culture Of Salivary Gland Biopsies
The salivary gland biopsy was placed in a 60mm tissue culture dish (Corning) 
containing 2ml of salivary gland (SG) medium (Dulbecco's MEM Nutrient mix 
F12 (HAM) medium supplemented with 15mM hepes buffer, 10% FCS, 400U 
penicillin, 400pg/ml streptomycin, 2mM glutamine) (all Life Technologies). The 
tissue was cut into 5-10 smaller pieces using sterile fine forceps and scissors. 
The pieces of salivary gland were transferred to a 25cm2 tissue culture flask 
(Costar) and 2ml SG medium added. The flask was gassed with CO2  and 
incubated at 37°C. If enough pieces of tissue were available 2 such flasks 
were set up. Initially an enzymatic digestion step was included after 
mechanically dissecting the biopsy. The tissue was incubated in 2ml SG 
medium containing 1U Dispase (BCL) for 1 hr in a shaking water bath at 37°C 
and then placed in tissue culture flasks as above.
Tissue culture flasks from different manufacturers or treated Costar flasks were 
used in initial experiments to optimise conditions for the successful outgrowth of 
cells from tissue explants. The types of flask employed were 25cm2 tissue 
culture flasks obtained from Bibby, Nunc and Costar and Costar flasks pre­
coated with extracellular matrix (ECM) (Biological Industries) or coated with 
laminin, a constituent of ECM. Laminin (Sigma) was dissolved in PBS to a final 
concentration of 50pg/ml and stored in 1ml aliquots at -80°C. One millilitre of 
the stock laminin was added to a 25cm2 Costar flask to provide the
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manufacturers recommended concentration of 2|jg/cm2 and incubated for 45 
minutes at room temperature. Excess fluid was removed and the flask briefly 
washed with PBS. The lam in in-coated flasks were then used as above for the 
culture of salivary gland tissues.
For experiments that involved live cell fluorescence (see section 5.2.8), pieces 
of salivary gland tissue were placed directly onto plastic coverslips in a tissue 
culture flask (Leighton tubes, Costar). These cultures were fed with 1ml of SG 
medium.
The SG medium in salivary gland tissue cultures was changed twice every 
week with total medium replacement. Outgrowth of cells from pieces of tissue 
was usually observed 7-10 days after initiation of the culture. Cultures were 
maintained until at least 3 of the pieces of tissue in any one flask produced an 
outgrowth of cells.
5.2.4 Adenovirus Tvpe-2 Infection Of Salivary Gland Cell Cultures
Adenovirus type-2 was kindly provided by Quality Biotech Ltd. at a titre of 10® 
plaque-forming units (PFU) per ml and stored at -80°C. The epithelial cell line 
Hep-2 was maintained in complete medium plus 10%FCS. Hep-2 or salivary 
gland cells were inoculated with either 1 or 10 PFU per cell of adenovirus type- 
2. A rough estimate of salivary gland cell numbers was obtained by viewing 
under the light microscope. Cells of non-epithelial morphology were removed 
from salivary gland cultures by brief exposure to trypsin-EDTA (1x) (Life 
Technologies) twice in the preceeding 7 days before inoculation with virus as 
detailed in 5.2.10. Hep-2 cell numbers were calculated using a counting 
chamber, placed in a flask overnight to allow adherence and the appropriate 
amount of virus added. Cells were harvested and cytocentrifuged 24 or 48 
hours later onto microscope slides (see 5.2.6).
5.2.5 Treatment With lnterferon-7
Salivary gland cultures were treated with SG medium containing human 
recombinant IFN-y (BCL) at 500U/ml for 3 days. The medium was changed 
daily and fresh IFN-7  added. The cells were cytocentrifuged onto slides and 
fixed as described below (5.2.6).
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5.2.6 Preparation Of Cytocentrifuqe Slides
Cytocentrifuge slides were prepared from salivary gland or Hep-2 cell cultures. 
The supernatant was removed from the flask and the cell monolayers washed 
once with PBS. Two millilitres of Trypsin-EDTA solution were added and the 
flask incubated at 37°C until all of the adherent cells had lifted from the surface, 
aided by shaking the flask. The cells were washed once in SG medium and 
once with HBSS. The cell number was counted and adjusted to 1 0 ^ cells per 
100pl. Cytocentrifuge slides were prepared by centrifugation at 400rpm for 10 
minutes on a Cytospin 2 (Shandon). Each slide (Fisons) was prepared with 
105 cells. The slides were air-dried and fixed in the appropriate fixative for 10 
minutes. Cells derived from adenovirus infected or IFN-7  treated cultures and 
subsequently stained with La-specific monoclonal antibodies were fixed in ice- 
cold acetone. Cells subsequently stained for cytokeratins were fixed with ice- 
cold methanol (BDH). Fixed slides were stored at -20°C until use.
5.2.7 Indirect Immunofluorescence Assay
Salivary gland epithelial cells were probed with MoAbs diluted in PBS 
comprising: (i) A combination of 2 anti-La MoAbs, SW1 and SW5, both lgG2b 
isotype (Smith et at., 1985) used at a 1:50 dilution (kindly provided by Dr. P. 
Venables, Kennedy Institute), (ii) Anti- cytokeratin-18 and -19 MoAbs (Sigma) 
used at dilutions of 1:100 and 1:20 respectively, (iii) Anti-adenovirus group 
antigen MoAb, lgG1 isotype (Chemicon), used at a dilution of 1:200. (iv) Anti- 
SV40 large T antigen specific MoAb (Chemicon) used at a 1:10 dilution, (v) 
MoAb AGF2.3 (kindly provided by Dr. G. Brown, Birmingham University) which 
reacts with a nuclear membrane antigen in selected transformed cell lines (Lord 
et at., 1988), used neat, (vi) Anti-HLA-DR MoAb (the Binding Site) used at a 
dilution of 1:20. (vii) Anti-human fibronectin MoAb (Sigma) used at a 1:200 
dilution, (viii) Anti-CD25 MoAb (Scottish Antibody Production Unit) was used at 
a 1 : 1 0  dilution as a negative primary antibody control in experiments where 
enough cytocentrifuge slides were available.
Thirty microlitres of the antibody dilution were spotted onto the slide and 
incubated at room temperature for 1 hr in a moisture chamber. The slides were 
washed over 20 minutes with 2 changes of PBS and incubated for a further 30 
minutes at room temperature with a 1:20 dilution of FITC-conjugated goat anti­
mouse IgG (Sigma). The slides were then washed as above and mounted
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using 2.5% 1,4 diazobicyclo-2.2.2.octane in PBS/glycerol(1:1v/v) and viewed 
under a Leitz Laborlux fluorescent microscope with either a x25 or x50 water 
immersion lens (both Leitz).
For double staining of La and adenovirus antigen, a mixture of two conjugates 
was used - a sheep anti-mouse lgG2b antibody (FITC-labelled) used at 1:20 
and a tetramethyl rhodamine isothiocyanate (TRITC)-labelled sheep anti-mouse 
lgG1 antibody used at 1:10 (both The Binding Site).
5.2.8 Live Cell Fluorescence
For cells grown on Leighton tube coverslips and probed with MoAbs, the 
procedure was identical to that detailed in 5.2.7 except that the primary and 
secondary antibody incubations were carried out on viable cells prior to fixation. 
Particular care was taken to ensure that cells on coverslips did not dry out 
during the assay. Viability of the cells after completion of the IFA was checked 
by incubating the coverslips in 0.2% trypan blue (Sigma) for 1 minute followed 
by a wash in PBS. The cells were then fixed in ice cold acetone/methanol 
(1 :1 v/v) before mounting and viewing under the fluorescent microscope.
Following treatment with IFN-7 , salivary gland cells were examined for the cell 
surface expression of HLA-DR molecules and La antigen. Cells were 
trypsinised into suspension and washed once in SG medium and once in PBS. 
The cells were resuspended in 30pl of PBS/0.2% bovine serum albumin/0.1 % 
sodium azide (diluent) (all Sigma), containing either the anti-HLA-DR or anti-La 
MoAbs. The cells were incubated on ice for 30 minutes and washed twice in 
diluent. The cells were resuspended in 30|il of FITC-labelled goat anti-mouse 
IgG and incubated for a further 30 minutes on ice. The cells were washed as 
above, fixed in 1% paraformaldehyde (Sigma), spotted onto a Teflon-coated 
Multitest slide and viewed under the fluorescent microscope.
5.2.9 Photography
Photographs of cell cultures and IFA slides were taken using an Olympus PM- 
10AK system attached to the appropriate microscope. Fuji 50asa 35mm slide 
film was used for light field photographs and Fuji 400asa 35mm slide film for 
fluorescent field photographs.
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5.2.10 Harvesting Primary Culture Cells For Polymerase Chain Reaction
For the first PCR experiments, salivary gland cultures were harvested when a 
sizeable outgrowth of cells was evident by viewing under the light microscope. 
Tissue explants were removed from the cultures by dislodgement with a 1ml 
pipette, taking care not to score the surrounding cell monolayer. The tissue 
was then discarded. The flask was washed twice with 5mI PBS to remove any 
remaining suspension cells and debris. The adherent cells were removed by 
scraping the surface of the flask with a cell scraper (Costar) in a 1 ml volume of 
PBS. The cell suspension was transferred to two microcentrifuge 1.5ml flip-top 
tubes and pelleted in a microcentrifuge at maximum speed for 30 seconds. The 
supernatant was discarded and cell pellets stored at -80°C until used for PCR. 
An equal number of control tubes containing PBS were set up at the same time 
for use as negative controls. PBS (0.5ml) was added to flip-top tubes, 
centrifuged, PBS removed and control tubes stored at -80°C. Air controls were 
also set up in order to identify airborne contamination of samples during 
handling. Empty flip-top tubes that had been open for the duration of the cell 
harvesting procedure in the safety cabinet were utilised and stored at -80°C 
until use.
For the second set of PCR experiments, care was taken to remove adherent 
cells lacking epithelial cell morphology prior to harvesting the cell pellets. When 
sufficient outgrowth of cells from tissues had occurred, the pieces of tissue 
were removed as above. A trypsinisation step was utilised to remove non- 
epithelial cells from cultures. The flask was washed with 5ml PBS and the 
supernatant containing cells in suspension and debris removed. Two millilitres 
of Trypsin-EDTA solution were added and the flask incubated at 37°C for 3min. 
The flask was shaken gently until cells of non-epithelial morphology were seen 
to lift from the flask surface into suspension. The trypsin-EDTA was removed 
and the flask washed twice with 3ml SG medium. The culture was then fed with 
fresh SG medium. This trypsinisation step was repeated 3 days later and 
cultures fed with fresh SG medium.
The remaining adherent cells were then harvested a further 3 days later. The 
flasks were washed with PBS and 2ml trypsin-EDTA added and incubated at 
37°C until all of the adherent cells had lifted from the surface, aided by gentle 
shaking of the flask. The cell suspension was made up to a volume of 10ml 
with SG medium in a 10ml conical-tube (Costar) and centrifuged at 2500 for 5
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minutes. The supernatant was removed and the cells washed twice in 5ml 
PBS. The cells were counted and aliquoted at 1 0 ^ cells per 1.5ml flip-top tube, 
pelleted in a microcentrifuge and cell pellets stored at -80°C until use. 
Negative controls consisting of PBS were set up as above. No air controls were 
included for the second set of PCR samples.
5.2.11 Polymerase Chain Reaction
(i) HHV- 6  PCR
The primers used in the PCR experiments were derived from the pZVH14 clone 
of HHV- 6  (Josephs etal., 1986) and amplify a DNA fragment of 161 base pairs 
(Jarrett et al., 1990). This clone does not have any known homology to other 
human herpesviruses (Josephs et al., 1986) and the primers do not amplify 
sequences from cells infected by EBV, CMV, or HHV-7 (data not shown). The 
nucleotide sequences of the 5' and 3' primers are:
5’> TCTCACAGCCCAGGACAATGGATTATATAT < 3’
5'> TGAGATCATTCTCCCGTTCTTGAGGG < 3'
Tubes containing cell pellets and control tubes (PBS/air) were digested with 
Proteinase K (Sigma) in NIB buffer. Twenty-five microlitres of NIB buffer 
containing 1.5pg Proteinase K were added to each tube and overlayed with 
mineral oil (Sigma). The tubes were incubated at 56°C for 30 minutes in a 
waterbath and then steamed for 1 0  minutes in a boiling waterbath to inactivate 
the Proteinase K. Twenty-five microlitres of the master mix were added through 
the mineral oil to give a final reaction volume of 50pl. The master mix 
contained reagents that gave a final concentration per reaction of 1U Amplitaq 
(Cetus), 50picomoles (pmol) of each primer and 200pmol/L of each 
deoxynucleoside triphosphate in 10mM Tris (pH8.4), 50mM KCI, and 1.5mM 
MgCl2 - The positive control consisted of a cell pellet containing 1 0  ^ J JHAN 
plus 100 HHV-6 -infected J JHAN cells.
Thermal cycling was performed using an Intelligent Heating Block (Cambio). 
Reactions were initially denatured by heating to 94°C for 5 minutes followed by 
40 cycles of 94°C for 0.1 minute, 50°C for 0.1 minute, and 72°C for 1.5 
minutes. The products from the HHV- 6  PCR reactions (cell pellets and
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controls) were assayed subsequently using nested primers which amplify an 
internal fragment of 90 base pairs. The nucleotide sequences of the 5’ and 3' 
nested primers are:
5' > TCCACTACTTAAAACCGA < 3'
5' > TGATGAAGTATGTGATAG < 3'
Five microlitres of a 50-fold dilution of the reaction products in H2 O were used 
per assay. Reaction conditions and thermal cycling were as above except that 
the 72°C step was omitted.
(ii) EBV PCR
The primers used amplify a 140bp DNA sequence within the BamH1-W region 
of the EBV genome and have been described previously (Deacon et al, 1991). 
The 5' and 3' primers were respectively:
5' > TG ACTTC ACC A AAG GTC AG G < 3'
5' > AGGACCACTTTATACCAGGG < 3'
The cell pellets were treated with a Proteinase K digestion step in NIB buffer as 
detailed for HHV- 6  in section 5.2.11 .(i) above. Apart from the different primer 
set the reaction mixture and conditions of thermal cycling were the same as for 
HHV-6 . No nested primers were used in the EBV assay. The positive control 
was a pellet of 1 0 ^ B95.8 cells.
(iii) p-alobin PCR
As a control to determine the presence of amplifiable DNA in the sample tubes, 
a region of the human p-globin gene was also amplified using identical reaction 
conditions to those for HHV- 6  and EBV PCR assays. The primer sequences 
have previously been described (Saiki etal., 1988). The 5' and 3' primers were 
respectively:
5' > ACACAACTGTGTGTTCACTAGC < 3'
5' > CTCCTGAGGAGAAGTCTGC < 3’
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This set of primers amplifies a 110bp region of the [3-globin gene.
(iv) Analysis of samples
Reaction products were analysed by polyacrylamide gel electrophoresis 
(PAGE). Twenty microlitres of the PCR reaction product were added to 5pl of 
gel loading buffer. Ten microlitres of this were analysed on an 8 % 
polyacrylamide gel on a Bio-Rad Mini Protean II gel system. Acrylamide (8 %) 
was made up from stock solutions of PAGE"! Liquidacrylamide (30%) and 
PAGE"! Bisacrylamide (2%) (both BCL) in TBE and polymerised by the addition 
of 0.06% (w/v) ammonium persulphate and 0.12% (v/v) N.N.N'.n'- 
tetramethylethyldiamine. DNA molecular weight markers, PhiX174 Hae III 
markers (Life Technologies) were run on each gel. Electrophoresis was carried 
out at 100 Volts (V) for approximately 1 hour in a TBE buffer until the dye front 
had reached the bottom of the gel. The gel was subsequently stained using 
ethidium bromide (Sigma) at a concentration of 0.5mg/L. The gel was 
immersed in this solution for 15 minutes, the buffer removed and replaced with 
distilled H2 O. The stained gel was viewed under UV-light using a Foto/Prep I 
transilluminator (Fotodyne) and the gel photographed using a Polaroid MP-4 
Land Camera with Polaroid High Speed 4x5 Instant Sheet film. In PCR 
experiments with HHV- 6  nested primers and p-globin primers, the results were 
scored following visualisation of ethidium bromide stained gels.
For identification of reaction products by hybridisation with specific probes, the 
gels were washed first in denaturing buffer for 8  minutes followed by 8  minutes 
in neutralising buffer. Electrophoresed products were then transferred to a 
nylon membrane, Hybond-N (Amersham), using a Bio-Rad Trans-Blot Cell. 
The gels were electroblotted overnight at 15V in TAE buffer. Filters were 
hybridised to an oligonucleotide probe specific for each amplified sequence. 
The DNA sequence of the oligonucleotide probes were as follows:
HHV- 6  5' > CTTCCATCGAGGCCTCATCTATCACATACT < 3'
EBV 5' > AGCGCGTTTACGTAAGCCAGACAGCAGCCAATTGTCAGTT < 3'
The probes were synthesised "in-house" employing an automated 
oligonucleotide synthesiser (Model 381 A, Applied Biosystems). Probes were 
end-labelled with y 32p_A<jenosine Triphosphate (ATP) (specific activity
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3000Ci/mmol) (ICN). Seventy picomoles of probe were mixed with 10|il of 
10xkinase buffer, 2pl T4 kinase (Life Technologies), 70pmol y 32p_ATP, the 
volume made up to 100pl with ultrapure H2 O and incubated at 37°C in a 
waterbath for 1 hour. The probe was added to the top of a pre-packed 
Sephadex G-50 column (Pharmacia) previously equilibrated with TE, and 400pl 
TE added immediately. The solution was allowed to run through. A fresh 400pl 
TE was added and the eluted solution collected, providing 400pl of 32p.|abelled 
probe.
Filters were prehybridised in 2.5ml of hybridisation buffer in a 50ml Falcon 
conical tube on a roller in a 37°C hotroom for 1 hour. Fifteen microlitres of the 
probe were added to each filter and incubated on the roller at 37°C overnight. 
Filters were washed twice in 6 xSSC, 0.1% SDS (Sigma) at room temperature 
and a further 2 washes of 30 minutes at 60°C. Filters were then exposed to 
Hyperfilm-MP (Amersham) at -70°C.
(v) Avoidance of contamination
Great care was taken to avoid contamination of reactions. The culturing of 
salivary gland cells and their subsequent harvesting as cell pellets was carried 
out in a safety hood where routine virus propagation was not done. The master 
mixes for all of the PCR experiments were prepared outside the department. 
Positive displacement pipettes were used throughout the setting up of 
reactions. Positive controls were set up in a different safety cabinet after the 
sample reactions had been completed. In the course of these experiments no 
contamination of PBS or air controls occurred.
5.2.12 Ultrastructural Examination Of Salivary Gland Cells By Electron 
Microscopy
The ultrastructure of cells cultured from a salivary gland biopsy was examined 
by EM. The medium was removed from the flask and 2mI of 
paraformaldehyde/gluteraldehyde fixative added. The cell monolayer was 
scraped off immediately using a cell scraper. The supernatant was removed 
and centrifuged at 400cj for 7 minutes. Fresh fixative was added to the cell 
pellet. The pellet was processed and examined by EM as outlined in 4.2.4.
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5.2.13 Inoculation With A Transforming Virus
Salivary gland cultures were inoculated at a multiplicity of infection of 
10OPFU/cell with an adenovirus type-5/SV40 recombinant virus (Van Doren and 
Gluzman, 1984). This virus was the kind gift of Professor P. Gallimore, CRC 
Laboratories, Birmingham, UK. Virus stock was stored at -80°C at a titre of 
1x109 PFU/0.2ml. Infected cultures were fed twice weekly. Cultures that 
reached confluence were split either 1 :2  or 1:5. Cytocentrifuge slides of a 
culture that had been propagated in such a manner for over 2 0  passages were 
prepared, fixed in acetone, and stained with a MoAb specific for SV40 large T 
antigen.
Experimental work with the adenovirus type-5/SV40 recombinant virus was 
carried out in a Category 2 containment facility within a Class II microbiological 
safety cabinet. Waste infectious material was treated first with Virkon Virucidal 
Disinfectant followed by autoclaving. As is the practice in this laboratory, no 
glassware or sharps were used apart from microscope slides and the 
cytocentriguge slide holders and rotor bucket were treated with Virkon and 70% 
ethanol following each use. The cytocentrifuge rotor bucket was sealed and 
opened only within the safety cabinet.
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5.3 RESULTS
5.3.1 Primary Salivary Gland Cultures
The tissue culture conditions were successful in promoting the outgrowth of 
cells with an epithelial morphology from salivary gland tissue explants. The 
protocol was based on the the studies of Lamey et al. (1984), although certain 
modifications were made. In this study, Dulbecco's MEM/F12 medium 
supplemented with 10%FCS was used as opposed to Medium 199 (Gibco-BRL) 
supplemented with 20%FCS. Also, salivary gland cultures were grown in tissue 
culture flasks rather than on sterile glass coverslips housed in petri-dishes.
Initially flasks from three manufacturers were used. The most satisfactory 
growth of salivary gland cells was obtained using Costar 25cm2 flasks and 
therefore, the majority of biopsies were cultured in such flasks. The use of 
Costar flasks either pre-coated with ECM or laminin, a constituent of ECM, did 
not promote greater cellular outgrowth from tissue explants. However, cells 
adhered at a faster rate on laminin or ECM when passaging salivary gland 
epithelioid cell lines. Greater cell numbers in these flasks were not apparent 
compared to those untreated.
The majority of salivary gland biopsies yielded outgrowth of cells to varying 
degrees. Figure 5.3.1 shows the cellular outgrowth from a piece of labial 
salivary gland biopsy. Frequently the cell numbers obtained were insufficient 
for further experimentation. In a number of cultures, fibroblast cell growth 
masked the presence of epithelial-like cells. In this study salivary gland cells 
were not routinely passaged. The culture conditions were designed to produce 
in vitro epithelial cells with differentiation states as close to their in vivo 
equivalent and not to derive epithelioid cell lines as has been done previously 
(Lamey et at., 1984). Salivary gland cells were able to grow on plastic 
coverslips housed in Leighton tubes although not as successfully as in Costar 
flasks and fibroblast contamination was more common.
The majority of cells in culture had an epithelial morphology. The main visible 
contaminant was fibroblast-like cells. These cells were less adherent to the 
flask surface and were selectively removed from cultures following brief 
exposure to trypsin-EDTA. Two approaches were used to confirm the epithelial 
nature of cellular outgrowths. First, the ultrastructure of a salivary gland cell
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Figure 5.3.1
LABIAL SALIVARY GLAND CELL CULTURE
Figure 5.3.1 Salivary gland cell cultures. A. Cells growing out from a piece of 
labial salivary gland biopsy (x40). B. Monolayer of cells with epithelial 
morphology from a salivary gland culture (x400).
population was examined by electron microscopy. The presence ot epithelial 
cell-junctions, namely desmosomes with tonofilament bundles, was identified 
(Fig. 5.3.2). Secondly, the cells were examined for cytokeratin expression. 
One hundred percent of a salivary gland cell culture examined stained positive 
with either an anti-cytokeratin no.18 or 19 antibody by IFA (Fig. 5.2.3).
5.3.2 Viral-lnfection Of Salivary Gland Cells
Following inoculation with 10PFU adenovirus type-2 a proportion of cells 
stained positively with antibodies against adenovirus group antigen (Fig. 5.3.4). 
Control salivary gland epithelial cells probed with the two anti-La MoAbs 
displayed a uniform staining pattern confined to the cell nucleus (Fig. 5.3.5). 
Following inoculation with either 1 or 10 PFU of adenovirus per cell, the staining 
pattern altered in a proportion of cells either 24 or 48hr later. Some of the cells 
had a similar distribution of La within the nucleus as untreated cells although 
the staining appeared brighter and more granular. A number of the cells 
revealed a more punctate nuclear staining pattern particularly obvious in the 
region of the nuclear membrane (Fig. 5.3.5). Double-staining for both La and 
adenovirus suggested that this altered nuclear staining pattern was confined to 
adenovirus infected cells (Fig. 5.3.6). No cytoplasmic La was detected 48hr 
following viral infection.
5.3.3 Effect Of IFN-7  On Salivary Gland Cells
Following treatment with high-doses of IFN-7  (500U/ml), viable salivary gland 
cells in suspension were examined by IFA for the cell surface expression of 
HLA-DR and La antigens. Cell membrane expression of HLA-DR molecules 
was observed to varying degrees on all cells (Fig. 5.3.7). No cell surface 
expression of La was detected. However, following treatment with IFN-y, 
salivary gland epithelial cells displayed clear cytoplasmic as well as nuclear 
staining using anti-La MoAbs (Fig. 5.3.7).
5.3.4 Live Cell Fluorescence Of Coverslip Cultures
Viable salivary gland or Hep-2 cells cultured on coverslips and either untreated 
or inoculated with 10PFU of adenovirus per cell, were examined by IFA for the 
cell surface expression of La. No surface expression of La was detected 48hr 
after infection on Hep-2 cells. In a number of coverslip cultures which were
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Figure 5.3.2
ULTRASTRUCTURAL EXAMINATION OF SALIVARY GLAND CELLS BY
ELECTRON MICROSCOPY
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Figure 5.3.2 Ultrastructural examination of salivary gland cells. Examination 
revealed the presence of epithelial cell-junctions. The tonofilament bundles and 
desmosomes of the cell-junction in the centre of the photograph are clearly 
visible (x40,000).
Figure 5.3.3
EXPRESSION OF CYTOKERATIN POLYPEPTIDES BY SALIVARY GL\ND
CELLS
Figure 5.3.3 Expression of cytokeratin polypeptides in salivary gland cells. 
Immunofluorescent microscopy of salivary gland epithelial cells using MoAd to 2 
different cytokeratins A. cytokeratin no. 18. B. cytokeratin no. 19. 100% Df the 
cells exhibited positive staining with both cytokeratin MoAbs (x500).
Figure 5.3.4
ADENOVIRUS INFECTION OF SALIVARY GLAND EPITHELIAL CELLS
Figure 5.3.4 Immunofluorescent microscopy of infected salivary gland cells 
using anti-adenovirus group antigen MoAb. The cells were infected for 48hr with 
adenovirus type 2 (10PFU/cell) (x250).
Figure 5.3.5
DETECTION OF LA ANTIGEN IN ADENOVIRUS-INFECTED AND 
UNINFECTED SALIVARY GLAND CELLS
A.
B.
Figure 5.3.5 Immunofluorescent microscopy of salivary gland cells using anti-La 
MoAbs.
A. Uninfected cells. The anti-La MoAbs produce a uniform staining pattern 
confined to the cell nucleus. B. 48hr after infection with adenovrus type-2 
(10PFU/cell). A number of cells display a more punctate staining pattern in the 
region of the nuclear membrane (x250)
Figure 5.3.6
DOUBLE-STAINING OF LA AND ADENOVIRUS ANTIGENS IN INFECTED
SALIVARY GLAND CELLS
Figure 5.3.6 Immunofluorescent microscopy of salivary gland cells double­
stained using anti-La and anti-adenovirus MoAbs, 48hr after infection with 
adenovirus.
A. Anti-La MoAbs. Many of the smaller cells display a uniform staining pattern 
of La similar to uninfected cells. A proportion of the cells exhibit a more 
speckled staining pattern in the region of the nuclear membrane. B. Anti­
adenovirus MoAb. Detection of adenovirus antigen appears to be restricted to 
cells with an altered distribution of La within the nucleus (x250).
Figure 5.3.7
EXPRESSION OF HLA-DR AND LA BY SALIVARY GLAND CELLS TREATED
WITH INTERFERON-^
Figure 5.3.7 Immunofluorescent microscopy of salivary gland cells teated with 
500U/ml IFN-y for 72hr.
A. Viable cells probed with anti-HLA-DR MoAb showing cell surface 
fluorescence (x250). B. Acetone-fixed cells reacted with anti-La MoAbs
revealing cytoplasmic as well as nuclear expression of La (x500).
either infected or uninfected with adenovirus, treated or untreated with IFN-7 , 
areas of the cell monolayer stained positively with the anti-La MoAbs. The 
staining pattern was found over individual cells or areas of cells (Fig. 5.3.8). 
Bachmann et ai. (1991) reported an extracellular location for La under certain 
laboratory conditions. The authors suggested that extracellularly the La antigen 
was associated with fibronectin in the ECM. Cultures derived from the same 
salivary gland biopsy were stained by live cell IFA for either La or fibronectin. 
The distribution of fibronectin as expected was found in regions surrounding 
cells (Fig. 5.3.9) and was different from the areas stained positive with the anti- 
La antibodies.
To investigate with which feature of the cell monolayer the anti-La antibody 
stained areas was associated, viable salivary gland cells stained with the La 
antibodies were examined using confocal microscopy by Dr. A. Entwistle 
(Ludwig Institute, London). The positively stained areas were considered to be 
non-specific and were not associated with any specific feature of the cell 
monolayer (data not shown). Interestingly Hep-2 cells, either untreated or 
treated with IFN-y, showed no positive staining with the same antibodies (data 
not shown). Thus, the non-specific reaction was a feature of salivary gland 
cells cultured on coverslips.
5.3.5 Detection Of HHV-6 And EBV Bv PCR
Initially salivary gland cell populations cultured from 1 1 different biopsies were 
assayed by PCR for HHV-6 . The results are shown in Table 5.3.1. Following 
the first round of amplification one strongly positive and 2  weakly positive bands 
were detected by autoradiography after a 7-day exposure. Using the HHV- 6  
nested primers only these 3 positive samples gave rise to fragments of the 
correct size, which were visualised on ethidium bromide stained gels. The 3 
positive samples were derived from 2 persons diagnosed with SS ( 1 primary 
and 1 secondary) according to the criteria proposed by Daniels, (1984) and one 
person diagnosed with non-specific sialadenitis. The 8  HHV- 6  negative 
samples were derived from 1 person with SS and 7 persons with non-specific 
sialadenitis.
An unsatisfactory element of the first group of PCR samples was that cell 
pellets were not uniform in cell number. In addition, Kondo et al. (1991) 
described monocytes as a possible site of HHV- 6  latency in vivo. Under tissue
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Figure 5.3.8
REACTIVITY OF VIABLE SALIVARY GLAND CELL MONOLAYERS WITH
ANTI-LA ANTIBODIES
Figure 5.3.8 Immunofluorescent microscopy of salivary gland viable cell 
monolayers probed with anti-La MoAbs.
A. Positive fluorescence corresponding to the surface area of individual cells.
B. An area of positive fluorescence spanning a number of cells (x500). 
Confocal microscopy did not identify these positively-stained areas with any 
feature of the cell monolayer.
Figure 5.3.9
DISTRIBUTION OF FIBRONECTIN IN SALIVARY GLAND CELL
MONOLAYERS
Figure 5.3.9 Immunofluorescent microscopy of a viable salivary gland cell 
monolayer using an anti-fibronectin MoAb. Fibronectin is detected in regions 
surrounding cells. The distribution of fibronectin does not appear to correspond 
to the staining pattern obtained with anti-La MoAbs on similar cell monolayers 
(Fig. 5.3.8) (x500).
Table 5.3.1
DETECTION OF HHV- 6  BY PCR IN IN VITRO CULTURED SALIVARY
GLAND CELLS-1
Patient Ref. Age/Sex HHV- 6  PCR Diagnosis
Result
A 18/M - NSS
B 60/F - NSS
C 57/F - NSS
D 71/F + 2YSS
E 6 6 /M + NSS
F 69/F - 1Y SS
G 46/F + 1Y SS
H 55/F - NSS
I 80/F - NSS
J 34/M - NSS
K ?/M - NSS
NSS=non-specific sialadenitis; 2y=secondary; iy=primary.
culture conditions monocytes are adherent cells. In order to minimise the risk 
of monocyte contamination of salivary gland cultures, trypsinisation steps were 
introduced prior to the harvesting of cells in a second group of samples. The 
trypsinisation step was successful in removing fibroblasts and in the one culture 
examined, 100% of cells were cytokeratin positive by IFA.
A further 10 cell populations were tested for HHV- 6  by PCR. EBV PCR 
investigations were performed on 9 of the 10 samples, p-globin PCR was 
included to confirm there was amplifiable DNA in sample tubes. A uniform cell 
pellet number of 1 0 ^ was used except for EBV PCR where only 1 0 ^ cells were 
available for 3 of the samples. The results of the PCRs are shown in Table 
5.3.2. Two of the 10 were HHV- 6  positive following amplification with the first 
set of primers and hybridisation with the HHV-6 -specific probe (Fig. 5.3.10). No 
further positive samples were detected following amplification with the HHV- 6  
nested primers and visualisation of amplified product on ethidium-bromide 
stained gels (Fig. 5.3.10). The 9 samples tested for EBV by PCR were negative 
following hybridisation with the EBV-specific probe (Fig. 5.3.11). All of the 10 
samples were p-globin gene positive demonstating the presence of amplifiable 
DNA (Fig. 5.3.11).
The two HHV- 6  positive epithelial cell populations were grown from biopsies 
from persons with non-specific sialadenitis. Epithelial cell cultures from 
biopsies from 3 persons diagnosed with SS (1 primary and 2 secondary) 
(Daniels, 1984) and a further 5 cultures from persons with non-specific 
sialadenitis were negative for HHV- 6  and EBV by PCR.
5.3.6 Immortalisation Of Salivary Gland Epithelial Cells
Using a recombinant adenovirus type-5 containing the large T antigen of SV40, 
attempts were made to infect and immortalise primary salivary gland cells. The 
majority of cultures infected with this virus developed massive outgrowths of 
fibroblast-like cells. However, in one infected culture, epithelial-like cells grew 
to confluence and were then passaged at least once per week for 4 months. 
The morphology of these cells remained unchanged over this time period 
although the cells ceased to grow after 4 months. Expression of SV40 large T 
antigen was detected in the nucleus of 100% of these cells (Fig. 5.3.12). It is 
probable that the transforming virus altered the growth properties of the cells in 
this culture, but was insufficient to immortalise them.
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Table 5,3-2
DETECTION OF HHV- 6  AND EBV BY PCR IN IN VITRO CULTURED 
SALIVARY GLAND CELLS - 2
Patient
Ref.
Aae/Sex HHV- 6
PCR
Result
EBV PCR 
Result
p-globin
ECB
Result
Diagnosis
1
2
3
4
5
6
7
8
9
10
49/F 
70/F 
?/F 
47/F 
76/F 
65/F 
41/F 
60/F 
52/F 
73/F
+
+
+
+
+
+
+
+
+
+
+
2y ss
NSS
NSS
NSS
NSS
NSS
NSS
iyss
NSS 
2V SS
*=  10^ cells used per reaction; NSS=non-specific sialadenitis; iy=primary; 
2 y=secondary
Figure 5.3.10
DETECTION OF HHV-6 IN CULTURED SALIVARY GLAND EPITHELIAL
CELLS BY PCR
A.
161bp I
6 - 7 - 8 - 9 - 10 -
B.
90bp-
Figure 5.3.10 Detection of HHV-6 in the second group of salivary gland 
epithelial cell cultures by PCR.
A. Autoradiograph of samples 6-10 following one round of HHV-6 PCR. 
Samples 7 and 9 are positive.
B. Ethidium bromide stained polyacrylamide gel of nested HHV-6 PCR on 
samples 6-10 and their controls. Positive bands of the correct size are found for 
samples 7 and 9 only.
Numbers correspond to sample numbers; - = accompanying negative control; + 
= positive control; M = DNA molecular weight markers.
Figure 5.3.11
RESULTS OF EBV AND (3-GLOBIN PCR USING CULTURED SALIVARY
GLAND EPITHELIAL CELLS
A.
140bp
M 1 - 2 - 3 - 4 -  5 - +
B.
110bp-
Fiqure 5.3.11 Results of EBV and (3-globin PCR on salivary gland epithelial 
cells.
A. Autoradiograph of samples 1-5 following EBV PCR. All the samples are 
negative.
B. Ethidium bromide stained polyacrylamide gel of p-globin PCR on samples 1- 
5 and their controls. Bands of the correct size (110bp) are found for each of the 
salivary gland epithelial cell samples, demonstrating the presence of amplifiable 
DNA.
Numbers correspond to sample numbers; - = accompanying negative control;
+ = positive control; M = DNA molecular weight markers.
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Figure 5.3.12
CHARACTERISATION OF ANTIGEN EXPRESSION IN SALIVARY GLAND
CELLS INFECTED WITH A TRANSFORMING VIRUS
A.
B.
Figure 5.3.12 Immunofluorescent microscopy of salivary gland cells infected 
with an adenovirus/SV40 hybrid transforming virus. A. Cells probed with anti- 
SV40 large T antigen MoAb showing nuclear staining in 100% of cells. The cells 
were from a salivary gland culture that had been infected with the virus and 
passaged once a week for 4 months (x500).
B. Cells probed with AGF2.3 MoAb showing nuclear membrane staining in the 
majority of cells. This antibody detects a nuclear membrane antigen expressed 
by certain transformed epithelial cell lines (x250).
Following inoculation with the transforming virus, primary salivary gland cells 
showed a brighter staining with the AGF2.3 antibody which detects a nuclear 
membrane protein present in certain transformed epithelial cells (Fig. 5.3.12). 
The presence of this antigen was either absent or weakly-stained in untreated 
cells. These results provided further evidence for the epithelial nature of 
primary salivary gland culture cells.
5.3.7 Detection Of Putative Retroviral Antigens In Salivary Gland Cultures
A number of primary salivary gland cultures grown in our laboratory were 
examined by workers at the Kennedy Institute of Rheumatology for expression 
of antigens that reacted with antibodies raised against retroviral antigens. The 
results of these investigations have previously been reported (Shattles et al., 
1992; Brookes et al., 1992). A MoAb (197 Ab) that reacts with HTLV-1 p19 
detected an antigen, designated 197 Ag, expressed in primary salivary gland 
cells (Fig. 5.3.13). The antigen detected was unlikely to be HTLV-1 derived as 
persons from which these cultures were derived were HTLV-1 seronegative. 
Primary salivary gland cells were also found to express an antigen detected 
with an antisera raised against a predicted amino acid sequence of a protein of 
HRES.1 (Fig. 5.3.13). Thus, these particular antibody reagents may be 
detecting antigens in salivary gland tissue encoded by retroviruses.
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Figure 5.3.13
DETECTION OF PUTATIVE RETROVIRAL ANTIGENS IN CULTURED
SALIVARY GLAND CELLS
Figure 5.3.13 Immunofluorescent microscopy of salivary gland epithelial cells 
using antibodies directed against retroviral antigens.
A. Cells probed with 197 MoAb showing cytoplasmic staining. This antibody 
reacts with HTLV-1 p19 antigen. The putative antigen it reacts with in salivary 
gland tissue has been designated 197 antigen.
B. Cells probed with purified antisera against a predicted peptide of HRES-1 
showing bright, speckled nuclear staining. The antigen detected in salivary 
gland tissue has been proposed to be an endogenous retroviral product. 
Photographs kindly supplied by Dr. Sharon Brookes.
5.4 DISCUSSION
The aetiology of SS and the mechanism by which autoimmune responses 
develop in the disease remain unknown. I have utilised salivary gland epithelial 
cell cultures as a model to investigate viral involvement and mechanisms of 
autoimmunity associated with SS.
Examination of the ultrastructure of cultured salivary gland cells by electron 
microscopy by ourselves and others (Lamey et al., 1984), revealed cell- 
junctions characteristic of epithelial cells. The epithelial components of salivary 
gland consist of ductal, acinar and myoepithelial cells. The cells in culture 
expressed both cytokeratin no. 18 and 19. In an immunohistological study, 
Geiger et al. (1987) identified cytokeratin no. 18 expression in both the ductal 
and acinar elements of salivary glands. Cytokeratin no.19 was only 
demonstrated in the ductal component. Thus, expression of cytokeratins 
suggests that the cultured cells are ductal in origin although rapid acinar to 
ductal transdifferentiation has been observed in cultured human pancreas (Hall 
and Lemoine, 1992). Similarly, based on the detection of the enzyme 11(3- 
hydroxysteroid dehydrogenase, it has been suggested previously that the 
majority of cells in primary explant cultures are ductal (Lamey e ta !., 1984).
The salivary gland cultures provided an opportunity to examine mechanisms by 
which the La antigen could be presented to the immune system. The role of 
membrane expression of nuclear antigens including La in autoimmunity has 
recently been reviewed (Venables and Brookes, 1992b). I was able to 
demonstrate an altered nuclear distribution of La in adenovirus-infected cells. 
This is in contrast to the study of Baboonian et al. (1989) where similar 
conditions of infection of a continuous epithelial cell line, Hep-2, resulted in 
cytoplasmic and cell membrane expression of La. However, similar 
experiments carried out in this project were unable to repeat this phenomenon. 
A translocation of La to the cytoplasm and cell surface has also been observed 
in HSV-1 infected CV-1 cells (Bachmann et al, 1989; Bachmann et al., 1992). 
It is possible that methodological differences such as virus titre at inoculation, 
and time at which cells were examined post-infection may explain the difference 
in results. Alternatively, the differences may be due to the use of primary 
salivary gland cultures, which are a more representative cell type to study, 
rather than continuous cell lines.
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A number of other experimental stimuli have been proposed that alter the 
cellular location of La. UV-irradiation of human keratinocytes or stimulation with 
estradiol resulted in cell surface La expression (Furukawa et al., 1990; 
Bachmann etal., 1990; Furukawa et al., 1991) and EBV-transformed cell lines 
also express cytoplasmic La (Smith etal., 1985). Serum-starvation of cells was 
reported to result in a translocation of La to the cell surface and an extracellular 
phase of the antigen observed (Bachmann et al., 1991). IFN-y treatment can 
result in cytoplasmic or membrane expression of La depending on the cell type 
(Venables and Brookes, 1992b), although this has not been examined 
previously in salivary gland cultures.
IFN-y treatment of salivary gland epithelial cells resulted in a translocation of La 
from the nucleus to the cell cytoplasm. Exposure to IFN-y also resulted in the 
cell surface expression of HLA-DR molecules. IFN-y positive lymphocytes are 
found in normal salivary glands (Brett et al., 1992) probably as a result of 
constant antigenic challenge from resident microbial flora (Bocci, 1988). In SS, 
the infiltrating mononuclear cell population, including many activated T cells, is 
likely to provide a greater source of this cytokine. Bottazzo et al. (1983) 
hypothesised that IFN-y induced aberrant expression of MHC class II molecules 
in association with self-antigens could result in an autoimmune response such 
as thyroid autoimmunity. Our results suggest that a similar mechanism may be 
operating in SS. As well as HLA-DR, the expression of MHC class II subregion 
products HLA-DP and -DQ might be an important feature of salivary gland 
epithelium in SS (Thrane et al., 1993). Our model for the in vitro culture of 
salivary gland cells should prove useful in studying the cytokine-induced 
expression of different MHC class II products.
Although autoantibodies to La are a common feature, they are not detected in 
all cases of SS. The number of patients with SS who have detectable 
autoantibodies to La can vary from 25-87% depending on the assay used 
(Slobbe etal., 1991). Viral infection of salivary glands may be important as an 
initial target for the immune system and, in areas of high IFN-y secretion, a 
translocation of La to the cytoplasm and cell surface might occur. In vivo, 
cytoplasmic La has been demonstrated in conjuctival epithelial cells imprinted 
from SS patients (Yannopoulos et al., 1992). A possible consequence of the 
cycling of La through different cellular compartments, perhaps including an 
extracellular phase, is the processing and presentation of the antigen in 
association with MHC molecules, including class II. Such an event could
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stimulate a cell-mediated immune response. Alternatively, surface expression 
of La could act as a target for autoantibody-mediated damage.
Shattles et al. (1992) using an antibody, 197 MoAb, directed against the p19 
(gag) protein of HTLV-1 detected an antigen, 197 Ag, in 3 of 6  in vitro cultured 
salivary gland cell cultures grown in our laboratory. The 197 Ag expression 
was induced by IFN-y at high doses in PBMCs and an epithelial cell line. 
Immunohistochemical staining detected the antigen in 31% of primary and 24% 
of secondary SS patients, 21% of patients with sicca symptoms and 12.5% of 
patients with other connective tissue diseases. The antigen was not expressed 
in 13 normal salivary glands. None of the patients included in the study of 
Shattles etal. (1992) was HTLV-1 seropositive. The 197 Ag may be a product 
of an endogenous retrovirus, induced by IFN-y and thus secondary to 
inflammation.
Salivary gland cells cultured in vitro were shown to express another antigen 
which is possibly a product of a human endogenous retrovirus, HRES-1 
(Brookes et al, 1992). Expression of this antigen however was not disease- 
specific. Elevated antibody titres to a peptide of HRES-1 were also found in SS 
(Banki etal., 1992; Brookes et al., 1992). The importance of expression of this 
antigen and 197 Ag in salivary gland epithelial cells is at present unknown. 
These antigens could be presented to the immune system as antigens that 
have bypassed tolerance or act as superantigens (Choi et al., 1991) and 
activate T cells expressing particular T cell receptor (TCR)|3 genes. 
Interestingly, V|32 and V|313 genes were found to be predominantly expressed 
in T cells in lip specimens from SS patients (Sumida et al., 1992). In sicca 
syndrome in the context of HIV infection, an overrepresentation of particular 
TCR rearrangements was found (Dwyer et al., 1993). In this case, the 
proliferation of T cells in salivary glands may be antigen driven rather than 
stimulated by a superantigen (Dwyer et al., 1993). At present the presence of 
TCR restriction in autoimmunity remains inconclusive (Navarrete and Bottazzo, 
1993).
The role of hormones in SS and autoimmunity is not clearly defined, but may 
affect endogenous retroviral and La expression. Estradiol treatment followed 
by progesterone stimulated a human endogenous retroviral sequence in a 
human breast cancer cell line (Ono et al., 1987). Estradiol-treatment of human 
keratinocytes can result in the expression of La at the cell surface (Furukawa et
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al., 1991). Thus, the occurrence of SS predominantly in elderly women may 
reflect hormonal influences which could be important in the development of SS. 
A number of different techniques have been used to identify viral DNA or 
protein in salivary glands and determine if the presence of a virus occurs with 
increased frequency in SS. PCR has the advantage of sensitivity whereas in 
situ hybridisation techniques reveal the cellular localisation of the virus. The 
mononuclear cell infiltrate in SS glands may harbour either HHV- 6  or EBV 
infected cells that provide a source of virus when PCR is applied to fixed 
tissues. Krueger etai. (1990) observed HHV- 6  infected mononuclear as well as 
epithelial cells in salivary gland tissue sections from SS patients. A possible 
site of HHV- 6  latency is monocytes/macrophages (Kondo et ai., 1991). In this 
study, the sensitivity of PCR has been applied to purified salivary gland 
epithelial cell populations to investigate viral presence.
The initial findings of 3 HHV- 6  positive cultures, 2 of which were grown from 
persons with SS had to be interpreted cautiously as the cultures could possibly 
have harboured contaminating monocytes. Also, uniform cell numbers 
amongst samples were not available. Although monocytes/macrophages have 
adherent properties under tissue culture conditions, we are confident that the 
refined protocol adopted for the second set of PCR assays removed cells of 
non-epithelial morphology including residual macrophages.
In this second group of samples, two of ten primary salivary gland epithelial cell 
cultures were HHV- 6  positive although the presence of HHV- 6  was not 
associated with SS. This is the first demonstration of HHV- 6  in primary salivary 
gland epithelial cell cultures of which we are aware. Rhim et ai. (1989) reported 
the ability to transform primary human parotid gland epithelial cell cultures with 
an adenovirus/SV40 hybrid virus, but did not detect HHV-6 , EBV, or CMV in 
these cell populations by PCR. HHV- 6  has previously been localised to 
epithelial cells in salivary glands using avidin-biotin detection systems in fixed 
tissues (Fox etai., 1990a; Krueger etal., 1990). Endogenous biotin in salivary 
tissue however, may interfere in assays utilising biotin-labelled reagents (Green 
et al., 1992). Our results confirm that HHV- 6  is present in salivary gland 
epithelium, which may be a site of replication and persistence for the virus. 
Whether HHV- 6  infection in genetically-predisposed individuals, or HHV- 6  
infection of a particular cell type, is involved in the pathogenesis of SS remains 
to be clarified.
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There is no clear consensus regarding the increased detection of EBV in 
salivary gland tissue in SS compared to normal controls using in situ 
hybridisation (Venables et ai., 1989; Mariette et al., 1991; Karameris et al., 
1992) or PCR (Deacon etal., 1991; Mariette et al., 1991; Deacon et al., 1992) 
as methods of detection. The EBV genome has been detected by in situ 
hybridisation and PCR with increased frequency compared to controls and also 
latent and lytic antigens identified in the lacrimal glands of SS patients 
(Pflugfelder et al., 1993). The inability to detect EBV in any of the cultures 
tested is not likely to have resulted from the insensitivity of the PCR assay. The 
most likely explanation is that EBV infected cells were not present in culture at 
the time of harvesting. This does not exclude the presence of EBV infected 
cells at the initiation of cultures as such cells may be unable to persist as a 
result of lytic infection.
The association between HHV- 6  or EBV and lymphomas occurring in the 
context of SS is stronger than with the autoimmune disease itself (Josephs et 
al., 1988; Jarrett etal., 1988; Fox etal., 1989). It is possible that the infiltrating 
lymphocytes found in salivary glands in SS provide a larger than usual 
susceptible population for infection by either of these herpesviruses. EBV, 
which can immortalise B cells in vitro, or HHV- 6  could facilitate B cell 
hyperreactivity which is a feature of SS. B cell hyperreactivity may give rise to 
oligoclonal lymphocyte populations which have been detected by receptor gene 
rearrangement studies in SS salivary and lacrimal glands (Freimark etal., 1989; 
Pepose et al., 1990). The emergence of a neoplastic cell may require a 
chromosomal alteration. Detectable t(14;18) translocations have been shown 
in SS lymphomas but were not found in pre-lymphoma biopsies, even those 
which exhibited oligoclonal immunoglobulin gene rearrangements (Pisa et al., 
1991).
In summary, the ability to grow salivary gland epithelial cells in culture has 
allowed preliminary investigations into mechanisms of autoimmunity associated 
with SS and to search for viruses linked with the disease. This model provides 
a basis for future research aimed at clarifying the role of cytokines, particularly 
IFN-y,in the autoimmune process, and to investigate the presence of retroviral 
gene products in salivary gland epithelia.
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CHAPTER 6
GENERAL DISCUSSION
112
6.1 HHV-6 AND LYMPHOMA/LEUKAEMIA
An important aim of this study was to examine the role of HHV- 6  in a range of 
human lymphomas and leukaemias. The availability of sera from a large 
epidemiological survey of such malignancies has allowed the combination of 
epidemiological data with serological investigations. The number of sera in the 
disease and control groups plus the design of the original study from which sera 
were derived have made this the most complete examination of HHV- 6  
serology in malignancy so far. An important consideration in the design of a 
seroepidemiological survey is to obtain sera from as appropriate controls as 
possible. Antibody titres to viral antigens can vary with age and sex. For HHV- 
6 , higher antibody levels are found in children (Yanagi etal., 1990) and females 
(Clark et al., 1990). An initial study described the presence of higher HHV- 6  
seropositivity in ALL (Ablashi et al., 1988). In a later matched case-control 
study such a finding was not found (Levine et al., 1992a) and the younger age 
distribution of ALL cases is likely to have proved misleading in the original study 
(Ablashi et al., 1988). The results presented here were derived from a case- 
control study and adjustments for age and sex were included in all of the 
statistical analyses. Significant differences in HHV- 6  antibody titres between 
cases and controls were identified in AML, LG-NHL, and HD.
The relevance of elevated antibody titres in each of these three malignancies 
remains unclear. An increase in HHV- 6  replication and expression of viral 
antigens is one possible explanation. Factors such as the disease process 
itself or subsequent therapy could lead to reactivation of the virus from latency. 
The sites of HHV- 6  replication and latency in vivo are not fully characterised. 
Good evidence exists for replication occurring in salivary glands (Fox et al., 
1990a). Latency may be established in a lymphoid cell as the virus was 
detected by PCR in a rare cell in PBMCs (Gopal et al., 1990; Jarrett et al., 
1990). The inability to isolate HHV- 6  from blood in healthy individuals suggests 
the virus is present in a non-infectious latent form, possibly in 
monocytes/macrophages (Kondo etal., 1991). Molecular studies have failed to 
identify HHV- 6  in tumour tissue from AML cases and the majority of NHLs using 
southern blot hybridisation or PCR as methods of detection (Josephs et al., 
1988; Jarrett et al., 1988; Torelli et al., 1991). It seems unlikely therefore that 
HHV- 6  can be present in the tumour cells of these malignancies.
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The detection of virus in the RS cells of HD may be problematic owing to their 
frequent paucity in the total cell population. One possible way around this 
would be to obtain single RS cells from biopsy tissue and examine the genome 
for evidence of viral sequences. Recently Trumper et al. (1993) were able to 
pick single RS cells and by general amplification of cDNA examine gene 
expression pattern including genes characteristic of haematopoietic lineages.
Features of the biology and epidemiology of HD are suggestive of a viral 
aetiology (discussed Chapter 3). Only EBV has consistently been associated 
with the disease and the results presented in this thesis confirmed the presence 
of elevated antibody titres to EBV antigens in HD. The availability of sensitive 
assays for the detection of EBV nucleic acid and protein have clearly 
demonstrated the presence of clonal EBV in HD tumour tissue and localised 
viral gene expression to within the RS cell (Gledhill et al., 1991; Pallesen etal., 
1991a; Armstrong etal., 1992b). EBV-associated HD has been identified more 
frequently in paediatric and older cases of HD, and in the MC subtype group 
(Jarrett etal., 1991; Armstrong etal., 1993; Weinreb etal., 1992). A preliminary 
study presented here did not however, find a correlation between raised EBV 
antibody titres to lytic cycle antigens and HD cases with detectable virus within 
RS cells. The detection of replicative EBV within RS cells has recently been 
reported. Brousset et al. (1993) found that biopsy tissue from 3 of 40 EBV- 
associated HD cases stained positive with antibodies to the ZEBRA protein. 
One of the cases was also stained with anti-EA-restricted-component antibody, 
which indicated early gene expression. Thus, EBV replication in RS cells can 
occur although it would appear to be a rare event. It remains a possibility that 
such a form of replication, including abortive lytic cycles, could affect antibody 
titres to antigens such as EBV-EA and EBV-VCA.
The elevated EBV antibody titres may reflect a particularly severe past infection 
which could account for the altered antibody response that has been detected 
preceeding diagnosis (Mueller etal., 1989). A consequence of severe infection 
is the manifestation of IM which has been associated with the development of 
HD. RS-like cells containing LMP have been detected in acute IM (Isaacson et 
al., 1992) and may be progenitor RS cells. Likewise RS-like cells which are 
LMP positive have been found in NHL (Khan et al., 1993). IM has a peak 
incidence in young adults and it is possible this severe EBV infection is directly 
associated with the development of EBV-associated HD. However, EBV- 
associated HD cases are found less frequently in the young adult age group. It
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is tempting to speculate that another virus is involved in the pathogenesis of 
young adult HD. Perhaps of some relevance is the identification of a stronger 
association of HHV- 6  antibody titres to HD in this age category. The 
development of sensitive in situ detection assays are necessary to clarify the 
role of HHV- 6  in HD. In the absence of direct involvement, it is possible that the 
HHV- 6  antibody levels are acting as a marker for delayed infection to common 
infectious agents. One of these may prove to be a virus associated with HD.
The associations of HHV- 6  and EBV antibody with HD were, in part, 
independent of each other. Therefore, the elevated antibody titres to HHV- 6  in 
HD were unlikely to represent a consequence of an interaction with EBV. This 
can not be excluded however, and interactions between HHV- 6  and other 
viruses have been proposed. Primary infection with EBV or CMV can affect 
HHV- 6  antibody levels, most likely by stimulating reactivation. Alternatively in 
vitro studies have reported that EBV-negative B cell lines not permissive for 
HHV- 6  infection become permissive following infection with EBV (Lusso et al., 
1992). Only a small minority of the cells were productively infected. Latent or 
non-productive infection was proposed in others. The nature of this interaction 
is not known although the authors hypothesised that either EBV infection could 
result in the expression of the membrane receptor for HHV- 6  or the presence of 
EBV in the same cell could somehow bypass putative cellular factors restricting 
HHV- 6  expression. If this phenomenon occurs in vivo, then an expanded 
number of EBV-infected B cells would provide an increased target cell 
population for HHV- 6  infection. A reversal of this situation has been proposed 
to occur between HHV- 6  and HIV-1 (Lusso et al., 1993). HHV- 6  infection of 
natural killer cells is cytopathic and also induces the expression of CD4, thereby 
predisposing them to infection with HIV-1. Thus, there is evidence that HHV- 6  
infection can potentially suppress the natural anti-viral immunity of the host.
6.2 HHV- 6  AND HHV-7 INFECTION IN CHILDREN AND ADULTS
Serological assays to detect antibodies to particular HHV- 6  antigens could 
prove valuable in future studies. To-date an I FA has been the most commonly 
used HHV- 6  antibody detection assay. At present, tests that detect a whole 
range of lytic cycle antigens and one that detects HHV-6 -EA antibodies have 
been developed. Levine et al. (1992b) found that HHV- 6  antibody titres in the 
same sera varied depending on the assay. In that study an IFA and ELISA 
were used that utilised chronically-infected cells and purified virus respectively
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as HHV- 6  antigen. As for EBV, antibody profiles to various antigens may vary 
in health and disease.
The ubiquitous nature of HHV- 6  and the fact that the majority of healthy 
persons are seropositive makes the interpretation of HHV- 6  serology in health 
and disease difficult. As used here, a case-control study has proved valuable in 
highlighting the association of HHV- 6  with particular malignancies. Another 
approach to examine the role of HHV- 6  in particular conditions is the detection 
of seroconversion at the time of illness. This would seem to have its drawbacks 
since IgM antibodies to HHV- 6  are detected not only during primary infection, 
but also reactivation (Fox et al., 1990b). The majority of persons with 
detectable HHV- 6  IgM antibodies with IM-like symptoms in this study showed 
serological evidence of primary EBV infection. Therefore, apparent HHV- 6  
seroconversions should be considered in the context of findings to other 
viruses. As for serology, the detection of HHV- 6  DNA in tissue samples from 
healthy persons and the ability to isolate the virus, mainly from saliva, limits the 
conclusion that can be taken from similar findings in disease. For a common 
virus that persists in the host, a method of choice to examine disease 
associations is the in situ identification of virus in tissue where its presence is 
not normally found. There are already a range of HHV- 6  specific MoAbs and 
DNA probes which hopefully will further help characterise the relationship 
between HHV- 6  and disease.
An important value of serology is that with relatively simple technology the 
seroprevalence of a virus can be examined in large numbers of people. The 
sole requirement is that the virus can be propagated in tissue culture to provide 
a constant source of antigen. Therefore, an IFA was the method chosen to 
study the prevalence of the recently discovered HHV-7. The results have 
shown that, like HHV-6 , infection with the virus is common with 28/29 adults 
seropositive. Again, similar to HHV-6 , infection with HHV-7 occurs early in life 
as the majority of children had HHV-7 antibody by the age of 2 years. Saliva is 
likely to be an important vehicle for HHV-7 transmission as the virus was 
isolated from this source (Wyatt et al., 1991; Chapter4). The availability of 
HHV-7 specific DNA probes (Berneman et al., 1992a; Black et al., 1993) will 
further help determine the role of HHV-7 in human disease which is at present 
unknown. In a large series of HD and NHL biopsy samples HHV-7 was not 
detected by Southern blot hybridisation (R. Jarrett, personal communication in 
collaboration with Z. Berneman).
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In addition to the association with certain malignacies, viruses have been 
associated with particular chronic diseases. In order to study viral involvement 
in SS an in vitro model was developed. This was based on the ability to culture 
epithelial cells from labial salivary gland biopsies. Preliminary studies did not 
find a link between the presence of HHV- 6  or EBV in such cultures and SS. 
The results of this study do however indicate the important role IFN-7  may play 
in precipitating an autoimmune response in SS. The salivary gland cultures 
proved useful as a model to study mechanisms of autoimmunity including 
autoantibody production. Similarly, they can be used to further study the 
possible role of endogenous retroviral antigen expression in SS.
An important consideration for future studies on HHV- 6  is the relevance of 
different viral strains in human disease. A number of studies have reported 
nucleotide sequence and antigenic variations between HHV- 6  isolates which 
can be categorised into 2 groups (Jarrett et al., 1989; Wyatt et al., 1990; 
Schirmer et al., 1991; Gompels et al., 1993; Dewhurst et al., 1993). Such 
findings culminated in the recent assignment of new nomenclature for HHV- 6  
as two subgroups - variant A and variant B (Ablashi et al., 1993). Initial 
investigations have reported the almost exclusive involvement of HHV- 6  variant 
B in symptomatic primary infection in children (Dewhurst et al., 1993). At 
present there is no serological assay available for large scale screening that 
distinguishes between variant A and variant B. The development of such an 
assay will be of great value in future studies of the epidemiology of HHV-6 .
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